BioTech Nation ... with Dr. Moira Gunn Transistor (https://transistor.fm) https://feeds.transistor.fm/biotech-nation Welcome to BIOTECH NATION !!! With understandable interviews requiring no background in science, BTN attracts a wide global audience. From everyday people looking for hope in treatments in development, to bioentrepreneurs interested in the experience of their fellow travelers, to venture capitalists looking for possibilities in cutting-edge breakthroughs, to scientists simply interested in the work of others, BioTech Nation is the voice of human endeavor, driving science to new realities for everyone. These interviews are drawn directly from the public radio program, "Tech Nation", which also can be heard in numerous global radio and podcasting venues. Tech Nation Media b4ce85f5-d57e-5c22-91f7-8a0f70642789 no en Tue, 31 Mar 2026 18:09:29 -0700 Tue, 31 Mar 2026 18:10:13 -0700 http://biotechnation.com https://img.transistorcdn.com/bBueVfZqS7fWNVUPplIyGOBq2rVAuu759lNJt9IPH_k/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMxMTgyLzE2NTM3/NjI1NzctYXJ0d29y/ay5qcGc.jpg BioTech Nation ... with Dr. Moira Gunn http://biotechnation.com episodic Moira Gunn Welcome to BIOTECH NATION !!! With understandable interviews requiring no background in science, BTN attracts a wide global audience. From everyday people looking for hope in treatments in development, to bioentrepreneurs interested in the experience of their fellow travelers, to venture capitalists looking for possibilities in cutting-edge breakthroughs, to scientists simply interested in the work of others, BioTech Nation is the voice of human endeavor, driving science to new realities for everyone. These interviews are drawn directly from the public radio program, "Tech Nation", which also can be heard in numerous global radio and podcasting venues. Welcome to BIOTECH NATION !!. biotech, entrepreneurship, bioentrepreneurship BioTech Nation Team No No Who is Medically Qualified to Go to Space??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 26013 26013 Who is Medically Qualified to Go to Space??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full 71bb11b3-0e28-48f7-b9d1-237d67fc70c0 https://share.transistor.fm/s/ac08ebbe On this week's BioTech Nation...want to go to space? Well...it's never too late to follow your dreams, and Tech Nation Health Chief Correspondent Dr. Daniel Kraft joins us to talk about who could medically qualify to climb aboard and rocket into orbit. His answers may surprise you...

]]> On this week's BioTech Nation...want to go to space? Well...it's never too late to follow your dreams, and Tech Nation Health Chief Correspondent Dr. Daniel Kraft joins us to talk about who could medically qualify to climb aboard and rocket into orbit. His answers may surprise you...

]]> Tue, 31 Mar 2026 13:49:45 -0700 Moira Gunn Moira Gunn 598 On this week's BioTech Nation...want to go to space? Well...it's never too late to follow your dreams, and Tech Nation Health Chief Correspondent Dr. Daniel Kraft joins us to talk about who could medically qualify to climb aboard and rocket into orbit. His answers may surprise you...

]]> biotech, entrepreneurship, bioentrepreneurship No Big Tech & Healthcare...Dr. Marschall Runge, Author, "The Great Healthcare Disruption" 26012 26012 Big Tech & Healthcare...Dr. Marschall Runge, Author, "The Great Healthcare Disruption" full 324eb4d9-f40e-434c-a5bd-6df4ff5c22d6 https://share.transistor.fm/s/0cef0b97 On this week's BioTech Nation...what could the future of American Healthcare look like? Moira speaks with Dr. Marschall Runge, University of Michigan Medical School Professor, about how Big Tech is quickly redefining the entire healthcare system. His book is, “The Great Healthcare Disruption: Big Tech, Bold Policy, and the Future of American Medicine.” 

]]> On this week's BioTech Nation...what could the future of American Healthcare look like? Moira speaks with Dr. Marschall Runge, University of Michigan Medical School Professor, about how Big Tech is quickly redefining the entire healthcare system. His book is, “The Great Healthcare Disruption: Big Tech, Bold Policy, and the Future of American Medicine.” 

]]> Tue, 24 Mar 2026 07:00:00 -0700 Moira Gunn Moira Gunn 2531 On this week's BioTech Nation...what could the future of American Healthcare look like? Moira speaks with Dr. Marschall Runge, University of Michigan Medical School Professor, about how Big Tech is quickly redefining the entire healthcare system. His book is, “The Great Healthcare Disruption: Big Tech, Bold Policy, and the Future of American Medicine.” 

]]> biotech, entrepreneurship, bioentrepreneurship No Regaining Function After Spinal Cord Injury: A New Path Forward? Dr. Adam Rogers, CEO, NervGen Pharma 26011 26011 Regaining Function After Spinal Cord Injury: A New Path Forward? Dr. Adam Rogers, CEO, NervGen Pharma full 3ffb6982-9fe6-4882-9835-e4412b4d9b8a https://share.transistor.fm/s/2c14e551 On this week’s BioTech Nation, Moira speaks with Dr. Adam Rogers, CEO of NervGen Pharma, about a new treatment that’s showing significant trial results for patients with spinal cord injuries. While typically, patient progress is defined by the early months of recovery after the injury, some trial participants have seen increased function as much as 10 years post-trauma. 

]]> On this week’s BioTech Nation, Moira speaks with Dr. Adam Rogers, CEO of NervGen Pharma, about a new treatment that’s showing significant trial results for patients with spinal cord injuries. While typically, patient progress is defined by the early months of recovery after the injury, some trial participants have seen increased function as much as 10 years post-trauma. 

]]> Tue, 17 Mar 2026 07:24:16 -0700 Moira Gunn Moira Gunn 1325 On this week’s BioTech Nation, Moira speaks with Dr. Adam Rogers, CEO of NervGen Pharma, about a new treatment that’s showing significant trial results for patients with spinal cord injuries. While typically, patient progress is defined by the early months of recovery after the injury, some trial participants have seen increased function as much as 10 years post-trauma. 

]]> biotech, entrepreneurship, bioentrepreneurship No A New Approach to Treating ALS...Dr. Arun Swaminathan, CEO, Coya Therapeutics 26010 26010 A New Approach to Treating ALS...Dr. Arun Swaminathan, CEO, Coya Therapeutics full 7c583ab3-2449-4aaa-b062-4501e594f10f https://share.transistor.fm/s/b86d25d0 On this week’s Biotech Nation, Moira speaks with Dr. Arun Swaminathan about an intervention for ALS that Coya Therapeutics is taking into phase two clinical trials. The goal? To stop progression of the disease in its tracks. It could even help in patients with Parkinson’s, Alzheimers, and Frontotemporal Dementia.

]]> On this week’s Biotech Nation, Moira speaks with Dr. Arun Swaminathan about an intervention for ALS that Coya Therapeutics is taking into phase two clinical trials. The goal? To stop progression of the disease in its tracks. It could even help in patients with Parkinson’s, Alzheimers, and Frontotemporal Dementia.

]]> Tue, 10 Mar 2026 09:02:05 -0700 Moira Gunn Moira Gunn 1116 On this week’s Biotech Nation, Moira speaks with Dr. Arun Swaminathan about an intervention for ALS that Coya Therapeutics is taking into phase two clinical trials. The goal? To stop progression of the disease in its tracks. It could even help in patients with Parkinson’s, Alzheimers, and Frontotemporal Dementia.

]]> biotech, entrepreneurship, bioentrepreneurship No The Future of Early Cancer Screening...Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 26009 26009 The Future of Early Cancer Screening...Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full 307374d2-6177-4790-a0cb-79ebc083986b https://share.transistor.fm/s/03fe123f What if you could routinely screen for early cancer, detecting it while it's easier to treat? Tech Nation Health Chief Correspondent, Dr. Daniel Kraft discusses the latest diagnostics that could allow us to do just that. From blood tests to full-body scans, the future of cancer screening could mean finding cancer before obvious symptoms even begin...

]]> What if you could routinely screen for early cancer, detecting it while it's easier to treat? Tech Nation Health Chief Correspondent, Dr. Daniel Kraft discusses the latest diagnostics that could allow us to do just that. From blood tests to full-body scans, the future of cancer screening could mean finding cancer before obvious symptoms even begin...

]]> Tue, 03 Mar 2026 07:09:23 -0800 Moira Gunn Moira Gunn 458 What if you could routinely screen for early cancer, detecting it while it's easier to treat? Tech Nation Health Chief Correspondent, Dr. Daniel Kraft discusses the latest diagnostics that could allow us to do just that. From blood tests to full-body scans, the future of cancer screening could mean finding cancer before obvious symptoms even begin...

]]> biotech, entrepreneurship, bioentrepreneurship No AI in the Exam Room, Dr. Robert Wachter, Author, "A Giant Leap" 26008 26008 AI in the Exam Room, Dr. Robert Wachter, Author, "A Giant Leap" full 3e37d7bf-3e31-4424-9770-72a898e0dbe5 https://share.transistor.fm/s/052cb547 On this week’s Biotech Nation, how doctors and hospitals are using AI, and how it could change the practice of medicine. Moira speaks with Dr. Robert Wachter about his book, “A Giant Leap: How AI is Transforming Healthcare and What That Means for Our Future”.

]]> On this week’s Biotech Nation, how doctors and hospitals are using AI, and how it could change the practice of medicine. Moira speaks with Dr. Robert Wachter about his book, “A Giant Leap: How AI is Transforming Healthcare and What That Means for Our Future”.

]]> Tue, 24 Feb 2026 06:57:50 -0800 Moira Gunn Moira Gunn 1752 On this week’s Biotech Nation, how doctors and hospitals are using AI, and how it could change the practice of medicine. Moira speaks with Dr. Robert Wachter about his book, “A Giant Leap: How AI is Transforming Healthcare and What That Means for Our Future”.

]]> biotech, entrepreneurship, bioentrepreneurship No ChatGPT...for Healthcare? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 26007 26007 ChatGPT...for Healthcare? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full 77dd0ed5-fb52-439a-88be-46cd20cf8e9c https://share.transistor.fm/s/d0483044 You may already use "Dr. ChatGPT" to answer your medical questions... but now, OpenAI has announced the rollout of ChatGPT Health and OpenAI for Healthcare. Dr. Daniel Kraft has the latest on how each platform will work, and what happens with the health data you share. 

]]> You may already use "Dr. ChatGPT" to answer your medical questions... but now, OpenAI has announced the rollout of ChatGPT Health and OpenAI for Healthcare. Dr. Daniel Kraft has the latest on how each platform will work, and what happens with the health data you share. 

]]> Tue, 17 Feb 2026 06:52:27 -0800 Moira Gunn Moira Gunn 564 You may already use "Dr. ChatGPT" to answer your medical questions... but now, OpenAI has announced the rollout of ChatGPT Health and OpenAI for Healthcare. Dr. Daniel Kraft has the latest on how each platform will work, and what happens with the health data you share. 

]]> biotech, entrepreneurship, bioentrepreneurship No AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering & Head of Biohub, Chicago 26006 26006 AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering & Head of Biohub, Chicago full 9ca4f9f7-018a-4997-96ab-4fc1f64f5f94 https://share.transistor.fm/s/16fa1a2c This week on BioTech Nation, what is AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering and Head of Biohub, Chicago for the Chan-Zuckerberg Initiative, discusses how AI can be used to accelerate research, and what this could mean for the future.  

]]> This week on BioTech Nation, what is AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering and Head of Biohub, Chicago for the Chan-Zuckerberg Initiative, discusses how AI can be used to accelerate research, and what this could mean for the future.  

]]> Tue, 10 Feb 2026 08:36:38 -0800 Moira Gunn Moira Gunn 1563 This week on BioTech Nation, what is AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering and Head of Biohub, Chicago for the Chan-Zuckerberg Initiative, discusses how AI can be used to accelerate research, and what this could mean for the future.  

]]> biotech, entrepreneurship, bioentrepreneurship No A Euphoria-Suppressing Opioid, Ketan Mehta, Founder & CEO, Tris Pharma 26005 26005 A Euphoria-Suppressing Opioid, Ketan Mehta, Founder & CEO, Tris Pharma full 7ee2c999-e9f7-4b4f-909f-5b97f85172b1 https://share.transistor.fm/s/e0a3d3a2

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation...
Ever wonder what makes opioids so addictive? Moira speaks with Ketan Mehta, Founder and CEO of Tris Pharma, about opioid-induced euphoria...and an opioid that's actually meant to suppress this response. 

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]>

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation...
Ever wonder what makes opioids so addictive? Moira speaks with Ketan Mehta, Founder and CEO of Tris Pharma, about opioid-induced euphoria...and an opioid that's actually meant to suppress this response. 

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> Tue, 03 Feb 2026 09:58:03 -0800 Moira Gunn Moira Gunn 964

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation...
Ever wonder what makes opioids so addictive? Moira speaks with Ketan Mehta, Founder and CEO of Tris Pharma, about opioid-induced euphoria...and an opioid that's actually meant to suppress this response. 

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> biotech, entrepreneurship, bioentrepreneurship No You’ve Had Back Pain for 7-10 Years? Neil Klompas, CEO, Augurex 26004 26004 You’ve Had Back Pain for 7-10 Years? Neil Klompas, CEO, Augurex full 22e71cb7-da26-4f8c-ac9e-e732a23543ba https://share.transistor.fm/s/653f69ec

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation...Moira speaks with Neil Klompas of Augurex Life Sciences, about a new diagnostic for chronic, long-term back pain that pinpoints a form of arthritis. On average, patients with this condition could go 7-10 years without a diagnosis, having to first eliminate everything else with an odyssey of tests. Now, a simple blood test could be the answer.

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]>

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation...Moira speaks with Neil Klompas of Augurex Life Sciences, about a new diagnostic for chronic, long-term back pain that pinpoints a form of arthritis. On average, patients with this condition could go 7-10 years without a diagnosis, having to first eliminate everything else with an odyssey of tests. Now, a simple blood test could be the answer.

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> Tue, 27 Jan 2026 09:50:47 -0800 Moira Gunn Moira Gunn 544

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation...Moira speaks with Neil Klompas of Augurex Life Sciences, about a new diagnostic for chronic, long-term back pain that pinpoints a form of arthritis. On average, patients with this condition could go 7-10 years without a diagnosis, having to first eliminate everything else with an odyssey of tests. Now, a simple blood test could be the answer.

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> biotech, entrepreneurship, bioentrepreneurship No A Fast-Acting Dupixent? Dr. Barry Quart, CEO, Connect Biopharma 26003 26003 A Fast-Acting Dupixent? Dr. Barry Quart, CEO, Connect Biopharma full 121edd6d-4547-4509-bd4d-7c4554d08ef3 https://share.transistor.fm/s/77550ede

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation, Moira speaks with Dr. Barry Quart, CEO of Connect Biopharma, about a new fast-acting treatment for inflammatory conditions like Asthma, COPD, and Eczema. Often, these conditions can be managed with anti-inflammatory therapeutics like Dupixent, but even then, sudden and painful flare-ups can occur. We take a closer look at a new anti-inflammatory in late-stage development which starts working quickly, much needed when those flare-ups develop. 

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]>

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation, Moira speaks with Dr. Barry Quart, CEO of Connect Biopharma, about a new fast-acting treatment for inflammatory conditions like Asthma, COPD, and Eczema. Often, these conditions can be managed with anti-inflammatory therapeutics like Dupixent, but even then, sudden and painful flare-ups can occur. We take a closer look at a new anti-inflammatory in late-stage development which starts working quickly, much needed when those flare-ups develop. 

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> Tue, 20 Jan 2026 10:18:12 -0800 Moira Gunn Moira Gunn 670

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation, Moira speaks with Dr. Barry Quart, CEO of Connect Biopharma, about a new fast-acting treatment for inflammatory conditions like Asthma, COPD, and Eczema. Often, these conditions can be managed with anti-inflammatory therapeutics like Dupixent, but even then, sudden and painful flare-ups can occur. We take a closer look at a new anti-inflammatory in late-stage development which starts working quickly, much needed when those flare-ups develop. 

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> biotech, entrepreneurship, bioentrepreneurship No A Speedy Intervention for Heart Attacks, Dr. Harry Selker & Dr. Atul Deshpande, Immediate Therapeutics 26002 26002 A Speedy Intervention for Heart Attacks, Dr. Harry Selker & Dr. Atul Deshpande, Immediate Therapeutics full 7c7513b0-fe16-43f6-bafb-f559b948a504 https://share.transistor.fm/s/285241c0

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation...
Dr. Harry Selker & Dr. Atul Deshpande of Immediate Therapeutics speak with Moira about a new treatment that could be administered to heart attack patients right away...potentially before they even arrive at the hospital. Already successfully tested in Phase 2, it’s ready to go into final pivotal trials in Ambulances and Emergency Rooms.

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]>

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation...
Dr. Harry Selker & Dr. Atul Deshpande of Immediate Therapeutics speak with Moira about a new treatment that could be administered to heart attack patients right away...potentially before they even arrive at the hospital. Already successfully tested in Phase 2, it’s ready to go into final pivotal trials in Ambulances and Emergency Rooms.

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> Tue, 13 Jan 2026 11:50:33 -0800 Moira Gunn Moira Gunn 1270

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation...
Dr. Harry Selker & Dr. Atul Deshpande of Immediate Therapeutics speak with Moira about a new treatment that could be administered to heart attack patients right away...potentially before they even arrive at the hospital. Already successfully tested in Phase 2, it’s ready to go into final pivotal trials in Ambulances and Emergency Rooms.

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> biotech, entrepreneurship, bioentrepreneurship No A New Way to Treat Cancer, Cyriac Roeding & Dr. David Suhy, Co-Founders, Earli 26001 26001 A New Way to Treat Cancer, Cyriac Roeding & Dr. David Suhy, Co-Founders, Earli full 4b0ac1b8-87b7-4364-b86d-4aecbdd1da2f https://share.transistor.fm/s/28ff0b54

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation: Can cancer cells be turned against themselves? Moira speaks with Cyriac Roeding and Dr. David Suhy, Co-Founders of Earli, about an innovative new approach to treating solid tumor cancer. They discuss their effort to turn the cancer cells inside solid tumors into factories that produce their own cancer-fighting therapeutic.

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]>

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation: Can cancer cells be turned against themselves? Moira speaks with Cyriac Roeding and Dr. David Suhy, Co-Founders of Earli, about an innovative new approach to treating solid tumor cancer. They discuss their effort to turn the cancer cells inside solid tumors into factories that produce their own cancer-fighting therapeutic.

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> Tue, 06 Jan 2026 13:19:02 -0800 Moira Gunn Moira Gunn 1449

This is the 2026 BioTech Nation "5":
Five Companies Ready to Make a Difference.
We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5


On this episode of BioTech Nation: Can cancer cells be turned against themselves? Moira speaks with Cyriac Roeding and Dr. David Suhy, Co-Founders of Earli, about an innovative new approach to treating solid tumor cancer. They discuss their effort to turn the cancer cells inside solid tumors into factories that produce their own cancer-fighting therapeutic.

For more information about BioTech Nation and the companies featured here, visit: TechNation.com

]]> biotech, entrepreneurship, bioentrepreneurship No Decoding Diseases of Aging...Dr. Martin Borch Jensen and Dr. Francisco LePort, Gordian Biotechnology 25049 25049 Decoding Diseases of Aging...Dr. Martin Borch Jensen and Dr. Francisco LePort, Gordian Biotechnology full 7aedebb0-7a6a-42cd-bd05-eb0cced90fe6 https://share.transistor.fm/s/6c9204b7 This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.

]]> This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.

]]> Tue, 30 Dec 2025 21:12:49 -0800 Moira Gunn Moira Gunn 1551 This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.

]]> biotech, entrepreneurship, bioentrepreneurship No When Your Immune System Overreacts...Prof. Dr. Niels Riedemann, Co-Founder & CEO, InflaRx 25048 25048 When Your Immune System Overreacts...Prof. Dr. Niels Riedemann, Co-Founder & CEO, InflaRx full 0bb4ae33-51f7-4f3d-8de4-fcae6c1e2fe8 https://share.transistor.fm/s/97b89da8 This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies. 

]]> This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies. 

]]> Tue, 23 Dec 2025 08:33:41 -0800 Moira Gunn Moira Gunn 1312 This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies. 

]]> biotech, entrepreneurship, bioentrepreneurship No Renewed Potential: Reviving an ALS Drug...Dr. Ari Azhir, Founder & CEO, Neuvivo 25047 25047 Renewed Potential: Reviving an ALS Drug...Dr. Ari Azhir, Founder & CEO, Neuvivo full 8c3fbc13-fdec-4ac7-ad71-8f975f88983c https://share.transistor.fm/s/19e06802 This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s.

]]> This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s.

]]> Wed, 17 Dec 2025 12:24:26 -0800 Moira Gunn Moira Gunn 1067 This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s.

]]> biotech, entrepreneurship, bioentrepreneurship No Preventing Pressure Injuries: Detecting the Invisible Signs, Martin Burns, CEO Bruin Biometrics 25046 25046 Preventing Pressure Injuries: Detecting the Invisible Signs, Martin Burns, CEO Bruin Biometrics full c2036ad7-4632-40eb-a8e5-e30027116341 https://share.transistor.fm/s/18bb3860 This week on BioTech Nation, Bruin Biometrics CEO Martin Burns talks about a new diagnostic tool being used to detect and prevent potentially fatal bedsores in their earliest stages.

]]> This week on BioTech Nation, Bruin Biometrics CEO Martin Burns talks about a new diagnostic tool being used to detect and prevent potentially fatal bedsores in their earliest stages.

]]> Tue, 09 Dec 2025 14:06:21 -0800 Moira Gunn Moira Gunn 1222 This week on BioTech Nation, Bruin Biometrics CEO Martin Burns talks about a new diagnostic tool being used to detect and prevent potentially fatal bedsores in their earliest stages.

]]> biotech, entrepreneurship, bioentrepreneurship No Are we moving from Dr. Google to Dr. ChatGPT??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 25041 25041 Are we moving from Dr. Google to Dr. ChatGPT??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full ba2a67ba-25d4-4cf2-8abb-b36fec3914c1 https://share.transistor.fm/s/abd56da8 For years, we've all turned to Google to self-diagnose every cough, rash, and weird pain. Dr. Daniel Kraft says the shift is happening, from Dr. Google to Dr. ChatGPT.

]]> For years, we've all turned to Google to self-diagnose every cough, rash, and weird pain. Dr. Daniel Kraft says the shift is happening, from Dr. Google to Dr. ChatGPT.

]]> Thu, 04 Dec 2025 17:07:47 -0800 Moira Gunn Moira Gunn 448 For years, we've all turned to Google to self-diagnose every cough, rash, and weird pain. Dr. Daniel Kraft says the shift is happening, from Dr. Google to Dr. ChatGPT.

]]> biotech, entrepreneurship, bioentrepreneurship No Connecting the Data that Changes Medicine, Dr. Lincoln Nadauld, President & CEO, Culmination Bio 25045 25045 Connecting the Data that Changes Medicine, Dr. Lincoln Nadauld, President & CEO, Culmination Bio full c867e381-7139-4b68-b091-283e35218345 https://share.transistor.fm/s/bc55e3f4 This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.

]]> This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.

]]> Thu, 27 Nov 2025 23:54:24 -0800 Moira Gunn Moira Gunn 1107 This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.

]]> biotech, entrepreneurship, bioentrepreneurship No Correcting Gene-based Frontotemporal Dementia, Lisa Deschamps, CEO Aviado Bio 25044 25044 Correcting Gene-based Frontotemporal Dementia, Lisa Deschamps, CEO Aviado Bio full 56a91a0a-d436-4fd4-a764-c8bd1e921b10 https://share.transistor.fm/s/d26eccd3 What if we could fix the gene that causes dementia? In this episode, Aviado Bio CEO Lisa Deschamps tells us how her team is working to correct the gene driving many cases of frontotemporal dementia. 

]]> What if we could fix the gene that causes dementia? In this episode, Aviado Bio CEO Lisa Deschamps tells us how her team is working to correct the gene driving many cases of frontotemporal dementia. 

]]> Tue, 18 Nov 2025 22:18:48 -0800 Moira Gunn Moira Gunn 881 What if we could fix the gene that causes dementia? In this episode, Aviado Bio CEO Lisa Deschamps tells us how her team is working to correct the gene driving many cases of frontotemporal dementia. 

]]> biotech, entrepreneurship, bioentrepreneurship No Tuning your own DNA?? Dr. Derek Jantz, Chief Scientific Officer, Tune Therapeutics 25043 25043 Tuning your own DNA?? Dr. Derek Jantz, Chief Scientific Officer, Tune Therapeutics full 9914f507-d7e2-404e-84c7-607cc8b81fa2 https://share.transistor.fm/s/5f035a06 What if you could tune your DNA to fix any mistakes? Dr. Derek Jantz from Tune Therapeutics talks about tuning DNA, not just with humans, but stopping the Hepatitis B virus in its tracks.

]]> What if you could tune your DNA to fix any mistakes? Dr. Derek Jantz from Tune Therapeutics talks about tuning DNA, not just with humans, but stopping the Hepatitis B virus in its tracks.

]]> Tue, 11 Nov 2025 22:29:28 -0800 Moira Gunn Moira Gunn 1058 What if you could tune your DNA to fix any mistakes? Dr. Derek Jantz from Tune Therapeutics talks about tuning DNA, not just with humans, but stopping the Hepatitis B virus in its tracks.

]]> biotech, entrepreneurship, bioentrepreneurship No A New Way to Treat Wounds?? Dr. Ned Swanson, Co-Founder, President & Chief Medical Officer, Polarity Bio 25042 25042 A New Way to Treat Wounds?? Dr. Ned Swanson, Co-Founder, President & Chief Medical Officer, Polarity Bio full 8ede61b1-63a4-4b76-afc5-439848424351 https://share.transistor.fm/s/5effc161 Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.

]]> Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.

]]> Tue, 04 Nov 2025 20:10:38 -0800 Moira Gunn Moira Gunn 902 Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.

]]> biotech, entrepreneurship, bioentrepreneurship No Treating the Untreatable in Rheumatoid Arthritis! Rob Armstrong, CEO, Artax Biopharma 25040 25040 Treating the Untreatable in Rheumatoid Arthritis! Rob Armstrong, CEO, Artax Biopharma full eee28324-2414-4812-a354-380e74f4c1f9 https://share.transistor.fm/s/6306e76f 40% of all rheumatoid arthritis patients do not respond to any of the current drugs. Rob Armstrong, CEO of Artax Biopharma, aims to bring new hope for those patients who've been left without effective treatment options.

]]> 40% of all rheumatoid arthritis patients do not respond to any of the current drugs. Rob Armstrong, CEO of Artax Biopharma, aims to bring new hope for those patients who've been left without effective treatment options.

]]> Wed, 29 Oct 2025 15:09:03 -0700 Moira Gunn Moira Gunn 1032 40% of all rheumatoid arthritis patients do not respond to any of the current drugs. Rob Armstrong, CEO of Artax Biopharma, aims to bring new hope for those patients who've been left without effective treatment options.

]]> biotech, entrepreneurship, bioentrepreneurship No Treating babies with congenital heart defects... Dr. Joshua Hare, Co-Founder and Chief Scientific Officer, Longeveron 25039 25039 Treating babies with congenital heart defects... Dr. Joshua Hare, Co-Founder and Chief Scientific Officer, Longeveron full 49343989-8766-4e74-a7d6-34c286c68e8c https://share.transistor.fm/s/c9565c80 Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talks about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.

]]> Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talks about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.

]]> Tue, 21 Oct 2025 18:18:47 -0700 Moira Gunn Moira Gunn 1437 Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talks about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.

]]> biotech, entrepreneurship, bioentrepreneurship No A New Approach to Flu Shots! Dr. Jeff Stein, President & CEO, Cidara Therapeutics 25038 25038 A New Approach to Flu Shots! Dr. Jeff Stein, President & CEO, Cidara Therapeutics full a7591d27-0708-416f-8517-39635af7f0b7 https://share.transistor.fm/s/d2c4f53e This week on BioTech Nation, Dr. Jeff Stein, President & CEO of Cidara Therapeutics, brings up promising news about a new approach to flu shots.

]]> This week on BioTech Nation, Dr. Jeff Stein, President & CEO of Cidara Therapeutics, brings up promising news about a new approach to flu shots.

]]> Thu, 16 Oct 2025 13:25:27 -0700 Moira Gunn Moira Gunn 1163 This week on BioTech Nation, Dr. Jeff Stein, President & CEO of Cidara Therapeutics, brings up promising news about a new approach to flu shots.

]]> biotech, entrepreneurship, bioentrepreneurship No New treatment being tested for pre-term babies... Dr. Marc Salzberg, CEO and Chief Medical Officer, Airway Therapeutics 25037 25037 New treatment being tested for pre-term babies... Dr. Marc Salzberg, CEO and Chief Medical Officer, Airway Therapeutics full 78f00ec7-5056-458a-adbd-6476642de4ba https://share.transistor.fm/s/0eeab2e3 Dr. Marc Salzberg, CEO & Chief Medical Officer of Airway Therapeutics, talks about what they are doing to help preterm babies. It may all boil down to delivering these babies a single protein as soon as they are born. 

]]> Dr. Marc Salzberg, CEO & Chief Medical Officer of Airway Therapeutics, talks about what they are doing to help preterm babies. It may all boil down to delivering these babies a single protein as soon as they are born. 

]]> Thu, 02 Oct 2025 17:15:09 -0700 Moira Gunn Moira Gunn 1340 Dr. Marc Salzberg, CEO & Chief Medical Officer of Airway Therapeutics, talks about what they are doing to help preterm babies. It may all boil down to delivering these babies a single protein as soon as they are born. 

]]> biotech, entrepreneurship, bioentrepreneurship No A Smarter Path to Curing Diseases… Dr. Avak Kahvejian Founding CEO, Cellarity 25036 25036 A Smarter Path to Curing Diseases… Dr. Avak Kahvejian Founding CEO, Cellarity full e7082161-dd8b-422d-819f-1a4216dd906e https://share.transistor.fm/s/1c1dbf5b Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.

]]> Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.

]]> Mon, 22 Sep 2025 16:57:56 -0700 Moira Gunn Moira Gunn 1184 Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.

]]> biotech, entrepreneurship, bioentrepreneurship No No More Vaccines? Research Funding? Paul Hastings, CEO, Nkarta and former Chair, BIO 25035 25035 No More Vaccines? Research Funding? Paul Hastings, CEO, Nkarta and former Chair, BIO full c7ff7383-8e15-448c-afb1-b548ba921e5b https://share.transistor.fm/s/dc28a3eb This week on Biotech Nation, Paul Hastings, CEO of Nkarta and former chair of BIO—the Biotechnology Innovation Organization—discusses the impact of cuts to research funding and stepping away from recommending vaccines—what this means for you and the biotech industry. 

]]> This week on Biotech Nation, Paul Hastings, CEO of Nkarta and former chair of BIO—the Biotechnology Innovation Organization—discusses the impact of cuts to research funding and stepping away from recommending vaccines—what this means for you and the biotech industry. 

]]> Mon, 15 Sep 2025 17:18:34 -0700 Moira Gunn Moira Gunn 1478 This week on Biotech Nation, Paul Hastings, CEO of Nkarta and former chair of BIO—the Biotechnology Innovation Organization—discusses the impact of cuts to research funding and stepping away from recommending vaccines—what this means for you and the biotech industry. 

]]> biotech, entrepreneurship, bioentrepreneurship No How Hydrated are YOU? A Simple Wearable can do it! Dr. Mark Kendall, CEO, WearOptimo 25034 25034 How Hydrated are YOU? A Simple Wearable can do it! Dr. Mark Kendall, CEO, WearOptimo full 594fc2fa-ce68-4799-9460-984356c3afcb https://share.transistor.fm/s/34f2d7ae This week on BioTech Nation, Dr. Mark Kendall, CEO of WearOptimo, tells us about progress with their new wearable. You could be dehydrated and not even know it … And exactly how hydrated are you right now, anyway? The old “if you’re thirsty, drink something” turns out to be a little too late. 

]]> This week on BioTech Nation, Dr. Mark Kendall, CEO of WearOptimo, tells us about progress with their new wearable. You could be dehydrated and not even know it … And exactly how hydrated are you right now, anyway? The old “if you’re thirsty, drink something” turns out to be a little too late. 

]]> Mon, 08 Sep 2025 17:16:37 -0700 Moira Gunn Moira Gunn 1208 This week on BioTech Nation, Dr. Mark Kendall, CEO of WearOptimo, tells us about progress with their new wearable. You could be dehydrated and not even know it … And exactly how hydrated are you right now, anyway? The old “if you’re thirsty, drink something” turns out to be a little too late. 

]]> biotech, entrepreneurship, bioentrepreneurship No The BioTech Nation session at NextMed Health 2025... Dr. Daniel Kraft, Tech Nation Health, Chief Correspondent 25033 25033 The BioTech Nation session at NextMed Health 2025... Dr. Daniel Kraft, Tech Nation Health, Chief Correspondent full f2a41784-8d31-4bab-a728-0eb52b8c5089 https://share.transistor.fm/s/7f8d9dfb

]]>

]]> Wed, 03 Sep 2025 17:12:37 -0700 Moira Gunn Moira Gunn 497

]]> biotech, entrepreneurship, bioentrepreneurship No Insulin Cells WITHOUT Immunosuppressants... Dr. Steve Harr, CEO, Sana Biotechnology 25032 25032 Insulin Cells WITHOUT Immunosuppressants... Dr. Steve Harr, CEO, Sana Biotechnology full 743a8ba2-79d5-494f-9d76-508f0a0ff1b7 https://share.transistor.fm/s/af5b2c06 This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without immunosuppressant drugs.


]]> This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without immunosuppressant drugs.


]]> Mon, 25 Aug 2025 17:15:32 -0700 Moira Gunn Moira Gunn 898 This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without immunosuppressant drugs.


]]> biotech, entrepreneurship, bioentrepreneurship No Focused Ultrasound - Treating Disease Without Surgery... Dr. Neil Kassell, Founder and Chair, Focused Ultrasound Foundation 25031 25031 Focused Ultrasound - Treating Disease Without Surgery... Dr. Neil Kassell, Founder and Chair, Focused Ultrasound Foundation full e06e5785-66db-478c-a9f0-d0933b878857 https://share.transistor.fm/s/9b8abdb2 This week on BioTech Nation, Dr. Neal Kassell, founder of the Focused Ultrasound Foundation, introduces us to a powerful, non-invasive technology that’s already changing lives, and it doesn’t involve surgery, injections, or pills. 

]]> This week on BioTech Nation, Dr. Neal Kassell, founder of the Focused Ultrasound Foundation, introduces us to a powerful, non-invasive technology that’s already changing lives, and it doesn’t involve surgery, injections, or pills. 

]]> Wed, 20 Aug 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1101 This week on BioTech Nation, Dr. Neal Kassell, founder of the Focused Ultrasound Foundation, introduces us to a powerful, non-invasive technology that’s already changing lives, and it doesn’t involve surgery, injections, or pills. 

]]> focused ultrasound, non-invasive treatment, sound wave therapy, Neal Kassell, BioTech Nation, brain health, cancer treatment, Parkinson’s, Alzheimer’s, essential tremor, depression, addiction, drug delivery, medical technology, clinical trials, FDA approved, no surgery, new medical treatment, ultrasound therapy, Focused Ultrasound Foundation, healthcare innovation No A New Way to Treat Skin Cancer... No Surgery Required??? Dr. Raza Bokhari, CEO and Chairman, Medicus Pharma Ltd. 25030 25030 A New Way to Treat Skin Cancer... No Surgery Required??? Dr. Raza Bokhari, CEO and Chairman, Medicus Pharma Ltd. full c817fe33-e06c-44b7-81fc-797b0cd070c9 https://share.transistor.fm/s/e736e96b This week on BioTech Nation, Dr. Raza Bokhari, CEO of Medicus Pharma, shares a new non-surgical treatment approach for basal cell carcinoma, the most common form of skin cancer. Their novel microneedle patch delivers a powerful cancer drug directly into the skin, avoiding the scarring, cost, and discomfort of Mohs surgery. With promising phase 2 trials underway in the US and Europe, this could change the way we treat millions of skin cancer cases every year. 

]]> This week on BioTech Nation, Dr. Raza Bokhari, CEO of Medicus Pharma, shares a new non-surgical treatment approach for basal cell carcinoma, the most common form of skin cancer. Their novel microneedle patch delivers a powerful cancer drug directly into the skin, avoiding the scarring, cost, and discomfort of Mohs surgery. With promising phase 2 trials underway in the US and Europe, this could change the way we treat millions of skin cancer cases every year. 

]]> Wed, 13 Aug 2025 17:11:11 -0700 Moira Gunn Moira Gunn 721 This week on BioTech Nation, Dr. Raza Bokhari, CEO of Medicus Pharma, shares a new non-surgical treatment approach for basal cell carcinoma, the most common form of skin cancer. Their novel microneedle patch delivers a powerful cancer drug directly into the skin, avoiding the scarring, cost, and discomfort of Mohs surgery. With promising phase 2 trials underway in the US and Europe, this could change the way we treat millions of skin cancer cases every year. 

]]> skin cancer, basal cell carcinoma, non-melanoma skin cancer, Medicus Pharma, Raza Bokhari, microneedle patch, Mohs surgery alternative, non-surgical treatment, Doxorubicin, transdermal drug delivery, cancer immunotherapy, dermatology, oncology innovation, clinical trials, phase 2 study, topical treatment, medical technology, biotech, cancer research, BioTech Nation No Part II: "Super Agers … An Evidenced-Based Approach to Longevity".... Dr. Eric Topol, Author, Prof., and EVP, Scripps Ranch 25029 25029 Part II: "Super Agers … An Evidenced-Based Approach to Longevity".... Dr. Eric Topol, Author, Prof., and EVP, Scripps Ranch full d6bf590f-a640-4943-a9ae-8acabca1bfa1 https://share.transistor.fm/s/c689d028 This week on BioTech Nation, Dr. Eric Topol returns to continue his conversation on, "Super Agers … An Evidenced-Based Approach to Longevity", his evidence-based approach to living longer, healthier lives. He shares why longevity must be accessible to everyone, not just the wealthy, and how new tools like AI, personalized diagnostics, and even gut hormones are reshaping the future of health. 

]]> This week on BioTech Nation, Dr. Eric Topol returns to continue his conversation on, "Super Agers … An Evidenced-Based Approach to Longevity", his evidence-based approach to living longer, healthier lives. He shares why longevity must be accessible to everyone, not just the wealthy, and how new tools like AI, personalized diagnostics, and even gut hormones are reshaping the future of health. 

]]> Wed, 06 Aug 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1028 This week on BioTech Nation, Dr. Eric Topol returns to continue his conversation on, "Super Agers … An Evidenced-Based Approach to Longevity", his evidence-based approach to living longer, healthier lives. He shares why longevity must be accessible to everyone, not just the wealthy, and how new tools like AI, personalized diagnostics, and even gut hormones are reshaping the future of health. 

]]> longevity, aging, super agers, Eric Topol, AI in healthcare, health equity, personalized medicine, GLP-1 drugs, gut hormones, polygenic risk scores, omics, diagnostics, vaccine misinformation, inflammation, preventive health, immune system, deep sleep, healthy lifestyle, microbiome, data-driven health, healthspan, public health, BioTech Nation No Part I: "Super Agers … An Evidenced-Based Approach to Longevity".... Dr. Eric Topol, Author, Prof., and EVP, Scripps Ranch 25028 25028 Part I: "Super Agers … An Evidenced-Based Approach to Longevity".... Dr. Eric Topol, Author, Prof., and EVP, Scripps Ranch full e5ba4d38-892e-4959-af21-c6d170267af1 https://share.transistor.fm/s/da72d696 This week on BioTech Nation, Dr. Eric Topol, professor and Executive Vice President at Scripps Research and author of "Super Agers … An Evidenced-Based Approach to Longevity", breaks down what science really says about aging well and what is just marketing. From immune-boosting cell therapy to the myth of magic longevity pills, Dr. Topol explains how evidence-based prevention, personalized health data, and AI are changing the future of aging. 

]]> This week on BioTech Nation, Dr. Eric Topol, professor and Executive Vice President at Scripps Research and author of "Super Agers … An Evidenced-Based Approach to Longevity", breaks down what science really says about aging well and what is just marketing. From immune-boosting cell therapy to the myth of magic longevity pills, Dr. Topol explains how evidence-based prevention, personalized health data, and AI are changing the future of aging. 

]]> Wed, 30 Jul 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1313 This week on BioTech Nation, Dr. Eric Topol, professor and Executive Vice President at Scripps Research and author of "Super Agers … An Evidenced-Based Approach to Longevity", breaks down what science really says about aging well and what is just marketing. From immune-boosting cell therapy to the myth of magic longevity pills, Dr. Topol explains how evidence-based prevention, personalized health data, and AI are changing the future of aging. 

]]> Eric Topol, Super Agers, longevity, aging, health span, lifespan, AI in medicine, immune system, cell therapy, personalized health, omics, prevention, chronic disease, Mediterranean diet, anti-aging myths, pseudoscience, evidence-based medicine, Scripps Research, BioTech Nation, Moira Gunn, healthy aging, wellness, welderly, ground truth, personalized medicine, nutrition and aging, alcohol and aging, inflammation, medical AI No Solving Genetic Diseases??? Dr. Neil Kumar, Founder & CEO, BridgeBio Pharma 24027 24027 Solving Genetic Diseases??? Dr. Neil Kumar, Founder & CEO, BridgeBio Pharma full 68ba412c-8068-4b7b-9608-c4c56401aa4a https://share.transistor.fm/s/5ed33364 This week on Biotech Nation, Dr. Neil Kumar, founder and CEO of BridgeBio Pharma. Dr. Kumar emphasizes that genetic diseases, particularly Mendelian diseases caused by single gene mutations, are solvable due to advancements in genetic measurement and understanding. He discusses BridgeBio Pharma's innovative corporate structure, which consists of multiple specialized companies under a centralized infrastructure to efficiently tackle various genetic diseases. This model allows for focused expertise on individual conditions while sharing common resources. Dr. Kumar highlights the company's commitment to using diverse therapeutic modalities, such as small molecules and gene therapies, to develop treatments that address the underlying causes of these diseases. 

]]> This week on Biotech Nation, Dr. Neil Kumar, founder and CEO of BridgeBio Pharma. Dr. Kumar emphasizes that genetic diseases, particularly Mendelian diseases caused by single gene mutations, are solvable due to advancements in genetic measurement and understanding. He discusses BridgeBio Pharma's innovative corporate structure, which consists of multiple specialized companies under a centralized infrastructure to efficiently tackle various genetic diseases. This model allows for focused expertise on individual conditions while sharing common resources. Dr. Kumar highlights the company's commitment to using diverse therapeutic modalities, such as small molecules and gene therapies, to develop treatments that address the underlying causes of these diseases. 

]]> Wed, 23 Jul 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1398 This week on Biotech Nation, Dr. Neil Kumar, founder and CEO of BridgeBio Pharma. Dr. Kumar emphasizes that genetic diseases, particularly Mendelian diseases caused by single gene mutations, are solvable due to advancements in genetic measurement and understanding. He discusses BridgeBio Pharma's innovative corporate structure, which consists of multiple specialized companies under a centralized infrastructure to efficiently tackle various genetic diseases. This model allows for focused expertise on individual conditions while sharing common resources. Dr. Kumar highlights the company's commitment to using diverse therapeutic modalities, such as small molecules and gene therapies, to develop treatments that address the underlying causes of these diseases. 

]]> Biotech Nation, Dr. Moira Gunn, Dr. Neil Kumar, BridgeBio Pharma, genetic diseases, Mendelian diseases, single gene mutations, genetic measurement, corporate structure, specialized companies, centralized infrastructure, therapeutic modalities, small molecules, gene therapies, disease treatment, innovation, drug discovery, patient care, biotechnology, pharmaceutical industr No No More Transfusions!!! Dr. John Scarlett, President and CEO of Geron Corporation 25026 25026 No More Transfusions!!! Dr. John Scarlett, President and CEO of Geron Corporation full bdb1d990-10a1-4ff8-a66f-da2c7f9f9f57 https://share.transistor.fm/s/15fd8fae Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval. 

]]> Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval. 

]]> Wed, 09 Jul 2025 13:17:57 -0700 Moira Gunn Moira Gunn 970 Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval. 

]]> blood transfusion, myelodysplastic syndrome (MDS), Imetelstat, telomerase inhibitor, Geron Corporation, phase three trials, transfusion dependence, cancer cells, bone marrow, PDUFA date, research and development No The Science of a Stronger Heart... Robert Blum, CEO, CytoKinetics 25025 25025 The Science of a Stronger Heart... Robert Blum, CEO, CytoKinetics full e5bf264f-a96e-413e-a3d7-2d4ea2be28fc https://share.transistor.fm/s/f45182d5 This week on BioTech Nation, Robert Blum, CEO of CytoKinetics, joins me to talk about the company’s decades-long mission to keep hearts beating stronger and longer. With one heart drug under FDA review and more in the pipeline, CytoKinetics is working to address the full spectrum of heart failure, from weak hearts to overactive ones, and even exploring muscle health beyond the heart to support healthy aging. 

]]> This week on BioTech Nation, Robert Blum, CEO of CytoKinetics, joins me to talk about the company’s decades-long mission to keep hearts beating stronger and longer. With one heart drug under FDA review and more in the pipeline, CytoKinetics is working to address the full spectrum of heart failure, from weak hearts to overactive ones, and even exploring muscle health beyond the heart to support healthy aging. 

]]> Wed, 02 Jul 2025 08:00:00 -0700 Moira Gunn Moira Gunn 947 This week on BioTech Nation, Robert Blum, CEO of CytoKinetics, joins me to talk about the company’s decades-long mission to keep hearts beating stronger and longer. With one heart drug under FDA review and more in the pipeline, CytoKinetics is working to address the full spectrum of heart failure, from weak hearts to overactive ones, and even exploring muscle health beyond the heart to support healthy aging. 

]]> heart failure, cardiac health, hypertrophic cardiomyopathy, FDA approval, Cytokinetics, Robert Blum, muscle activator, cardiac inhibitor, clinical trials, heart disease, biotech innovation, skeletal muscle, healthy aging, drug development, cardiology, heart function, gene-linked conditions, patient care, muscle biology, BioTech Nation No When Wounds Won't Heal... Jason Matuszewski, CEO, BioStem Technologies 25024 25024 When Wounds Won't Heal... Jason Matuszewski, CEO, BioStem Technologies full ec55c391-296e-4c1c-8edf-20e85c343b92 https://share.transistor.fm/s/8b00aee7 This week on BioTech Nation, BioSTEM Technologies CEO Jason Matuszewski explains how donated placental tissue is being used to treat chronic wounds that just won’t heal, from diabetic ulcers to pressure sores. With millions affected and traditional care often falling short, BioSTEM’s approach offers a new way to support healing and reduce scarring. 

]]> This week on BioTech Nation, BioSTEM Technologies CEO Jason Matuszewski explains how donated placental tissue is being used to treat chronic wounds that just won’t heal, from diabetic ulcers to pressure sores. With millions affected and traditional care often falling short, BioSTEM’s approach offers a new way to support healing and reduce scarring. 

]]> Wed, 25 Jun 2025 08:58:46 -0700 Moira Gunn Moira Gunn 586 This week on BioTech Nation, BioSTEM Technologies CEO Jason Matuszewski explains how donated placental tissue is being used to treat chronic wounds that just won’t heal, from diabetic ulcers to pressure sores. With millions affected and traditional care often falling short, BioSTEM’s approach offers a new way to support healing and reduce scarring. 

]]> wound care, chronic wounds, diabetic ulcers, pressure sores, placental tissue, BioSTEM Technologies, Jason Matuszewski, regenerative medicine, diabetic foot ulcers, venous leg ulcers, bedsores, amnion, chorion, Vendaje, tissue donation, immunoprivileged tissue, healing technology, wound healing, advanced wound treatment, biotech innovation, placenta-based therapy, medical waste repurposing, eye injury treatment, therapeutic tissue, growth factors, collagen, randomized controlled trials, regenerative biotech No Snake Bite Man meets Biotech Scientist creates Breakthrough Antivenom Vaccine … Dr. Jake Glanville, Founder, Chairman & CEO of Centivax 25023 25023 Snake Bite Man meets Biotech Scientist creates Breakthrough Antivenom Vaccine … Dr. Jake Glanville, Founder, Chairman & CEO of Centivax full baed7357-1169-4980-862c-ae9eb92444a5 https://share.transistor.fm/s/8fa56ef8 This week on BioTech Nation, Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider’s view of this Biotech Breakthrough – from the first telephone call through each significant step, all leading to the first breakthrough generalized antivenom vaccine in 125 years.  

]]> This week on BioTech Nation, Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider’s view of this Biotech Breakthrough – from the first telephone call through each significant step, all leading to the first breakthrough generalized antivenom vaccine in 125 years.  

]]> Mon, 16 Jun 2025 08:00:00 -0700 Moira Gunn Moira Gunn 2093 This week on BioTech Nation, Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider’s view of this Biotech Breakthrough – from the first telephone call through each significant step, all leading to the first breakthrough generalized antivenom vaccine in 125 years.  

]]> snakebite, antivenom, universal vaccine, Jake Glanville, Centivax, Tim Friede, biotechnology, broadly neutralizing antibodies, snake venom, universal antivenom, venom immunization, public health, neglected tropical diseases, antibody engineering, phage display, serum testing, human antibodies, pandemic prevention, Gates Foundation, Peter Kwong, ethical biotech, vaccine innovation, venomous snakes, global health, science breakthrough, immune system, biotech entrepreneurship No What’s Next in Health? Highlights from NextMed 2025... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 25022 25022 What’s Next in Health? Highlights from NextMed 2025... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full ce3ef1ab-e8aa-49ec-b4c6-3c76bceba99e https://share.transistor.fm/s/ea922997 This week on BioTech Nation, Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, returns with highlights from the 2025 NextMed Health conference. From AI-powered health agents to voice-based disease detection, hear what’s emerging at the intersection of medicine, technology, and global health equity. 

]]> This week on BioTech Nation, Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, returns with highlights from the 2025 NextMed Health conference. From AI-powered health agents to voice-based disease detection, hear what’s emerging at the intersection of medicine, technology, and global health equity. 

]]> Wed, 11 Jun 2025 20:58:19 -0700 Moira Gunn Moira Gunn 689 This week on BioTech Nation, Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, returns with highlights from the 2025 NextMed Health conference. From AI-powered health agents to voice-based disease detection, hear what’s emerging at the intersection of medicine, technology, and global health equity. 

]]> NextMed Health, Daniel Kraft, Tech Nation Health, health innovation, AI in medicine, digital health, voice biomarkers, personalized health, virtual health agents, early disease detection, wearable technology, health span, lifespan, global health equity, healthcare access, proactive care, generative health, smart health tools, medical AI, future of medicine, health tech trends, patient empowerment, mobile health, Jivi AI, NextMed 2025, Moira Gunn No How Can a Treatment Become a Vaccine??? Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics 25021 25021 How Can a Treatment Become a Vaccine??? Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics full 9c036b28-a043-4059-8fd5-74e4aa9470ae https://share.transistor.fm/s/51f1af2d Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body's immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.

]]> Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body's immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.

]]> Wed, 11 Jun 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1413 Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body's immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.

]]> moira gunn, peter demuth, elicio therapeutics, biotech, ctDNA, circulating tumor DNA, early detection, cancer cells, immune cells, treatment, vaccine, Eliseo Therapeutics, innovative approach, revolutionary, personalized cancer treatments, pancreatic cancer, KRAS mutation No PART II: A Regenerative Leap for Epilepsy… Dr. Cory Nicholas, Co-Founder and CEO, Neurona Therapeutics 25020 25020 PART II: A Regenerative Leap for Epilepsy… Dr. Cory Nicholas, Co-Founder and CEO, Neurona Therapeutics full 94c13709-f438-48ac-9f52-8b6b637ffe48 https://share.transistor.fm/s/9b5fbbca This week on BioTech Nation, Dr. Cory Nicholas, CEO of Neurona Therapeutics, returns for part two. With early results now in from Neurona’s first clinical trial, patients with severe epilepsy are seeing dramatic improvements, including seizure reductions of over 90 percent, and even full remission in some cases. This one-time treatment delivers new brain cells that help calm seizure activity without the side effects of traditional medications or the risks of surgery.

]]> This week on BioTech Nation, Dr. Cory Nicholas, CEO of Neurona Therapeutics, returns for part two. With early results now in from Neurona’s first clinical trial, patients with severe epilepsy are seeing dramatic improvements, including seizure reductions of over 90 percent, and even full remission in some cases. This one-time treatment delivers new brain cells that help calm seizure activity without the side effects of traditional medications or the risks of surgery.

]]> Wed, 21 May 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1623 This week on BioTech Nation, Dr. Cory Nicholas, CEO of Neurona Therapeutics, returns for part two. With early results now in from Neurona’s first clinical trial, patients with severe epilepsy are seeing dramatic improvements, including seizure reductions of over 90 percent, and even full remission in some cases. This one-time treatment delivers new brain cells that help calm seizure activity without the side effects of traditional medications or the risks of surgery.

]]> epilepsy, seizure treatment, brain health, Neurona Therapeutics, Dr. Cory Nicholas, one-time therapy, new medical treatment, brain balance, alternative to medication, breakthrough in epilepsy, PTSD, Alzheimer’s, brain injury, BioTech Nation, Moira Gunn, restoring brain function, regenerative therapy, drug-resistant epilepsy, brain repair, future of medicine, neuroscience innovation No PART 1: A Regenerative Leap for Epilepsy…Dr. Cory Nicholas, Co-Founder and CEO, Neurona Therapeutics 25019 25019 PART 1: A Regenerative Leap for Epilepsy…Dr. Cory Nicholas, Co-Founder and CEO, Neurona Therapeutics full da25a33a-8919-43fd-8e82-b962439cdf2a https://share.transistor.fm/s/08c55288 This week on BioTech Nation, Dr. Cory Nicholas, Co-Founder and CEO of Neurona Therapeutics, discusses their groundbreaking success in treating drug-resistant epilepsy. With a single, targeted delivery of lab-grown brain cells, Neurona is offering not just symptom control but the possibility of long-term seizure relief. This is Part 1 of a two-part series exploring the future of regenerative medicine in neurology.

]]> This week on BioTech Nation, Dr. Cory Nicholas, Co-Founder and CEO of Neurona Therapeutics, discusses their groundbreaking success in treating drug-resistant epilepsy. With a single, targeted delivery of lab-grown brain cells, Neurona is offering not just symptom control but the possibility of long-term seizure relief. This is Part 1 of a two-part series exploring the future of regenerative medicine in neurology.

]]> Wed, 14 May 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1467 This week on BioTech Nation, Dr. Cory Nicholas, Co-Founder and CEO of Neurona Therapeutics, discusses their groundbreaking success in treating drug-resistant epilepsy. With a single, targeted delivery of lab-grown brain cells, Neurona is offering not just symptom control but the possibility of long-term seizure relief. This is Part 1 of a two-part series exploring the future of regenerative medicine in neurology.

]]> epilepsy, regenerative medicine, Neurona Therapeutics, Dr. Cory Nicholas, brain health, GABA neurons, seizure treatment, drug-resistant epilepsy, cell therapy, neuroscience, PTSD, Alzheimer’s, Parkinson’s, neural repair, one-time therapy, biotech innovation, brain balance, neurological disorders, BioTech Nation, Moira Gunn, interneurons, neurotechnology, medical breakthrough, neuropsychiatric conditions, brain trauma, clinical trials No Fighting Cancer, Easing Pain... Dr. Lorin Johnson, CSO, Glycyx Therapeutics 25018 25018 Fighting Cancer, Easing Pain... Dr. Lorin Johnson, CSO, Glycyx Therapeutics full 565927ab-b97b-4f93-9c0a-b93c87f4b9f3 https://share.transistor.fm/s/6147d3e0 This week on BioTech Nation, we explore a new approach to cancer treatment that could help patients manage pain without compromising their care. Dr. Lorin Johnson, CSO of Glycyx Therapeutics explains how a new once-daily pill could help patients manage pain without blocking their treatment.

]]> This week on BioTech Nation, we explore a new approach to cancer treatment that could help patients manage pain without compromising their care. Dr. Lorin Johnson, CSO of Glycyx Therapeutics explains how a new once-daily pill could help patients manage pain without blocking their treatment.

]]> Wed, 07 May 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1043 This week on BioTech Nation, we explore a new approach to cancer treatment that could help patients manage pain without compromising their care. Dr. Lorin Johnson, CSO of Glycyx Therapeutics explains how a new once-daily pill could help patients manage pain without blocking their treatment.

]]> biotech, entrepreneurship, bioentrepreneurship No Freezing Out Chronic Pain…Sameer Sabir CEO, Brixton Biosciences 25017 25017 Freezing Out Chronic Pain…Sameer Sabir CEO, Brixton Biosciences full 95a86151-a2f4-43cc-85f5-21912f6d2e6b https://share.transistor.fm/s/09bbb432 This week on BioTech Nation, Sameer Sabir, CEO of Brixton Biosciences, shares how their breakthrough injectable cold therapy, Neural Ice, could offer lasting relief for osteoarthritis pain. With a drug-free, nerve-targeting approach currently in clinical trials, this innovation may change how we treat joint pain without pills or repeated steroid injections.

]]> This week on BioTech Nation, Sameer Sabir, CEO of Brixton Biosciences, shares how their breakthrough injectable cold therapy, Neural Ice, could offer lasting relief for osteoarthritis pain. With a drug-free, nerve-targeting approach currently in clinical trials, this innovation may change how we treat joint pain without pills or repeated steroid injections.

]]> Wed, 30 Apr 2025 08:00:00 -0700 Moira Gunn Moira Gunn 861 This week on BioTech Nation, Sameer Sabir, CEO of Brixton Biosciences, shares how their breakthrough injectable cold therapy, Neural Ice, could offer lasting relief for osteoarthritis pain. With a drug-free, nerve-targeting approach currently in clinical trials, this innovation may change how we treat joint pain without pills or repeated steroid injections.

]]> Neural Ice, Brixton Biosciences, osteoarthritis pain, chronic pain treatment, injectable cold therapy, nerve pain relief, drug-free pain relief, clinical trials, breakthrough device, FDA breakthrough, knee pain, hip pain, thumb joint pain, pain management innovation, nerve targeting therapy, cold therapy, Biotech Nation, Sameer Sabir, Moira Gunn, medical device innovation, alternative to steroids, non-opioid pain relief, musculoskeletal pain, regenerative medicine, healthcare innovation No Beyond the One-Size-Fits-All Cure... Jeff Liter, Founder & CEO, Luminary Therapeutics 25016 25016 Beyond the One-Size-Fits-All Cure... Jeff Liter, Founder & CEO, Luminary Therapeutics full 5b989a2c-d591-4135-bfea-2911f6b2cf9d https://share.transistor.fm/s/e1620e84 This week on BioTech Nation, Luminary Therapeutics CEO Jeff Liter shares how his team is working to make advanced cell therapy easier to access and more affordable. Instead of using each patient’s own cells, they use healthy donor cells that are ready to go. This approach could help more people get treated for cancer and autoimmune diseases like lupus, with just a single dose. 

]]> This week on BioTech Nation, Luminary Therapeutics CEO Jeff Liter shares how his team is working to make advanced cell therapy easier to access and more affordable. Instead of using each patient’s own cells, they use healthy donor cells that are ready to go. This approach could help more people get treated for cancer and autoimmune diseases like lupus, with just a single dose. 

]]> Wed, 23 Apr 2025 08:00:00 -0700 Moira Gunn Moira Gunn 681 This week on BioTech Nation, Luminary Therapeutics CEO Jeff Liter shares how his team is working to make advanced cell therapy easier to access and more affordable. Instead of using each patient’s own cells, they use healthy donor cells that are ready to go. This approach could help more people get treated for cancer and autoimmune diseases like lupus, with just a single dose. 

]]> cell therapy, cancer treatment, autoimmune disease, lupus, multiple myeloma, non-Hodgkin lymphoma, immunotherapy, off-the-shelf treatment, biotech innovation, Luminary Therapeutics, Jeff Liter, accessible medicine, affordable healthcare, one-dose therapy, donor cells, medical breakthrough, personalized medicine alternative, Biotech Nation, Moira Gunn No Beyond Pills and Shots... Sean Ainsworth, CEO, Immusoft 25015 25015 Beyond Pills and Shots... Sean Ainsworth, CEO, Immusoft full c6887e3d-cff5-4fbf-a71f-4fd9e6e70c32 https://share.transistor.fm/s/df690c4a This week on BioTech Nation, Sean Ainsworth, CEO of ImmuSoft, explains how modifying the body’s own B cells to produce therapeutic proteins could revolutionize drug delivery. From improving treatment for rare diseases like Hurler syndrome to potentially replacing injections for autoimmune and metabolic conditions, this new approach opens the door to long-term, patient-specific solutions.

]]> This week on BioTech Nation, Sean Ainsworth, CEO of ImmuSoft, explains how modifying the body’s own B cells to produce therapeutic proteins could revolutionize drug delivery. From improving treatment for rare diseases like Hurler syndrome to potentially replacing injections for autoimmune and metabolic conditions, this new approach opens the door to long-term, patient-specific solutions.

]]> Wed, 16 Apr 2025 08:00:00 -0700 Moira Gunn Moira Gunn 764 This week on BioTech Nation, Sean Ainsworth, CEO of ImmuSoft, explains how modifying the body’s own B cells to produce therapeutic proteins could revolutionize drug delivery. From improving treatment for rare diseases like Hurler syndrome to potentially replacing injections for autoimmune and metabolic conditions, this new approach opens the door to long-term, patient-specific solutions.

]]> B cells, gene therapy, drug delivery, chronic disease, Hurler syndrome, therapeutic proteins, ImmuSoft, Sean Ainsworth, biotech, GLP-1, autoimmune disease, cell therapy, rare disease, protein production, BioTech Nation No Breaking Barriers in Brain Cancer... Dr. Thomas Chen, Founder and CEO, NeOnc Technologies 25014 25014 Breaking Barriers in Brain Cancer... Dr. Thomas Chen, Founder and CEO, NeOnc Technologies full 116a1891-5d31-4056-96e2-2cdbc8f09373 https://share.transistor.fm/s/03aaf536 This week on BioTech Nation, Dr. Thomas Chen, Director of Neuro-Oncology at USC and Founder of NeOnc Technologies, shares treating glioblastoma by delivering a drug directly to the brain through nasal inhalation changes the drug delivery game, bypassing the blood-brain barrier. This technique is achieving results in clinical trials.

]]> This week on BioTech Nation, Dr. Thomas Chen, Director of Neuro-Oncology at USC and Founder of NeOnc Technologies, shares treating glioblastoma by delivering a drug directly to the brain through nasal inhalation changes the drug delivery game, bypassing the blood-brain barrier. This technique is achieving results in clinical trials.

]]> Wed, 09 Apr 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1479 This week on BioTech Nation, Dr. Thomas Chen, Director of Neuro-Oncology at USC and Founder of NeOnc Technologies, shares treating glioblastoma by delivering a drug directly to the brain through nasal inhalation changes the drug delivery game, bypassing the blood-brain barrier. This technique is achieving results in clinical trials.

]]> brain cancer, glioblastoma, brain tumor treatment, blood-brain barrier, nasal drug delivery, NeOnc Technologies, Dr. Thomas Chen, USC Neuro-Oncology, POH compound, perillyl alcohol, clinical trials, brain cancer research, innovative cancer treatment, targeted drug delivery, phase 2 clinical trial, IDH1 mutation, neuro-oncology, new cancer therapies, glioblastoma survival, brain cancer breakthrough, BioTech Nation, Moira Gunn, cancer treatment innovation, FDA-approved clinical trials, oncology advancements, tumor reduction, nasal brain delivery No The Future of Synthetic Biology... Dr. John Cumbers, Founder & CEO, SynBioBeta 25013 25013 The Future of Synthetic Biology... Dr. John Cumbers, Founder & CEO, SynBioBeta full c70acbce-306d-4ec6-b762-316288f7fb90 https://share.transistor.fm/s/1b99daf8 This week on BioTech Nation, I speak with Dr. John Cumbers, founder and CEO of SynBioBeta, the annual synthetic biology conference. We discuss how biology, AI, and technology are transforming industries, covering tracks on human health, planetary health, and hyperscale biology. SynBioBeta 2025 will take place in San Jose, CA, from May 5 to 8.

]]> This week on BioTech Nation, I speak with Dr. John Cumbers, founder and CEO of SynBioBeta, the annual synthetic biology conference. We discuss how biology, AI, and technology are transforming industries, covering tracks on human health, planetary health, and hyperscale biology. SynBioBeta 2025 will take place in San Jose, CA, from May 5 to 8.

]]> Wed, 02 Apr 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1133 This week on BioTech Nation, I speak with Dr. John Cumbers, founder and CEO of SynBioBeta, the annual synthetic biology conference. We discuss how biology, AI, and technology are transforming industries, covering tracks on human health, planetary health, and hyperscale biology. SynBioBeta 2025 will take place in San Jose, CA, from May 5 to 8.

]]> synthetic biology, SynBio Beta, AI and biotech, biotechnology conference, human health, planetary health, hyperscale biology, bioeconomy, biotech innovations, SynBio Beta 2025, biomanufacturing, future of biotech, bioengineering, biotech community, AI in biology, SynBio Beta conference, synthetic biology trends, bio and AI, biotech networking, biotech advancements, biotech startups, San Jose biotech event, DNA synthesizer, bioeconomy growth, space and biology, biopharma, climate tech, engineered human therapies, regenerative medicine, future of science, biotech ecosystem, biomanufacturing technology, synthetic biology tools, biotech education, SynBio Beta registration, AI and biopharma, biotech innovation summit, global biotech leaders, BioTech Nation, SynBio Beta discount No Reimagining Bone Marrow Transplants... Kevin Caldwell, Co-Founder & CEO, Ossium Health 25012 25012 Reimagining Bone Marrow Transplants... Kevin Caldwell, Co-Founder & CEO, Ossium Health full f8ae3e03-338f-4912-b079-80fb4116f09e https://share.transistor.fm/s/d0243a7a This week on BioTech Nation, Ossium Health co-founder and CEO Kevin Caldwell shares how their breakthrough approach is changing bone marrow transplants. By cryobanking marrow from organ donors, Ossium is reducing wait times, improving access, and preparing for future emergencies. With support from BARDA and promising clinical trial results, this new system could help thousands more receive lifesaving transplants—right when they need them. 

]]> This week on BioTech Nation, Ossium Health co-founder and CEO Kevin Caldwell shares how their breakthrough approach is changing bone marrow transplants. By cryobanking marrow from organ donors, Ossium is reducing wait times, improving access, and preparing for future emergencies. With support from BARDA and promising clinical trial results, this new system could help thousands more receive lifesaving transplants—right when they need them. 

]]> Wed, 26 Mar 2025 08:00:00 -0700 Moira Gunn Moira Gunn 809 This week on BioTech Nation, Ossium Health co-founder and CEO Kevin Caldwell shares how their breakthrough approach is changing bone marrow transplants. By cryobanking marrow from organ donors, Ossium is reducing wait times, improving access, and preparing for future emergencies. With support from BARDA and promising clinical trial results, this new system could help thousands more receive lifesaving transplants—right when they need them. 

]]> Bone marrow transplant, Bone marrow donation, Cryobanking, Organ donors, Blood cancer treatment, Leukemia, Lymphoma, Multiple myeloma, Stem cell therapy, Healthcare innovation, Cancer treatment, Transplant logistics, Clinical trials, Radiation sickness treatment, Public health preparedness, Biomedical innovation, Personalized medicine, Advanced therapies, Medical innovation, Regenerative medicine, Ossium Health, Ossium HOPE Program, Bone marrow registry, PRESERVE trial, BARDA No When Your Immune System Attacks You... Prof. Dr. Niels Riedemann, Co-Founder & CEO, Inflarx 25011 25011 When Your Immune System Attacks You... Prof. Dr. Niels Riedemann, Co-Founder & CEO, Inflarx full 798d2bce-be01-4925-a31c-b68316590f59 https://share.transistor.fm/s/462df084 This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies. 

]]> This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies. 

]]> Wed, 19 Mar 2025 08:00:00 -0700 Moira Gunn Moira Gunn 1312 This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies. 

]]> immune system, overactive immune response, autoimmune diseases, inflammation, rheumatoid arthritis, severe COVID-19, lung failure, ARDS, immune system attack, InflaRx, Niels Riedemann, C5a inhibitor, FDA emergency use, new treatments, biotech innovation, medical research, health technology, immune regulation, pandemic preparedness, biotech breakthroughs, immune therapy, medical advancements, BioTech Nation, Moira Gunn, healthcare innovation, government-backed research, chronic inflammation, life-threatening conditions, immune response control, drug development, medical science No Designing Healthcare for People... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 25010 25010 Designing Healthcare for People... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full 0028c5cb-5fa4-4de7-a3ac-70775b4a6e9b https://share.transistor.fm/s/dccee350 This week on BioTech Nation, Dr. Daniel Kraft explores how smarter design can make healthcare easier, less stressful, and more effective. From hospitals built for patient comfort to medical apps that adapt to your needs, the way we experience healthcare is evolving. Learn how design thinking and empathy are shaping the future of medicine. 

]]> This week on BioTech Nation, Dr. Daniel Kraft explores how smarter design can make healthcare easier, less stressful, and more effective. From hospitals built for patient comfort to medical apps that adapt to your needs, the way we experience healthcare is evolving. Learn how design thinking and empathy are shaping the future of medicine. 

]]> Wed, 12 Mar 2025 08:00:00 -0700 Moira Gunn Moira Gunn 479 This week on BioTech Nation, Dr. Daniel Kraft explores how smarter design can make healthcare easier, less stressful, and more effective. From hospitals built for patient comfort to medical apps that adapt to your needs, the way we experience healthcare is evolving. Learn how design thinking and empathy are shaping the future of medicine. 

]]> healthcare design, patient experience, medical technology, hospital innovation, user-friendly healthcare, design thinking, smart hospitals, digital health, patient-centered care, health apps, empathy in medicine, healthcare accessibility, innovation in healthcare, medical technology design, human-centered healthcare No Why One Drug Isn't Always Enough... Rich Daly, President & CEO, Catalyst Pharmaceuticals 25009 25009 Why One Drug Isn't Always Enough... Rich Daly, President & CEO, Catalyst Pharmaceuticals full d11c2956-0480-4779-a1d8-4f32ba0f4036 https://share.transistor.fm/s/3318f4ee This week on BioTech Nation, Catalyst Pharmaceuticals CEO Rich Daly discusses the complexities of treating epilepsy and rare diseases. From the challenges of polypharmacy—where patients need multiple drugs to manage a single condition—to the hurdles of diagnosing and treating ultra-rare diseases. 

]]> This week on BioTech Nation, Catalyst Pharmaceuticals CEO Rich Daly discusses the complexities of treating epilepsy and rare diseases. From the challenges of polypharmacy—where patients need multiple drugs to manage a single condition—to the hurdles of diagnosing and treating ultra-rare diseases. 

]]> Wed, 05 Mar 2025 08:00:00 -0800 Moira Gunn Moira Gunn 1141 This week on BioTech Nation, Catalyst Pharmaceuticals CEO Rich Daly discusses the complexities of treating epilepsy and rare diseases. From the challenges of polypharmacy—where patients need multiple drugs to manage a single condition—to the hurdles of diagnosing and treating ultra-rare diseases. 

]]> epilepsy, rare diseases, medical treatment, multiple medications, polypharmacy, Catalyst Pharmaceuticals, patient care, drug accessibility, seizure management, Ficompa, Firdapse, Lambert Eaton Myasthenic Syndrome, epilepsy treatment, medication challenges, pharmaceutical innovation, healthcare access, rare disease treatment, prescription drugs, patient support, specialty pharmacy, chronic illness, healthcare solutions, biotech industry, medical breakthroughs, Biotech Nation, Dr. Moira Gunn, Rich Daly No A Second Chance for an ALS Drug... Dr. Ari Azhir, Founder & CEO, Neuvivo 25008 25008 A Second Chance for an ALS Drug... Dr. Ari Azhir, Founder & CEO, Neuvivo full e4c7c91e-fecb-439b-b08b-4303f0f114c4 https://share.transistor.fm/s/8e707e4b This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s. 

]]> This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s. 

]]> Wed, 26 Feb 2025 08:00:00 -0800 Moira Gunn Moira Gunn 1067 This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s. 

]]> ALS, neurodegenerative disease, Neuvivo, Dr. Ari Azhir, biotech, FDA approval, clinical trials, phase two trials, Huntington’s disease, Alzheimer’s disease, vascular dementia, immune system, drug development, orphan drug, ALS treatment, neurological disorders, biotech innovation, pharmaceutical research, muscle function, survival benefit, medical breakthrough, biotech entrepreneurship, regenerative medicine, scientific discovery, drug repurposing, biotech investment, healthcare advancements, FDA submission, patient survival, neuroscience, biotechnology industry, drug approval process No The Mystery of "Dark" Proteins... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 25007 25007 The Mystery of "Dark" Proteins... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full c140863a-ff24-4853-86a2-71c9189bc50d https://share.transistor.fm/s/6d658182  This week on BioTech Nation, Dr. Daniel Kraft explores the discovery of "dark" proteins, thousands of previously unknown proteins in the human body. Scientists believe these hidden proteins could be the key to detecting diseases earlier and developing new treatments. 

]]>  This week on BioTech Nation, Dr. Daniel Kraft explores the discovery of "dark" proteins, thousands of previously unknown proteins in the human body. Scientists believe these hidden proteins could be the key to detecting diseases earlier and developing new treatments. 

]]> Thu, 20 Feb 2025 08:00:00 -0800 Moira Gunn Moira Gunn 569  This week on BioTech Nation, Dr. Daniel Kraft explores the discovery of "dark" proteins, thousands of previously unknown proteins in the human body. Scientists believe these hidden proteins could be the key to detecting diseases earlier and developing new treatments. 

]]> proteomics, dark proteins, protein discovery, disease detection, early diagnosis, personalized medicine, biotech, healthcare innovation, medical research, protein analysis, biomarker discovery, precision medicine, hidden proteins, protein science, new treatments, health technology, digital health, medical breakthroughs, Daniel Kraft, BioTech Nation No 9 Million Samples: A New Era of Medicine... Dr. Lincoln Nadauld, President & CEO, Culmination Bio 25006 25006 9 Million Samples: A New Era of Medicine... Dr. Lincoln Nadauld, President & CEO, Culmination Bio full cba5c29d-4afe-4e3d-8916-0fe9c3318a16 https://share.transistor.fm/s/c45dca84 This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.

]]> This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.

]]> Wed, 12 Feb 2025 08:00:00 -0800 Moira Gunn Moira Gunn 1107 This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.

]]> Culmination Bio, biospecimens, patient data, personalized medicine, disease diagnosis, cancer research, healthcare innovation, medical technology, predictive biomarkers, tissue samples, health outcomes, clinical history, digital diagnostics, healthcare research, Intermountain Health, genetic research, disease treatment, future of medicine, biotech advancements, patient care. No Mobility: The New Vital Sign….Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 25005 25005 Mobility: The New Vital Sign….Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full 08d89ca6-91d0-4671-980f-e2c12ac2f068 https://share.transistor.fm/s/ac1340c4 This week on Biotech Nation, Dr. Daniel Kraft discusses why mobility is emerging as a key indicator of health, just like heart rate or blood pressure. From wearable tech that tracks your gait to AI-powered exoskeletons and brain-computer interfaces, new innovations are transforming how we measure and maintain movement. 

]]> This week on Biotech Nation, Dr. Daniel Kraft discusses why mobility is emerging as a key indicator of health, just like heart rate or blood pressure. From wearable tech that tracks your gait to AI-powered exoskeletons and brain-computer interfaces, new innovations are transforming how we measure and maintain movement. 

]]> Wed, 05 Feb 2025 08:00:00 -0800 Moira Gunn Moira Gunn 830 This week on Biotech Nation, Dr. Daniel Kraft discusses why mobility is emerging as a key indicator of health, just like heart rate or blood pressure. From wearable tech that tracks your gait to AI-powered exoskeletons and brain-computer interfaces, new innovations are transforming how we measure and maintain movement. 

]]> mobility, vital sign, health technology, wearable tech, AI in healthcare, exoskeletons, brain-computer interfaces, digital health, fall prevention, physical therapy, aging, gait analysis, smart wearables, rehabilitation, neurology, musculoskeletal health, assistive technology, mobility tracking, biomechanics, medical innovation, future of healthcare, TechNation, Biotech Nation, Dr. Daniel Kraft, Moira Gunn No Reprogramming the Future... Dr. Martin Borch Jensen and Dr. Francisco LePort, Gordian Biotechnology 25004 25004 Reprogramming the Future... Dr. Martin Borch Jensen and Dr. Francisco LePort, Gordian Biotechnology full e6395510-9b17-4b97-b011-e1353d8e4c45 https://share.transistor.fm/s/4b4ecf45 This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.

]]> This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.

]]> Wed, 29 Jan 2025 08:00:00 -0800 Moira Gunn Moira Gunn 1551 This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.

]]> aging, age-related diseases, drug discovery, gene therapy, biotechnology, Gordian Biotechnology, arthritis, heart failure, fatty liver disease, medical innovation, clinical trials, healthcare technology, precision medicine, regenerative medicine, biotech research, disease prevention, pharmaceutical advancements, medical breakthroughs, biotech startups, Moira Gunn, Biotech Nation podcast No One Drug, Many Diseases??? Dr. David Fajgenbaum, UPenn School of Medicine Professor and President of Every Cure 25003 25003 One Drug, Many Diseases??? Dr. David Fajgenbaum, UPenn School of Medicine Professor and President of Every Cure full 4a43337a-6563-4d7c-a10c-81cc07c297ed https://share.transistor.fm/s/6b975344 Not just seeking treatment for every disease, but making sure the treatments we have already developed are being used in every possible way. I speak with Dr. David Fajgenbaum (Fay-gen-baum), a Professor of Translational Medicine and Human Genetics at the University of Pennsylvania School of Medicine, and President of Every Cure.

]]> Not just seeking treatment for every disease, but making sure the treatments we have already developed are being used in every possible way. I speak with Dr. David Fajgenbaum (Fay-gen-baum), a Professor of Translational Medicine and Human Genetics at the University of Pennsylvania School of Medicine, and President of Every Cure.

]]> Wed, 22 Jan 2025 08:00:00 -0800 Moira Gunn Moira Gunn 1676 Not just seeking treatment for every disease, but making sure the treatments we have already developed are being used in every possible way. I speak with Dr. David Fajgenbaum (Fay-gen-baum), a Professor of Translational Medicine and Human Genetics at the University of Pennsylvania School of Medicine, and President of Every Cure.

]]> Dr. David Fajgenbaum, moira gunn, tech nation, biotech nation, every cure No A Daily Pill to Fight Autoimmune Diseases…Ben Zimmer, CEO of Priovant Therapeutics 25002 25002 A Daily Pill to Fight Autoimmune Diseases…Ben Zimmer, CEO of Priovant Therapeutics full 43b0c9e4-6b32-4f46-a35e-87e9e25d37b5 https://share.transistor.fm/s/8b60210b This week on Biotech Nation, Priovant Therapeutics CEO Ben Zimmer shares how their once-a-day pill could transform the treatment of severe autoimmune diseases like dermatomyositis and non-infectious uveitis. With phase 3 trials in progress, Priovant is offering hope to patients with few modern treatment options.

]]> This week on Biotech Nation, Priovant Therapeutics CEO Ben Zimmer shares how their once-a-day pill could transform the treatment of severe autoimmune diseases like dermatomyositis and non-infectious uveitis. With phase 3 trials in progress, Priovant is offering hope to patients with few modern treatment options.

]]> Wed, 15 Jan 2025 08:00:00 -0800 Moira Gunn Moira Gunn 1313 This week on Biotech Nation, Priovant Therapeutics CEO Ben Zimmer shares how their once-a-day pill could transform the treatment of severe autoimmune diseases like dermatomyositis and non-infectious uveitis. With phase 3 trials in progress, Priovant is offering hope to patients with few modern treatment options.

]]> biotech, entrepreneurship, bioentrepreneurship No Fighting Inflammation, and Alzheimer's??? Dr. David Bearss, President & CEO Halia Therapeutics 25001 25001 Fighting Inflammation, and Alzheimer's??? Dr. David Bearss, President & CEO Halia Therapeutics full 6579cc0a-1e0c-402a-b961-e6d0dbf79e20 https://share.transistor.fm/s/ae13bc73 In this week's episode of BioTech Nation, Dr. David Bearss, President and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered protein complex critical in regulating inflammatory responses and its potential in treating chronic diseases like myelodysplastic syndrome and Alzheimer's. Dr. Bearss shares insights into Halia's groundbreaking approach and his relentless pursuit of medical breakthroughs.

]]> In this week's episode of BioTech Nation, Dr. David Bearss, President and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered protein complex critical in regulating inflammatory responses and its potential in treating chronic diseases like myelodysplastic syndrome and Alzheimer's. Dr. Bearss shares insights into Halia's groundbreaking approach and his relentless pursuit of medical breakthroughs.

]]> Wed, 08 Jan 2025 08:00:00 -0800 Moira Gunn Moira Gunn 1737 In this week's episode of BioTech Nation, Dr. David Bearss, President and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered protein complex critical in regulating inflammatory responses and its potential in treating chronic diseases like myelodysplastic syndrome and Alzheimer's. Dr. Bearss shares insights into Halia's groundbreaking approach and his relentless pursuit of medical breakthroughs.

]]> inflammation, alzheimer's, david bearss, halia therapeutics, moira gunn, biotech nation, tech nation No Alcohol-Associated Hepatitis Treatment on the Horizon!!! Dr. Jim Brown, CEO of DURECT 24053 24053 Alcohol-Associated Hepatitis Treatment on the Horizon!!! Dr. Jim Brown, CEO of DURECT full 99cf6e0f-d0b0-48e6-9e28-7aa1d63eca87 https://share.transistor.fm/s/c068fce3 Dr. Jim Brown from DURECT talks about their clinical trials for Alcohol-Associated Hepatitis, a condition for which there is no approved treatment.

]]> Dr. Jim Brown from DURECT talks about their clinical trials for Alcohol-Associated Hepatitis, a condition for which there is no approved treatment.

]]> Wed, 01 Jan 2025 08:00:00 -0800 Moira Gunn Moira Gunn 892 Dr. Jim Brown from DURECT talks about their clinical trials for Alcohol-Associated Hepatitis, a condition for which there is no approved treatment.

]]> alcohol-associated hepatitis, jim brown, durect, moira gunn, tech nation, biotech nation No Data for Good!!!... Sir Rory Collins, Oxford Professor and Principal Investigator, UK Biobank 24052 24052 Data for Good!!!... Sir Rory Collins, Oxford Professor and Principal Investigator, UK Biobank full 1e35526e-546f-4de5-901f-08d3a2015721 https://share.transistor.fm/s/daa6b587 Sir Rory Collins is a Professor of Medicine and Epidemiology at the University of Oxford and the Principal Investigator of the UK Biobank. With data from half a million people, it has served 30,000 scientists around the world, giving special support to young researchers and scientists in emergent countries.

]]> Sir Rory Collins is a Professor of Medicine and Epidemiology at the University of Oxford and the Principal Investigator of the UK Biobank. With data from half a million people, it has served 30,000 scientists around the world, giving special support to young researchers and scientists in emergent countries.

]]> Wed, 25 Dec 2024 08:00:00 -0800 Moira Gunn Moira Gunn 1534 Sir Rory Collins is a Professor of Medicine and Epidemiology at the University of Oxford and the Principal Investigator of the UK Biobank. With data from half a million people, it has served 30,000 scientists around the world, giving special support to young researchers and scientists in emergent countries.

]]> UK Biobank, health data, medical research, genetics, imaging, disease prevention, global scientists, human health, data analysis, biological samples, National Health Service, public health, big data, science collaboration, Sir Rory Collins, BioTech Nation No Building Technology and Solving Problems!!! Dave Pacitti, President & Head of the Americas, Siemens Healthineers 24051 24051 Building Technology and Solving Problems!!! Dave Pacitti, President & Head of the Americas, Siemens Healthineers full 6d6f120e-fc59-426d-9e64-fa5b2df90a5b https://share.transistor.fm/s/753347c5 When is a medical technology company more than a medical technology company? We’ll hear all about it when I speak with Dave Pacitti, the President and Head of the Americas at Siemens Healthineers. They’re out to solve problems bigger than the products they are known for.

]]> When is a medical technology company more than a medical technology company? We’ll hear all about it when I speak with Dave Pacitti, the President and Head of the Americas at Siemens Healthineers. They’re out to solve problems bigger than the products they are known for.

]]> Wed, 18 Dec 2024 08:00:00 -0800 Moira Gunn Moira Gunn 1230 When is a medical technology company more than a medical technology company? We’ll hear all about it when I speak with Dave Pacitti, the President and Head of the Americas at Siemens Healthineers. They’re out to solve problems bigger than the products they are known for.

]]> moira gunn, tech nation, biotech nation, siemens, healthineers, dave pacitti No Antidepressants Should Have Diagnostics??? Dr. Amit Etkin, Founder & CEO, Alto Neuroscience 24050 24050 Antidepressants Should Have Diagnostics??? Dr. Amit Etkin, Founder & CEO, Alto Neuroscience full ed438763-92a3-42be-a5b7-788d0492875a https://share.transistor.fm/s/8f955078 Major Depressive Disorder. Serious Depression. PTSD. Alto Neuroscience CEO, Dr. Amit Etkin talks about developing new and innovative drugs tied directly to each patient’s underlying biology. For every drug, there is a test...

]]> Major Depressive Disorder. Serious Depression. PTSD. Alto Neuroscience CEO, Dr. Amit Etkin talks about developing new and innovative drugs tied directly to each patient’s underlying biology. For every drug, there is a test...

]]> Wed, 11 Dec 2024 08:00:00 -0800 Moira Gunn Moira Gunn 1557 Major Depressive Disorder. Serious Depression. PTSD. Alto Neuroscience CEO, Dr. Amit Etkin talks about developing new and innovative drugs tied directly to each patient’s underlying biology. For every drug, there is a test...

]]> Major Depressive Disorder, PTSD, depression treatment, mental health, Alto Neuroscience, Dr. Amit Etkin, innovative drugs, personalized medicine, brain biology, mental health care, psychiatric disorders, targeted treatment, neuroscience, Biotech Nation, mental health innovation, hope for healing. No Can AI Discover Drugs Better Than Humans?? Dr. Vimal Mehta, Co-Founder & CEO BioXcel 24049 24049 Can AI Discover Drugs Better Than Humans?? Dr. Vimal Mehta, Co-Founder & CEO BioXcel full 8f5fc123-5475-44f6-b5c8-4441304e2df6 https://share.transistor.fm/s/e81f8b42 Discover how their AI technology is revolutionizing drug discovery with Dr. Vimal Mehta, Co-Founder and CEO BioXcel and how this is leading to the approval of their first drug for agitation in bipolar I and II and schizophrenia, and paving the way for new treatments.

]]> Discover how their AI technology is revolutionizing drug discovery with Dr. Vimal Mehta, Co-Founder and CEO BioXcel and how this is leading to the approval of their first drug for agitation in bipolar I and II and schizophrenia, and paving the way for new treatments.

]]> Wed, 04 Dec 2024 08:00:00 -0800 Moira Gunn Moira Gunn 1200 Discover how their AI technology is revolutionizing drug discovery with Dr. Vimal Mehta, Co-Founder and CEO BioXcel and how this is leading to the approval of their first drug for agitation in bipolar I and II and schizophrenia, and paving the way for new treatments.

]]> AIinDrugDiscovery, BioXcelTherapeutic, MachineLearningApproaches, UnbiasedApproach, ExistingKnowledge, DiseaseDrivers, NovelTreatments, BioTechInnovation, ArtificialIntelligence, FDAapproved, DrugDiscoveryAndDevelopment, ScientificResearch, BioTechIndustry, HealthcareInnovation, BiotechNation, VimalMehta, MoiraGunn No Food IS Medicine... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 24048 24048 Food IS Medicine... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full de41b90e-87c2-45bf-a675-b6a7563a326e https://share.transistor.fm/s/9858373b This week on Biotech Nation, Tech Nation Health Chief Correspondent, Dr. Daniel Kraft, talks about “food as medicine" and how eating real, minimally processed food can prevent chronic illnesses like diabetes and heart disease, starting with kids and school lunches. Programs like Eat Real and the federal Food is Medicine initiative are working to improve diets and health nationwide. 

]]> This week on Biotech Nation, Tech Nation Health Chief Correspondent, Dr. Daniel Kraft, talks about “food as medicine" and how eating real, minimally processed food can prevent chronic illnesses like diabetes and heart disease, starting with kids and school lunches. Programs like Eat Real and the federal Food is Medicine initiative are working to improve diets and health nationwide. 

]]> Wed, 27 Nov 2024 08:00:00 -0800 Moira Gunn Moira Gunn 637 This week on Biotech Nation, Tech Nation Health Chief Correspondent, Dr. Daniel Kraft, talks about “food as medicine" and how eating real, minimally processed food can prevent chronic illnesses like diabetes and heart disease, starting with kids and school lunches. Programs like Eat Real and the federal Food is Medicine initiative are working to improve diets and health nationwide. 

]]> food as medicine, real food, ultra-processed foods, school lunches, childhood obesity, type 2 diabetes, nutrition, dietary habits, health outcomes, Eat Real initiative, chronic diseases, food education, medically tailored meals, public health, food policy, school nutrition reform, proactive health, diet-related diseases, food subsidies, U.S. Department of Health and Human Services, Food is Medicine program, health and wellness, sustainability, sugar consumption, life expectancy, prevention, Daniel Kraft, Moira Gunn, NextMed Health, food advocacy, community health. No Rewiring the Brain... Dr. Peter Vanderklish, Chief Scientific Officer, Spinogenix 24047 24047 Rewiring the Brain... Dr. Peter Vanderklish, Chief Scientific Officer, Spinogenix full 14fb91a6-ebee-49d0-808e-add78f57a83f https://share.transistor.fm/s/8c063741 This week on BioTech Nation, Dr. Peter Vanderklish, Chief Scientific Officer at Spinogenix discusses their clinical trials focused on regenerating synapses to repair brain connections and offer hope for conditions like Alzheimer's, ALS, schizophrenia and depression. Phase 2 trials are underway. Check their website for patient recruitment information.

]]> This week on BioTech Nation, Dr. Peter Vanderklish, Chief Scientific Officer at Spinogenix discusses their clinical trials focused on regenerating synapses to repair brain connections and offer hope for conditions like Alzheimer's, ALS, schizophrenia and depression. Phase 2 trials are underway. Check their website for patient recruitment information.

]]> Wed, 20 Nov 2024 08:00:00 -0800 Moira Gunn Moira Gunn 1528 This week on BioTech Nation, Dr. Peter Vanderklish, Chief Scientific Officer at Spinogenix discusses their clinical trials focused on regenerating synapses to repair brain connections and offer hope for conditions like Alzheimer's, ALS, schizophrenia and depression. Phase 2 trials are underway. Check their website for patient recruitment information.

]]> brain health, synapse regeneration, Alzheimer's, ALS, schizophrenia, neurodegenerative diseases, Spinogenix, Dr. Peter Vanderklish, SBG-302, clinical trials, cognitive decline, synaptopathies, innovative treatments, memory loss, brain connections, neuroscience, medical breakthroughs, drug development, mental health, neurological disorders No Sepsis: First-Time-Ever Test... Dr. Rollie Carlson, CEO Immunexpress 24046 24046 Sepsis: First-Time-Ever Test... Dr. Rollie Carlson, CEO Immunexpress full c20e3b00-4159-4b5c-a0b5-ccc40de6d360 https://share.transistor.fm/s/bb896ff2 This week on BioTech Nation, Dr. Rollie Carlson, CEO of Immunexpress, talks about Sepsis—a deadly condition responsible for 1 in 5 deaths worldwide. Dr. Carlson talks about the FDA-cleared SeptiCyte test, a new tool that can quickly identify Sepsis within an hour, helping doctors treat it faster and avoid unnecessary antibiotics or even death.

]]> This week on BioTech Nation, Dr. Rollie Carlson, CEO of Immunexpress, talks about Sepsis—a deadly condition responsible for 1 in 5 deaths worldwide. Dr. Carlson talks about the FDA-cleared SeptiCyte test, a new tool that can quickly identify Sepsis within an hour, helping doctors treat it faster and avoid unnecessary antibiotics or even death.

]]> Wed, 13 Nov 2024 08:00:00 -0800 Moira Gunn Moira Gunn 762 This week on BioTech Nation, Dr. Rollie Carlson, CEO of Immunexpress, talks about Sepsis—a deadly condition responsible for 1 in 5 deaths worldwide. Dr. Carlson talks about the FDA-cleared SeptiCyte test, a new tool that can quickly identify Sepsis within an hour, helping doctors treat it faster and avoid unnecessary antibiotics or even death.

]]> Biotech Nation, Dr. Moira Gunn, Dr. Rollie Carlson, Immunexpress, SeptiCyte, sepsis, rapid diagnosis, life-threatening condition, infection response, antibiotics, SIRS, early detection, healthcare, global health, sepsis mortality, medical technology, hospital care No CRISPR Dilemma... Dr. Eben Kirksey, Anthropologist & Author, “The Mutant Project: Inside the Global Race to Genetically Modify Humans” 24045 24045 CRISPR Dilemma... Dr. Eben Kirksey, Anthropologist & Author, “The Mutant Project: Inside the Global Race to Genetically Modify Humans” full 83b57143-d61e-440f-8334-1968192c556b https://share.transistor.fm/s/24413d8d This week on BioTech Nation, we talk with Dr. Eben Kirksey about the ethical issues behind CRISPR, the gene-editing tool that made headlines with the birth of the first “CRISPR babies” in China. Dr. Kirksey shares his experiences investigating this controversial experiment and highlights the deeper questions it raises. He stresses the importance of public dialogue, urging us to consider carefully who benefits from such powerful technologies as we shape the future of gene editing. 

]]> This week on BioTech Nation, we talk with Dr. Eben Kirksey about the ethical issues behind CRISPR, the gene-editing tool that made headlines with the birth of the first “CRISPR babies” in China. Dr. Kirksey shares his experiences investigating this controversial experiment and highlights the deeper questions it raises. He stresses the importance of public dialogue, urging us to consider carefully who benefits from such powerful technologies as we shape the future of gene editing. 

]]> Wed, 06 Nov 2024 10:14:40 -0800 Moira Gunn Moira Gunn 2282 This week on BioTech Nation, we talk with Dr. Eben Kirksey about the ethical issues behind CRISPR, the gene-editing tool that made headlines with the birth of the first “CRISPR babies” in China. Dr. Kirksey shares his experiences investigating this controversial experiment and highlights the deeper questions it raises. He stresses the importance of public dialogue, urging us to consider carefully who benefits from such powerful technologies as we shape the future of gene editing. 

]]> CRISPR, gene editing, ethical issues, Dr. Eben Kirksey, Biotech Nation, Moira Gunn, CRISPR babies, China, genetic modification, He Jiankui, societal impact, eugenics, social divides, modern technology, public dialogue, science and justice, Mutant Project, biotechnology, genetic engineering, global innovation, healthcare ethics No AI & Better Health...Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 24044 24044 AI & Better Health...Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full bd4ede4a-46c6-422c-ab72-70cc7b97b36c https://share.transistor.fm/s/99a9496d This week on BioTech Nation, Dr. Daniel Kraft talks about how AI can personalize health advice using data from devices like your smartwatch. He explains how this technology can help people make better choices to stay healthy and avoid major illnesses. Dr. Kraft envisions AI as a personal health coach, offering real-time tips and reminders tailored to each person's needs.

]]> This week on BioTech Nation, Dr. Daniel Kraft talks about how AI can personalize health advice using data from devices like your smartwatch. He explains how this technology can help people make better choices to stay healthy and avoid major illnesses. Dr. Kraft envisions AI as a personal health coach, offering real-time tips and reminders tailored to each person's needs.

]]> Wed, 30 Oct 2024 08:00:00 -0700 Moira Gunn Moira Gunn 722 This week on BioTech Nation, Dr. Daniel Kraft talks about how AI can personalize health advice using data from devices like your smartwatch. He explains how this technology can help people make better choices to stay healthy and avoid major illnesses. Dr. Kraft envisions AI as a personal health coach, offering real-time tips and reminders tailored to each person's needs.

]]> AI, generative health, personalized health, wearables, behavior change, wellness, chronic disease prevention, health technology, digital health tools, smart devices, health coaching, data-driven insights, fitness tracking, personalized coaching, health nudges No A Smarter Path to Curing Diseases… Dr. Avak Kahvejian Founding CEO, Cellarity 24043 24043 A Smarter Path to Curing Diseases… Dr. Avak Kahvejian Founding CEO, Cellarity full 52af7726-41ae-4d13-803f-3a22b5bbfffc https://share.transistor.fm/s/2b245d00 Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.

]]> Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.

]]> Thu, 24 Oct 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1184 Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.

]]> Biotech, healthcare, drug discovery, cell behavior, holistic medicine, computational technology, AI in medicine, future of medicine, innovation, Cellarity, Dr. Avak Kahvejian, transcriptome, disease treatment, sickle cell disease, small molecules, pharmaceutical development, machine learning, Moira Gunn, Biotech Nation No Replacing Cells, Restoring Sight…Brian Culley, CEO, Lineage Cell Therapeutics 24042 24042 Replacing Cells, Restoring Sight…Brian Culley, CEO, Lineage Cell Therapeutics full 872eb28f-d527-49f8-86f8-4e4232e61866 https://share.transistor.fm/s/c626c455 Brian Culley, CEO of Lineage Cell Therapeutics, talks about a new approach to treating diseases called whole cell replacement therapy - which replaces damaged cells with new ones. Lineage is focusing this new therapy on dry age-related macular degeneration (AMD), a leading cause of blindness, through their collaboration with Genentech..

]]> Brian Culley, CEO of Lineage Cell Therapeutics, talks about a new approach to treating diseases called whole cell replacement therapy - which replaces damaged cells with new ones. Lineage is focusing this new therapy on dry age-related macular degeneration (AMD), a leading cause of blindness, through their collaboration with Genentech..

]]> Wed, 16 Oct 2024 08:00:00 -0700 Moira Gunn Moira Gunn 964 Brian Culley, CEO of Lineage Cell Therapeutics, talks about a new approach to treating diseases called whole cell replacement therapy - which replaces damaged cells with new ones. Lineage is focusing this new therapy on dry age-related macular degeneration (AMD), a leading cause of blindness, through their collaboration with Genentech..

]]> Cell replacement therapy, dry age-related macular degeneration (AMD), vision restoration, retinal cells, Lineage Cell Therapeutics, Genentech collaboration, geographic atrophy, blindness treatment, ophthalmology, clinical trials, whole cell therapy, regenerative medicine No Multimodal Health??? Dr. Daniel Kraft, Tech Nation Health, Chief Correspondent 24041 24041 Multimodal Health??? Dr. Daniel Kraft, Tech Nation Health, Chief Correspondent full 048fd83b-7b96-47d9-9097-9c710df93976 https://share.transistor.fm/s/80d1df4f Dr. Daniel Kraft, Tech Nation Health Chief Correspondent introduces "multimodal medicine", combining data like proteomics, wearables, and imaging for early disease detection. He stresses the importance of both advanced diagnostics and listening to patients' stories for effective healthcare.

]]> Dr. Daniel Kraft, Tech Nation Health Chief Correspondent introduces "multimodal medicine", combining data like proteomics, wearables, and imaging for early disease detection. He stresses the importance of both advanced diagnostics and listening to patients' stories for effective healthcare.

]]> Wed, 09 Oct 2024 08:00:00 -0700 Moira Gunn Moira Gunn 557 Dr. Daniel Kraft, Tech Nation Health Chief Correspondent introduces "multimodal medicine", combining data like proteomics, wearables, and imaging for early disease detection. He stresses the importance of both advanced diagnostics and listening to patients' stories for effective healthcare.

]]> multimodal medicine, proteomics, early disease detection, wearable technology, imaging, AI in healthcare, UK Biobank, Parkinson's prediction, personalized health, Dr. Daniel Kraft, health data integration, patient communication, proactive healthcare, advanced diagnostics, BioTech Nation No 15 Billion Vaccines Doses: COVID & the Patent Dilemma... Dr. Antony Taubman, Former Director of the Intellectual Property Division at the World Trade Organization 24040 24040 15 Billion Vaccines Doses: COVID & the Patent Dilemma... Dr. Antony Taubman, Former Director of the Intellectual Property Division at the World Trade Organization full 231c224c-ad35-4590-9994-1262fd1e6fdf https://share.transistor.fm/s/d62c8a45 Dr. Antony Taubman, the former Director of the Intellectual Property Division at the World Trade Organization, discusses the challenges faced during the COVID-19 pandemic, including the rapid development and distribution of 15 billion doses of Covid vaccines, and how international intellectual property rules influenced these efforts. 

]]> Dr. Antony Taubman, the former Director of the Intellectual Property Division at the World Trade Organization, discusses the challenges faced during the COVID-19 pandemic, including the rapid development and distribution of 15 billion doses of Covid vaccines, and how international intellectual property rules influenced these efforts. 

]]> Wed, 02 Oct 2024 12:00:00 -0700 Moira Gunn Moira Gunn 1394 Dr. Antony Taubman, the former Director of the Intellectual Property Division at the World Trade Organization, discusses the challenges faced during the COVID-19 pandemic, including the rapid development and distribution of 15 billion doses of Covid vaccines, and how international intellectual property rules influenced these efforts. 

]]> COVID-19 pandemic, vaccines, intellectual property, World Trade Organization, Dr. Antony Taubman, global health, equitable access, vaccine distribution, mRNA technology, patent rights, innovation, public health, Medicines Patent Pool, technology transfer, pharmaceutical industry, international trade, regulatory challenges, healthcare equity, COVID-19 lessons, pandemic response No From Illness to Wellness - Can Science Tell Us How Healthy We Really Are (Part II)?? Dr. Leroy Hood and Dr. Nathan Price 24039 24039 From Illness to Wellness - Can Science Tell Us How Healthy We Really Are (Part II)?? Dr. Leroy Hood and Dr. Nathan Price full 12d39a77-1a05-4a27-8088-11cd8f471aa9 https://share.transistor.fm/s/8e3f0dfb Part II - We continue our discussion with Dr. Leroy Hood and Dr. Nathan Price about the subject of their book "The Age of Scientific Wellness", delving into the role of artificial intelligence in healthcare and the ability to mine deep data to deliver hyper-personalized recommendations at a scale never before possible. 

]]> Part II - We continue our discussion with Dr. Leroy Hood and Dr. Nathan Price about the subject of their book "The Age of Scientific Wellness", delving into the role of artificial intelligence in healthcare and the ability to mine deep data to deliver hyper-personalized recommendations at a scale never before possible. 

]]> Wed, 25 Sep 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1503 Part II - We continue our discussion with Dr. Leroy Hood and Dr. Nathan Price about the subject of their book "The Age of Scientific Wellness", delving into the role of artificial intelligence in healthcare and the ability to mine deep data to deliver hyper-personalized recommendations at a scale never before possible. 

]]> biotechnation, biotech, personalized medicine, dr. leroy hood, dr. nathan price, moira gunn, tech nation No From Illness to Wellness - Can Science Tell Us How Healthy We Really Are (Part I)?? Dr. Leroy Hood and Dr. Nathan Price 24038 24038 From Illness to Wellness - Can Science Tell Us How Healthy We Really Are (Part I)?? Dr. Leroy Hood and Dr. Nathan Price full 1f6db57f-efab-4f59-b7aa-34c1ab20e21d https://share.transistor.fm/s/bffd7f5b Dr. Leroy Hood and Dr. Nathan Price delve into the subject of their book "The Age of Scientific Wellness", which highlights the advancements in science that enable the prediction and personalization of healthcare based on an individual's wellness level, and the potential advantages of early diagnosis and treatment of illnesses

]]> Dr. Leroy Hood and Dr. Nathan Price delve into the subject of their book "The Age of Scientific Wellness", which highlights the advancements in science that enable the prediction and personalization of healthcare based on an individual's wellness level, and the potential advantages of early diagnosis and treatment of illnesses

]]> Wed, 18 Sep 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1617 Dr. Leroy Hood and Dr. Nathan Price delve into the subject of their book "The Age of Scientific Wellness", which highlights the advancements in science that enable the prediction and personalization of healthcare based on an individual's wellness level, and the potential advantages of early diagnosis and treatment of illnesses

]]> Scientific Wellness, Personalized Healthcare, Disease Prevention, Early Detection, DNA, Systems Biology, Predictive Medicine, HealthTec, Wellness Assessment, Individualized Treatment, TechNation, DrLeroyHood, DrNathanPrice No One Pill to Stop Many Cancers??? Dr. Michael Weickert, CEO, Pacylex Pharmaceuticals 24037 24037 One Pill to Stop Many Cancers??? Dr. Michael Weickert, CEO, Pacylex Pharmaceuticals full 9fd72b56-196b-4dee-8f20-702cf3e75973 https://share.transistor.fm/s/34f967bc Dr. Michael Weickert, CEO of Pacylex Pharmaceuticals, about their once-daily pill in trials now for cancer treatment - it’s already showing early indicators of success in stopping cancer growth in not just one, but a number of cancers.

]]> Dr. Michael Weickert, CEO of Pacylex Pharmaceuticals, about their once-daily pill in trials now for cancer treatment - it’s already showing early indicators of success in stopping cancer growth in not just one, but a number of cancers.

]]> Wed, 11 Sep 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1014 Dr. Michael Weickert, CEO of Pacylex Pharmaceuticals, about their once-daily pill in trials now for cancer treatment - it’s already showing early indicators of success in stopping cancer growth in not just one, but a number of cancers.

]]> Pacylex, Zelenirstat, cancer treatment, once-daily pill, phase 1 trial, phase 2 trial, tumor reduction, colorectal cancer, lymphoma, leukemia, clinical trials, biotech, cancer therapy, oral medication, MD Anderson, Department of Defense funding, cancer research No Engineering the Future of Vaccines... Dr. Robert Coleman, CEO, Codagenix 24033 24033 Engineering the Future of Vaccines... Dr. Robert Coleman, CEO, Codagenix full cfcf3824-1100-4b00-90f5-b8cc80b36aa9 https://share.transistor.fm/s/2bd0eff7 Dr. Robert Coleman, CEO of Codagenix, discusses their innovative approach to virus engineering, which includes developing a nasally-delivered COVID-19 vaccine that targets multiple virus proteins for broader protection. Codagenix's "rational virus design" method creates genetically stable vaccines and therapeutics, reducing the risk of harmful mutations. Their work also extends to vaccines for other diseases and viral-based cancer treatments, with the potential to significantly advance global health. 

]]> Dr. Robert Coleman, CEO of Codagenix, discusses their innovative approach to virus engineering, which includes developing a nasally-delivered COVID-19 vaccine that targets multiple virus proteins for broader protection. Codagenix's "rational virus design" method creates genetically stable vaccines and therapeutics, reducing the risk of harmful mutations. Their work also extends to vaccines for other diseases and viral-based cancer treatments, with the potential to significantly advance global health. 

]]> Wed, 04 Sep 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1568 Dr. Robert Coleman, CEO of Codagenix, discusses their innovative approach to virus engineering, which includes developing a nasally-delivered COVID-19 vaccine that targets multiple virus proteins for broader protection. Codagenix's "rational virus design" method creates genetically stable vaccines and therapeutics, reducing the risk of harmful mutations. Their work also extends to vaccines for other diseases and viral-based cancer treatments, with the potential to significantly advance global health. 

]]> Codagenix, virus engineering, COVID-19 vaccine, nasally-delivered vaccine, rational virus design, genetic stability, vaccine development, viral-based therapeutics, global health, mRNA vaccine alternative, multi-protein targeting, cancer treatment, RSV vaccine, influenza vaccine, biotechnology, Moira Gunn, Biotech Nation No Did That Change To My Prescription Work??? -- Dr. Kal Patel, CEO, BrightInsight 24035 24035 Did That Change To My Prescription Work??? -- Dr. Kal Patel, CEO, BrightInsight full 77ccf13d-739b-4f09-bc51-3727f16b847f https://share.transistor.fm/s/a0747dd1 Continuous monitoring ... when we want it, when we don’t, should we share it? Or not. Or perhaps just part of it. Dr. Kal Patel, the Co-Founder and CEO of BrightInsight talks about this brave new frontier.

]]> Continuous monitoring ... when we want it, when we don’t, should we share it? Or not. Or perhaps just part of it. Dr. Kal Patel, the Co-Founder and CEO of BrightInsight talks about this brave new frontier.

]]> Wed, 28 Aug 2024 08:00:00 -0700 Moira Gunn Moira Gunn 2113 Continuous monitoring ... when we want it, when we don’t, should we share it? Or not. Or perhaps just part of it. Dr. Kal Patel, the Co-Founder and CEO of BrightInsight talks about this brave new frontier.

]]> Biotech nation, tech nation, moira gunn, Kal Patel, BrightInsight, prescriptions, treatments No Can the Mapping of Human Biology Lead to Better Drugs? Dr. Chris Gibson, Co-Founder & CEO Recursion Pharmaceuticals 23011 23011 Can the Mapping of Human Biology Lead to Better Drugs? Dr. Chris Gibson, Co-Founder & CEO Recursion Pharmaceuticals full 03dbed23-df08-48f7-a81c-911c421c3165 https://share.transistor.fm/s/93404e99 Dr. Chris Gibson, the co-founder and CEO of Recursion Pharmaceuticals in Salt Lake City. We talk about their efforts to map ALL of human biology, and how this mapping will lead to better drugs. 

]]> Dr. Chris Gibson, the co-founder and CEO of Recursion Pharmaceuticals in Salt Lake City. We talk about their efforts to map ALL of human biology, and how this mapping will lead to better drugs. 

]]> Wed, 21 Aug 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1302 Dr. Chris Gibson, the co-founder and CEO of Recursion Pharmaceuticals in Salt Lake City. We talk about their efforts to map ALL of human biology, and how this mapping will lead to better drugs. 

]]> biotech, biotech nation, tech nation, mapping, biology, Chris Gibson, Recursion Pharmaceuticals, Recursion, Pharmaceuticals No One Company, Two Different Drugs - It's All About Glucose - Too Much and Too Little! Nevan Charles Elam, Founder & CEO, Rezolute 23013 23013 One Company, Two Different Drugs - It's All About Glucose - Too Much and Too Little! Nevan Charles Elam, Founder & CEO, Rezolute full e7814bf9-9d0f-4240-94ea-dcd68013fb38 https://share.transistor.fm/s/a7cfe86d Glucose is essential for life. And the insulin we produce is designed to leave just the right of amount in our bodies for healthy functioning. Thus, when we underproduce insulin - or we overproduce it - the results can be devastating. Nevan Charles Elam, Founder and CEO of Rezolute, tells us about their work to treat the “diabetic eye condition”, DME, and a pediatric condition called Congenital hyperinsulinism. 

]]> Glucose is essential for life. And the insulin we produce is designed to leave just the right of amount in our bodies for healthy functioning. Thus, when we underproduce insulin - or we overproduce it - the results can be devastating. Nevan Charles Elam, Founder and CEO of Rezolute, tells us about their work to treat the “diabetic eye condition”, DME, and a pediatric condition called Congenital hyperinsulinism. 

]]> Wed, 14 Aug 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1132 Glucose is essential for life. And the insulin we produce is designed to leave just the right of amount in our bodies for healthy functioning. Thus, when we underproduce insulin - or we overproduce it - the results can be devastating. Nevan Charles Elam, Founder and CEO of Rezolute, tells us about their work to treat the “diabetic eye condition”, DME, and a pediatric condition called Congenital hyperinsulinism. 

]]> glucose, insulin, DME, biotech, pharmaceuticals, therpeutics, moira gunn, rezolute, congenital hyperinsulinism, diabetes, nevan charles elam No A Vaccine for Breast Cancer??? Dr. Amit Kumar, President & CEO, Anixa Biosciences 24032 24032 A Vaccine for Breast Cancer??? Dr. Amit Kumar, President & CEO, Anixa Biosciences full 32890f5f-2f92-4871-9086-c7c78c38243d https://share.transistor.fm/s/d07f6aaa This week on BioTech Nation, Dr. Amit Kumar, President and CEO of Anixa Biosciences, talks about their work on a breast cancer vaccine which targets a protein thought only to be expressed during breastfeeding. Building on research by the Cleveland Clinic, Dr. Kumar describes ongoing human clinical trials and their potential for women with BRCA mutations.

]]> This week on BioTech Nation, Dr. Amit Kumar, President and CEO of Anixa Biosciences, talks about their work on a breast cancer vaccine which targets a protein thought only to be expressed during breastfeeding. Building on research by the Cleveland Clinic, Dr. Kumar describes ongoing human clinical trials and their potential for women with BRCA mutations.

]]> Thu, 08 Aug 2024 10:18:49 -0700 Moira Gunn Moira Gunn 1539 This week on BioTech Nation, Dr. Amit Kumar, President and CEO of Anixa Biosciences, talks about their work on a breast cancer vaccine which targets a protein thought only to be expressed during breastfeeding. Building on research by the Cleveland Clinic, Dr. Kumar describes ongoing human clinical trials and their potential for women with BRCA mutations.

]]> Biotech Nation, Dr. Moira Gunn, Dr. Amit Kumar, Anixa Biosciences, triple-negative breast cancer, cancer vaccine, alpha-lactalbumin, Cleveland Clinic, BRCA mutations, clinical trials, phase 1 trials, Sarah Friar, Bloomberg News, social media, Instagram, No Filter, social media ownership, cancer prevention, immunotherapy, biotech innovation, oncology research No Are Your Genes Failing You??? Dr. Noah Davidsohn, Co-Founder & CSO Rejuvenate Bio 24031 24031 Are Your Genes Failing You??? Dr. Noah Davidsohn, Co-Founder & CSO Rejuvenate Bio full b1013231-d9ce-46a8-9947-5bbc4cbda9ff https://share.transistor.fm/s/68263b3d This week on Biotech Nation,  Dr. Noah Davidsohn, Co-Founder and Chief Scientific Officer of Rejuvenate Bio. The discussion centers around the regulation of protein expression and its implications for aging and health. Dr. Davidsohn explains how aging disrupts the balance of protein production, leading to various diseases. Rejuvenate Bio's gene therapies aim to restore this balance by targeting specific genes.

]]> This week on Biotech Nation,  Dr. Noah Davidsohn, Co-Founder and Chief Scientific Officer of Rejuvenate Bio. The discussion centers around the regulation of protein expression and its implications for aging and health. Dr. Davidsohn explains how aging disrupts the balance of protein production, leading to various diseases. Rejuvenate Bio's gene therapies aim to restore this balance by targeting specific genes.

]]> Wed, 31 Jul 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1010 This week on Biotech Nation,  Dr. Noah Davidsohn, Co-Founder and Chief Scientific Officer of Rejuvenate Bio. The discussion centers around the regulation of protein expression and its implications for aging and health. Dr. Davidsohn explains how aging disrupts the balance of protein production, leading to various diseases. Rejuvenate Bio's gene therapies aim to restore this balance by targeting specific genes.

]]> biotech, gene therapy, proteins, therapeutics, biotech nation, tech nation, moira gunn, noah davidsohn, rejuvenate bio No Living Longer??? Dr. Peter Diamandis, XPrize Founder and Author, "Longevity" 24030 24030 Living Longer??? Dr. Peter Diamandis, XPrize Founder and Author, "Longevity" full 421e2d5e-89b0-4129-a334-4c3496fe6b58 https://share.transistor.fm/s/a4fd7795 This week of BioTech Nation, Dr. Peter Diamandis about his new book, "Longevity: Your Practical Playbook on Sleep, Diet, Exercise, Mindset, Medications, and Not Dying from Something Stupid". We explore his lifelong interest in extending human health span and discuss practical steps for a healthier, longer life, including sleep, diet, exercise, and mindset. Dr. Diamandis introduces the "longevity escape velocity" concept and the HealthSpan XPRIZE, which aims to reverse aging's functional losses. 

]]> This week of BioTech Nation, Dr. Peter Diamandis about his new book, "Longevity: Your Practical Playbook on Sleep, Diet, Exercise, Mindset, Medications, and Not Dying from Something Stupid". We explore his lifelong interest in extending human health span and discuss practical steps for a healthier, longer life, including sleep, diet, exercise, and mindset. Dr. Diamandis introduces the "longevity escape velocity" concept and the HealthSpan XPRIZE, which aims to reverse aging's functional losses. 

]]> Wed, 24 Jul 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1533 This week of BioTech Nation, Dr. Peter Diamandis about his new book, "Longevity: Your Practical Playbook on Sleep, Diet, Exercise, Mindset, Medications, and Not Dying from Something Stupid". We explore his lifelong interest in extending human health span and discuss practical steps for a healthier, longer life, including sleep, diet, exercise, and mindset. Dr. Diamandis introduces the "longevity escape velocity" concept and the HealthSpan XPRIZE, which aims to reverse aging's functional losses. 

]]> Longevity, health span, Dr. Peter Diamandis, X Prize, BioTech Nation, Dr. Moira Gunn, sleep, diet, exercise, mindset, medications, aging, HealthSpan XPRIZE, longevity escape velocity, medical technology, lifestyle choices, practical playbook, human health, emerging technologies, reversing aging, health optimization No Psychedelics... Prodrugs... What else? Dr. Sam Clark, CEO of Terran Biosciences 24029 24029 Psychedelics... Prodrugs... What else? Dr. Sam Clark, CEO of Terran Biosciences full e9280820-e30f-4210-8640-85e3ea72ecf4 https://share.transistor.fm/s/c09ea15b This week on BioTech Nation, Dr. Sam Clark, CEO of Terran Biosciences, discusses prodrugs—modified drugs that improve absorption and efficacy. Also, Terran Biosciences is developing non-hallucinogenic psychedelics by blocking the serotonin 2A receptor and manufacturing psychedelics like LSD and psilocybin for research. Dr. Clark highlights Terran's innovative, tech-inspired approach to rapidly develop affordable medications. 

]]> This week on BioTech Nation, Dr. Sam Clark, CEO of Terran Biosciences, discusses prodrugs—modified drugs that improve absorption and efficacy. Also, Terran Biosciences is developing non-hallucinogenic psychedelics by blocking the serotonin 2A receptor and manufacturing psychedelics like LSD and psilocybin for research. Dr. Clark highlights Terran's innovative, tech-inspired approach to rapidly develop affordable medications. 

]]> Wed, 17 Jul 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1068 This week on BioTech Nation, Dr. Sam Clark, CEO of Terran Biosciences, discusses prodrugs—modified drugs that improve absorption and efficacy. Also, Terran Biosciences is developing non-hallucinogenic psychedelics by blocking the serotonin 2A receptor and manufacturing psychedelics like LSD and psilocybin for research. Dr. Clark highlights Terran's innovative, tech-inspired approach to rapidly develop affordable medications. 

]]> prodrugs, psychedelics, serotonin 2A receptor, non-hallucinogenic, drug absorption, Terran Biosciences, Dr. Sam Clark, LSD, psilocybin, clinical research, biotech innovation, affordable medications, tech-inspired approach, drug development, mental health treatments, therapeutic benefits No A Dual Approach to Combatting Hepatitis... Dr. Marianne De Backer, CEO at Vir Biotechnology 24028 24028 A Dual Approach to Combatting Hepatitis... Dr. Marianne De Backer, CEO at Vir Biotechnology full e21baebc-6e8f-4972-84c5-ba9f4564ffcb https://share.transistor.fm/s/f76dd088 This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans. 

]]> This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans. 

]]> Wed, 10 Jul 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1192 This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans. 

]]> hepatitis b, hepatitis d, Vir Biotechnology, clinical trials, antibody therapy, siRNA, liver damage, viral hepatitis, phase 2, preliminary results No The Next Ozempic or Wegovy... But Without the Injection??? Dr. Steffen-Sebastian Bolz, CSO, Aphaia Pharma 24026 24026 The Next Ozempic or Wegovy... But Without the Injection??? Dr. Steffen-Sebastian Bolz, CSO, Aphaia Pharma full f1b72a27-437f-4d78-becc-457dfef68faf https://share.transistor.fm/s/2219dbb5 What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2. 

]]> What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2. 

]]> Wed, 26 Jun 2024 09:00:06 -0700 Moira Gunn Moira Gunn 1516 What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2. 

]]> biotech, biotech nation, moira gunn, Aphaia Pharma, Ozempic, Wegovy, Weight loss No FDA Approval! A New Model for BioPharma... Dr. Sam Blackman, Founder & Head of Research and Development, Day One Biopharmaceuticals 24023 24023 FDA Approval! A New Model for BioPharma... Dr. Sam Blackman, Founder & Head of Research and Development, Day One Biopharmaceuticals full f563b0e3-8efc-4538-a95a-dcab4f4731ff https://share.transistor.fm/s/0a3233a1 This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. He talks about their innovative approach to starting a biopharma company and how it led to a newly FDA approved drug that treats the most common form of brain cancer in children

]]> This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. He talks about their innovative approach to starting a biopharma company and how it led to a newly FDA approved drug that treats the most common form of brain cancer in children

]]> Wed, 26 Jun 2024 08:53:45 -0700 Moira Gunn Moira Gunn 1870 This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. He talks about their innovative approach to starting a biopharma company and how it led to a newly FDA approved drug that treats the most common form of brain cancer in children

]]> Pediatric oncology, Brain cancer, Day 1 Biopharmaceuticals, FDA approval, Tovorafenib, BRAF alteration, FireFLY trial, Childhood cancer, Innovation, Breakthrough, Hope, Drug development No Everybody Has a Thyroid... What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma 24025 24025 Everybody Has a Thyroid... What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma full 060241f4-fe6a-4ea4-8899-76ba6f715398 https://share.transistor.fm/s/0ec6d1f2 This week we have a best of rerun with Dr. Mark Sumeray from Amolyt Pharma. Dr. Sumeray talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

]]> This week we have a best of rerun with Dr. Mark Sumeray from Amolyt Pharma. Dr. Sumeray talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

]]> Wed, 19 Jun 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1739 This week we have a best of rerun with Dr. Mark Sumeray from Amolyt Pharma. Dr. Sumeray talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

]]> moira gunn, amolyt pharma, mark sumeray, tech nation, biotech nation, thyroid No Wearable Wonders! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 24024 24024 Wearable Wonders! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full fd3b3e56-aadb-4d8f-a7d4-fbcd73be5d4b https://share.transistor.fm/s/5df665ad This week Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, discusses advanced health tech. Dr. Kraft highlights his use of wearables like the Apple Watch, Oura ring, and non-invasive blood pressure monitors. He also introduces "otherables," which track health without being worn, using devices like cameras and modified WiFi. These technologies enable continuous health monitoring and personalized care. 

]]> This week Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, discusses advanced health tech. Dr. Kraft highlights his use of wearables like the Apple Watch, Oura ring, and non-invasive blood pressure monitors. He also introduces "otherables," which track health without being worn, using devices like cameras and modified WiFi. These technologies enable continuous health monitoring and personalized care. 

]]> Wed, 12 Jun 2024 08:00:00 -0700 Moira Gunn Moira Gunn 818 This week Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, discusses advanced health tech. Dr. Kraft highlights his use of wearables like the Apple Watch, Oura ring, and non-invasive blood pressure monitors. He also introduces "otherables," which track health without being worn, using devices like cameras and modified WiFi. These technologies enable continuous health monitoring and personalized care. 

]]> wearables, health tech, Dr. Daniel Kraft, future, innovation, monitoring, personalized care No Robo-Docs & VR Surgery??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 24022 24022 Robo-Docs & VR Surgery??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full 71221e56-1998-4a95-99da-baeacb566d68 https://share.transistor.fm/s/415db702 This week on BioTech Nation, Dr. Moira Gunn and Dr. Daniel Kraft discuss how robotics, AI, and virtual reality are transforming surgery. These technologies make procedures less invasive and improve training and outcomes worldwide. Future advancements may include tiny robots performing internal procedures. Security is crucial to prevent hacking of medical devices. 

]]> This week on BioTech Nation, Dr. Moira Gunn and Dr. Daniel Kraft discuss how robotics, AI, and virtual reality are transforming surgery. These technologies make procedures less invasive and improve training and outcomes worldwide. Future advancements may include tiny robots performing internal procedures. Security is crucial to prevent hacking of medical devices. 

]]> Wed, 29 May 2024 09:00:00 -0700 Moira Gunn Moira Gunn 836 This week on BioTech Nation, Dr. Moira Gunn and Dr. Daniel Kraft discuss how robotics, AI, and virtual reality are transforming surgery. These technologies make procedures less invasive and improve training and outcomes worldwide. Future advancements may include tiny robots performing internal procedures. Security is crucial to prevent hacking of medical devices. 

]]> Robo-Docs, VR surgery, robotic surgery, AI in healthcare, augmented reality, virtual reality, medical technology, surgical innovations, digital health, Dr. Daniel Kraft, Dr. Moira Gunn, Biotech Nation, advanced surgery tools, nanomedicine, surgical training, wearable devices, medical security No Closing the Innovation Gap!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 24020 24020 Closing the Innovation Gap!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full da10cbf0-f813-4512-8acd-90df821ccfe2 https://share.transistor.fm/s/b444a13b Dr. Daniel Kraft, Tech Nation Health Chief Correspondent discusses the gap between medical innovation and its adoption into standard practice. He highlights that it typically takes 17 years for a medical discovery to become common practice, but big data and AI could accelerate this. He emphasizes the importance of sharing medical data and initiatives like Stuff That Works Health and EveryCure. 

]]> Dr. Daniel Kraft, Tech Nation Health Chief Correspondent discusses the gap between medical innovation and its adoption into standard practice. He highlights that it typically takes 17 years for a medical discovery to become common practice, but big data and AI could accelerate this. He emphasizes the importance of sharing medical data and initiatives like Stuff That Works Health and EveryCure. 

]]> Wed, 15 May 2024 08:00:00 -0700 Moira Gunn Moira Gunn 626 Dr. Daniel Kraft, Tech Nation Health Chief Correspondent discusses the gap between medical innovation and its adoption into standard practice. He highlights that it typically takes 17 years for a medical discovery to become common practice, but big data and AI could accelerate this. He emphasizes the importance of sharing medical data and initiatives like Stuff That Works Health and EveryCure. 

]]> Dr. Daniel Kraft, Biotech Nation podcast, medical innovation, standard practice, gap, big data, AI, sharing medical data, Stuff That Works Health, EveryCure, self-driving cars, healthcare adaptation, patient preferences No The Virtual Cell??? Dr. Steve Quake, Head of Science at Chan Zuckerberg Initiative 24019 24019 The Virtual Cell??? Dr. Steve Quake, Head of Science at Chan Zuckerberg Initiative full acf0adae-0a47-4ef0-9fd5-df09a5223c2a https://share.transistor.fm/s/1bee25b8 This week, Dr. Steve Quake from the Chan Zuckerberg Initiative about their goal to tackle all human diseases in the next century. We discuss CZI's innovative approach, including building Biohubs and funding collaborative research. Dr. Quake explains the importance of something called The Virtual Cell project, aiming to use AI to model every human cell. We also address ethical concerns about AI in bioweapons research and the need for regulatory measures. 

]]> This week, Dr. Steve Quake from the Chan Zuckerberg Initiative about their goal to tackle all human diseases in the next century. We discuss CZI's innovative approach, including building Biohubs and funding collaborative research. Dr. Quake explains the importance of something called The Virtual Cell project, aiming to use AI to model every human cell. We also address ethical concerns about AI in bioweapons research and the need for regulatory measures. 

]]> Wed, 08 May 2024 08:36:00 -0700 Moira Gunn Moira Gunn 1281 This week, Dr. Steve Quake from the Chan Zuckerberg Initiative about their goal to tackle all human diseases in the next century. We discuss CZI's innovative approach, including building Biohubs and funding collaborative research. Dr. Quake explains the importance of something called The Virtual Cell project, aiming to use AI to model every human cell. We also address ethical concerns about AI in bioweapons research and the need for regulatory measures. 

]]> Chan Zuckerberg Initiative, CZI, Dr. Steve Quake, Biohubs, Human Cell Atlas, AI, computational power, drug development, collaborative research, bioweapons, ethics, regulatory measures, healthcare, innovation, philanthropy No How Can Sound Deliver Drugs??? Dr. Neal Kassell, Founder & Chair of Focused Ultrasound Foundation 24018 24018 How Can Sound Deliver Drugs??? Dr. Neal Kassell, Founder & Chair of Focused Ultrasound Foundation full 4bde75d8-a489-4722-a797-32ba2b0a36ec https://share.transistor.fm/s/1c65e5d8 This week on Biotech Nation, I speak with Dr. Neal Kassell about focused ultrasound technology. We discuss its noninvasive approach, its diverse applications in treating various medical conditions, and its potential to revolutionize treatments for diseases like Alzheimer's, Parkinson's, and cancer. Dr. Kassell also shares insights into ongoing clinical trials and the rapid growth of focused ultrasound as a global standard of care.

]]> This week on Biotech Nation, I speak with Dr. Neal Kassell about focused ultrasound technology. We discuss its noninvasive approach, its diverse applications in treating various medical conditions, and its potential to revolutionize treatments for diseases like Alzheimer's, Parkinson's, and cancer. Dr. Kassell also shares insights into ongoing clinical trials and the rapid growth of focused ultrasound as a global standard of care.

]]> Wed, 01 May 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1008 This week on Biotech Nation, I speak with Dr. Neal Kassell about focused ultrasound technology. We discuss its noninvasive approach, its diverse applications in treating various medical conditions, and its potential to revolutionize treatments for diseases like Alzheimer's, Parkinson's, and cancer. Dr. Kassell also shares insights into ongoing clinical trials and the rapid growth of focused ultrasound as a global standard of care.

]]> focused ultrasound, noninvasive therapy, medical technology, Dr. Neal Kassell, Dr. Moira Gunn, clinical trials, neurodegenerative diseases, cancer immunotherapy, treatment, precision medicine, therapeutic effects, drug delivery, brain disorders, addiction, depression, OCD, transformational technology, biomedical innovation No 70% of Breast Cancers and a Link to Prostate Cancer... Dr. Sean Bohen, President & CEO, Olema Oncology 24017 24017 70% of Breast Cancers and a Link to Prostate Cancer... Dr. Sean Bohen, President & CEO, Olema Oncology full 9171aebb-6154-4ee5-be4e-e1e7e580fc68 https://share.transistor.fm/s/b01ea506 This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant, works to antagonize the estrogen receptor, halting cancer cell growth. They also touch on the ongoing Phase 3 trial, OPERA-01, and the potential for combining palazestrant with other treatments. 

]]> This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant, works to antagonize the estrogen receptor, halting cancer cell growth. They also touch on the ongoing Phase 3 trial, OPERA-01, and the potential for combining palazestrant with other treatments. 

]]> Wed, 24 Apr 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1382 This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant, works to antagonize the estrogen receptor, halting cancer cell growth. They also touch on the ongoing Phase 3 trial, OPERA-01, and the potential for combining palazestrant with other treatments. 

]]> Biotech Nation, cancer treatment, breast cancer, ER-positive, HER2-negative, metastatic breast cancer, Olema Oncology, Sean Bohen, palbociclib, estrogen receptor, Phase 3 trial, OPERA 1, combination therapy, endometrial cancer, prostate cancer, biological understanding, clinical trials. No Tiny RNAs, Big Cures!!! Dr. Sanjay Shukla, President and CEO, ATyr (ah-tire) Pharma 24016 24016 Tiny RNAs, Big Cures!!! Dr. Sanjay Shukla, President and CEO, ATyr (ah-tire) Pharma full 4bdc8537-96ea-49b1-8f7e-1c814f4342ab https://share.transistor.fm/s/0ed1912c This week - Dr. Sanjay Shukla, CEO of Atyr Pharma, discusses the revolutionary potential of mRNA technology in creating new medicines. They explore Atyr's pioneering approach to leveraging tRNA fragments for treating pulmonary sarcoidosis and other organ-specific conditions, aiming to improve patient outcomes while minimizing reliance on conventional therapies like steroids.

]]> This week - Dr. Sanjay Shukla, CEO of Atyr Pharma, discusses the revolutionary potential of mRNA technology in creating new medicines. They explore Atyr's pioneering approach to leveraging tRNA fragments for treating pulmonary sarcoidosis and other organ-specific conditions, aiming to improve patient outcomes while minimizing reliance on conventional therapies like steroids.

]]> Wed, 17 Apr 2024 09:57:00 -0700 Moira Gunn Moira Gunn 1194 This week - Dr. Sanjay Shukla, CEO of Atyr Pharma, discusses the revolutionary potential of mRNA technology in creating new medicines. They explore Atyr's pioneering approach to leveraging tRNA fragments for treating pulmonary sarcoidosis and other organ-specific conditions, aiming to improve patient outcomes while minimizing reliance on conventional therapies like steroids.

]]> mRNA, technology, Atyr Pharma, Dr. Sanjay Shukla, DNA, mRNA vaccines, tRNA, protein synthesis, Dr. Paul Schimmel, immunology, pulmonary sarcoidosis, Phase 3 trials, organ-specific conditions, innovative therapies, steroids, patient outcomes No Cancer Vaccines??? Dr. Chris Pirie, Co-Founder & COO of HDT Bio 24014 24014 Cancer Vaccines??? Dr. Chris Pirie, Co-Founder & COO of HDT Bio full b42e58ae-748b-414d-b535-d00d6ae72179 https://share.transistor.fm/s/f622f07c In this week's episode, Dr. Moira Gunn interviews Dr. Chris Pirie from HDT Bio about their novel approach to cancer prevention through vaccines. They discuss leveraging mRNA technology to target specific tumor mutations and prime the immune system to recognize and eliminate cancer cells. Dr. Pirie highlights ongoing efforts to develop vaccines for prostate, pancreatic, and breast cancers, emphasizing the importance of monitoring immune responses in clinical trials. They also explore the potential for broad-spectrum cancer vaccines and the need to shift towards preventive measures in cancer treatment.

]]> In this week's episode, Dr. Moira Gunn interviews Dr. Chris Pirie from HDT Bio about their novel approach to cancer prevention through vaccines. They discuss leveraging mRNA technology to target specific tumor mutations and prime the immune system to recognize and eliminate cancer cells. Dr. Pirie highlights ongoing efforts to develop vaccines for prostate, pancreatic, and breast cancers, emphasizing the importance of monitoring immune responses in clinical trials. They also explore the potential for broad-spectrum cancer vaccines and the need to shift towards preventive measures in cancer treatment.

]]> Wed, 03 Apr 2024 08:00:00 -0700 Moira Gunn Moira Gunn 1028 In this week's episode, Dr. Moira Gunn interviews Dr. Chris Pirie from HDT Bio about their novel approach to cancer prevention through vaccines. They discuss leveraging mRNA technology to target specific tumor mutations and prime the immune system to recognize and eliminate cancer cells. Dr. Pirie highlights ongoing efforts to develop vaccines for prostate, pancreatic, and breast cancers, emphasizing the importance of monitoring immune responses in clinical trials. They also explore the potential for broad-spectrum cancer vaccines and the need to shift towards preventive measures in cancer treatment.

]]> Biotech Nation, Dr. Moira Gunn, Dr. Chris Pirie, HDT Bio, cancer prevention, vaccines, mRNA technology, tumor mutations, immune system, clinical trials, prostate cancer, pancreatic cancer, breast cancer, broad-spectrum vaccines, preventive measures No Redefining Acute Myeloid Leukemia (AML) Treatment!!! Dr. Robert Ang, President & CEO of Vor Biopharma 24013 24013 Redefining Acute Myeloid Leukemia (AML) Treatment!!! Dr. Robert Ang, President & CEO of Vor Biopharma full 207c6719-221b-4d6b-a5c7-aefde3455a62 https://share.transistor.fm/s/ffb24cda This week I speak with Dr. Robert Ang from Vor Biopharma about their innovative approach to treating acute myeloid leukemia (AML). AML is a type of blood cancer that affects the bone marrow, leading to the overgrowth of cancerous cells. Dr. Ang explains that traditional treatments, such as chemotherapy and stem cell transplants, have limitations and risks. Dr. Ang emphasizes the potential of their treatment to revolutionize AML therapy and improve patient outcomes.

]]> This week I speak with Dr. Robert Ang from Vor Biopharma about their innovative approach to treating acute myeloid leukemia (AML). AML is a type of blood cancer that affects the bone marrow, leading to the overgrowth of cancerous cells. Dr. Ang explains that traditional treatments, such as chemotherapy and stem cell transplants, have limitations and risks. Dr. Ang emphasizes the potential of their treatment to revolutionize AML therapy and improve patient outcomes.

]]> Wed, 27 Mar 2024 08:00:00 -0700 Moira Gunn Moira Gunn 920 This week I speak with Dr. Robert Ang from Vor Biopharma about their innovative approach to treating acute myeloid leukemia (AML). AML is a type of blood cancer that affects the bone marrow, leading to the overgrowth of cancerous cells. Dr. Ang explains that traditional treatments, such as chemotherapy and stem cell transplants, have limitations and risks. Dr. Ang emphasizes the potential of their treatment to revolutionize AML therapy and improve patient outcomes.

]]> Acute Myeloid Leukemia (AML), Vore Biopharma, CD thirty-three (CD33), Bone marrow, Cancer cells, Chemotherapy, Stem cell transplant, Genetic modification, Clinical trials, Treatment innovation No Food as Medicine, A Personalized Prescription... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 24011 24011 Food as Medicine, A Personalized Prescription... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full f4330917-3598-4c08-a51f-a6db0b253913 https://share.transistor.fm/s/1f846256 Tech Nation Health, Chief Correspondent Dr. Daniel Kraft discusses the concept of "food as medicine." Dr. Kraft emphasizes the evolving understanding of nutrition and its profound impact on health, advocating for a shift towards personalized nutrition using cutting-edge technologies. From continuous glucose monitors to AI-powered apps and sensor toilets, we explore how these innovations enable individuals to measure and optimize their dietary choices. 

]]> Tech Nation Health, Chief Correspondent Dr. Daniel Kraft discusses the concept of "food as medicine." Dr. Kraft emphasizes the evolving understanding of nutrition and its profound impact on health, advocating for a shift towards personalized nutrition using cutting-edge technologies. From continuous glucose monitors to AI-powered apps and sensor toilets, we explore how these innovations enable individuals to measure and optimize their dietary choices. 

]]> Wed, 13 Mar 2024 08:00:00 -0700 Moira Gunn Moira Gunn 621 Tech Nation Health, Chief Correspondent Dr. Daniel Kraft discusses the concept of "food as medicine." Dr. Kraft emphasizes the evolving understanding of nutrition and its profound impact on health, advocating for a shift towards personalized nutrition using cutting-edge technologies. From continuous glucose monitors to AI-powered apps and sensor toilets, we explore how these innovations enable individuals to measure and optimize their dietary choices. 

]]> Daniel Kraft, Tech Nation, Health, moira gunn, biotech nation, medicine, nourish, technology No Repairing Minds, Naturally??? Mark Litton, President & CEO, Athira Pharma 24010 24010 Repairing Minds, Naturally??? Mark Litton, President & CEO, Athira Pharma full d7f4f783-6f7b-4a7d-b3f7-1fa0d19cfdd9 https://share.transistor.fm/s/849c44be Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovative treatments, and one such approach has entered late-stage human clinical trials. Dr. Mark Litton is the President and CEO of Athira Pharma.

]]> Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovative treatments, and one such approach has entered late-stage human clinical trials. Dr. Mark Litton is the President and CEO of Athira Pharma.

]]> Wed, 06 Mar 2024 08:00:00 -0800 Moira Gunn Moira Gunn 1358 Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovative treatments, and one such approach has entered late-stage human clinical trials. Dr. Mark Litton is the President and CEO of Athira Pharma.

]]> biotech, entrepreneurship, bioentrepreneurship, alzheimer's, parkinson's, neurodegenertive diseasesons No Combatting Blood Clots!!! Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics 24009 24009 Combatting Blood Clots!!! Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics full a9274d90-43e3-42d2-82f1-2d02260d5652 https://share.transistor.fm/s/e630e676 This week, Dr. Daniel Bloomfield from Anthos Therapeutics discusses the prevalence and dangers of blood clots, particularly in patients with cancer. Dr. Bloomfield explains the difference between normal and abnormal blood clotting, the risks associated with blood clots in arteries and veins, and the challenges in balancing clot prevention with the risk of bleeding. 

]]> This week, Dr. Daniel Bloomfield from Anthos Therapeutics discusses the prevalence and dangers of blood clots, particularly in patients with cancer. Dr. Bloomfield explains the difference between normal and abnormal blood clotting, the risks associated with blood clots in arteries and veins, and the challenges in balancing clot prevention with the risk of bleeding. 

]]> Wed, 28 Feb 2024 08:00:00 -0800 Moira Gunn Moira Gunn 871 This week, Dr. Daniel Bloomfield from Anthos Therapeutics discusses the prevalence and dangers of blood clots, particularly in patients with cancer. Dr. Bloomfield explains the difference between normal and abnormal blood clotting, the risks associated with blood clots in arteries and veins, and the challenges in balancing clot prevention with the risk of bleeding. 

]]> bleeding, blood clots, clots, anthos, daniel bloomfield, moira gunn No Heartburn, GERD, Cancer??? Dr. Lishan Aklog, CEO of Lucid Diagnostics 24008 24008 Heartburn, GERD, Cancer??? Dr. Lishan Aklog, CEO of Lucid Diagnostics full 723f5b23-ad78-4c0c-9fa8-2bdbbf80270f https://share.transistor.fm/s/5a5396d4 Dr. Lishan Aklog from Lucid Diagnostics tells us about the path from GERD to, unfortunately, esophageal cancer, and about Lucid’s two-minute diagnostic test which can detect precancerous cells. 

]]> Dr. Lishan Aklog from Lucid Diagnostics tells us about the path from GERD to, unfortunately, esophageal cancer, and about Lucid’s two-minute diagnostic test which can detect precancerous cells. 

]]> Wed, 21 Feb 2024 08:00:00 -0800 Moira Gunn Moira Gunn 1379 Dr. Lishan Aklog from Lucid Diagnostics tells us about the path from GERD to, unfortunately, esophageal cancer, and about Lucid’s two-minute diagnostic test which can detect precancerous cells. 

]]> tech nation, biotech nation, GERD, heartburn, esophageal cancer, Lucid Diagnostics, Lishan Aklog No From Tummy Tucks to Drug Trials??? Dr. Eric Merle, Chief Business Innovation Officer, GenoSkin 24007 24007 From Tummy Tucks to Drug Trials??? Dr. Eric Merle, Chief Business Innovation Officer, GenoSkin full 3189cf8a-8f93-4734-b498-af3d86291cc2 https://share.transistor.fm/s/4ff4b2db Dr. Eric Merle from GenoSkin talks about how they are transforming drug discovery using discarded human skin from surgeries like tummy tucks, revolutionizing the process and accelerating drug development timelines.

]]> Dr. Eric Merle from GenoSkin talks about how they are transforming drug discovery using discarded human skin from surgeries like tummy tucks, revolutionizing the process and accelerating drug development timelines.

]]> Wed, 14 Feb 2024 08:46:00 -0800 Moira Gunn Moira Gunn 863 Dr. Eric Merle from GenoSkin talks about how they are transforming drug discovery using discarded human skin from surgeries like tummy tucks, revolutionizing the process and accelerating drug development timelines.

]]> Eric Merle, GenoSkin, Moira Gunn, Tech Nation, Biotech Nation, Biotech, Skin No XPrize Foundation and $101 Million!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 24003 24003 XPrize Foundation and $101 Million!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full 9e342224-50f9-4b15-b58b-5a9f958846a4 https://share.transistor.fm/s/90232fdd Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about the newest XPrize worth an unprecedented $101 Million.

]]> Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about the newest XPrize worth an unprecedented $101 Million.

]]> Wed, 17 Jan 2024 08:00:00 -0800 Moira Gunn Moira Gunn 674 Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about the newest XPrize worth an unprecedented $101 Million.

]]> XPrize, Daniel Kraft, Moira Gunn, Tech Nation, Biotech nation No Wound Healing 2.0!!! Dr. Nik Sopko, Chief Scientific Officer at PolarityTE 24002 24002 Wound Healing 2.0!!! Dr. Nik Sopko, Chief Scientific Officer at PolarityTE full b3647f8e-4383-4955-8c93-5f17bfbd0d64 https://share.transistor.fm/s/03bfbb27 Dr. Nik Sopko, the Chief Scientific Officer of PolarityTE talks about their design for wound healing. Their first treatment candidate is diabetic foot ulcers.

]]> Dr. Nik Sopko, the Chief Scientific Officer of PolarityTE talks about their design for wound healing. Their first treatment candidate is diabetic foot ulcers.

]]> Wed, 10 Jan 2024 08:00:00 -0800 Moira Gunn Moira Gunn 919 Dr. Nik Sopko, the Chief Scientific Officer of PolarityTE talks about their design for wound healing. Their first treatment candidate is diabetic foot ulcers.

]]> Wound healing, moira gunn, Nik Sopko, PolarityTE No Harnessing Natural Killer Cells!!! Dr. Eric Vivier, SVP & CSO of Innate Pharma 24001 24001 Harnessing Natural Killer Cells!!! Dr. Eric Vivier, SVP & CSO of Innate Pharma full 9281b082-0991-4281-9763-a2731ae66f9d https://share.transistor.fm/s/07926421 Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

]]> Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

]]> Wed, 03 Jan 2024 08:00:00 -0800 Moira Gunn Moira Gunn 1225 Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

]]> Tech Nation, Moira Gunn, Eric Vivier, Pharmaceuticals, Immunotherapy No Can Every Medicine Be a Pill??? Dr. Ray Stevens, CEO of ShouTi Pharma 23052 23052 Can Every Medicine Be a Pill??? Dr. Ray Stevens, CEO of ShouTi Pharma full 835735d9-e129-44f3-a3ca-6fd3167a7a68 https://share.transistor.fm/s/32b161c9 Dr. Ray Stevens, CEO of ShouTi Pharma, talks about their approach in turning IV drugs into pills. Current projects include Diabetes and obesity, and two Pulmonary and Cardiovascular disorders. And these are just their first candidates …

]]> Dr. Ray Stevens, CEO of ShouTi Pharma, talks about their approach in turning IV drugs into pills. Current projects include Diabetes and obesity, and two Pulmonary and Cardiovascular disorders. And these are just their first candidates …

]]> Wed, 27 Dec 2023 08:00:00 -0800 Moira Gunn Moira Gunn 1464 Dr. Ray Stevens, CEO of ShouTi Pharma, talks about their approach in turning IV drugs into pills. Current projects include Diabetes and obesity, and two Pulmonary and Cardiovascular disorders. And these are just their first candidates …

]]> Moira Gunn, Ray Stevens, ShouTi Pharma, Tech Nation, IV Drugs, Pharmaceuticals No Gut-Brain Connections to Autism, Parkinson's, and More!!! Dr. Stewart Campbell, CEO Axial Therapeutics 23051 23051 Gut-Brain Connections to Autism, Parkinson's, and More!!! Dr. Stewart Campbell, CEO Axial Therapeutics full 95e097c9-863a-4ddd-8cc3-482329589316 https://share.transistor.fm/s/01437f2e Dr. Stewart Campbell, CEO of Axial Therapeutics, about their groundbreaking work in Autism–related irritability in teenagers, in Parkinson’s, and in complementing the latest cancer treatments.

]]> Dr. Stewart Campbell, CEO of Axial Therapeutics, about their groundbreaking work in Autism–related irritability in teenagers, in Parkinson’s, and in complementing the latest cancer treatments.

]]> Wed, 20 Dec 2023 08:00:00 -0800 Moira Gunn Moira Gunn 1538 Dr. Stewart Campbell, CEO of Axial Therapeutics, about their groundbreaking work in Autism–related irritability in teenagers, in Parkinson’s, and in complementing the latest cancer treatments.

]]> gut brain, autism, parkinsons, moira gunn, stewart campbell, axial therapeutics, tech nation No Ancient Viruses in our DNA??? Dr. Neil Shubin, Professor & Author University of Chicago 23050 23050 Ancient Viruses in our DNA??? Dr. Neil Shubin, Professor & Author University of Chicago full 9f077f55-8ee3-4064-97bb-103c290f8464 https://share.transistor.fm/s/c52f1d16 On this week’s BioTech Nation University of Chicago professor Dr. Neil Shubin talks about his book “Some Assembly required … Decoding Four Billion Years of Life, from Ancient Fossils to DNA.” Ancient viruses in our DNA? And what about “jumping genes”?

]]> On this week’s BioTech Nation University of Chicago professor Dr. Neil Shubin talks about his book “Some Assembly required … Decoding Four Billion Years of Life, from Ancient Fossils to DNA.” Ancient viruses in our DNA? And what about “jumping genes”?

]]> Wed, 13 Dec 2023 08:00:00 -0800 Moira Gunn Moira Gunn 1735 On this week’s BioTech Nation University of Chicago professor Dr. Neil Shubin talks about his book “Some Assembly required … Decoding Four Billion Years of Life, from Ancient Fossils to DNA.” Ancient viruses in our DNA? And what about “jumping genes”?

]]> biotech, biotech nation, tech nation, neil shubin, moira gunn, dna, viruses No Treating Diseases with Brain Implants??? Nicolas Vachicouras, CEO & Co-Founder Neurosoft Bioelectronics 23049 23049 Treating Diseases with Brain Implants??? Nicolas Vachicouras, CEO & Co-Founder Neurosoft Bioelectronics full c9672f56-c6ff-405b-a4ac-dc43c9b69bbc https://share.transistor.fm/s/67beba3b This week we visit the brain, and look at what a flexible brain implant might do – from sensing how your brain is working to actual treatment. Nicolas Vachicouras from Neurosoft Bioelectronics in Geneva, Switzerland talks about the target for their first treatment: severe tinnitus. 

]]> This week we visit the brain, and look at what a flexible brain implant might do – from sensing how your brain is working to actual treatment. Nicolas Vachicouras from Neurosoft Bioelectronics in Geneva, Switzerland talks about the target for their first treatment: severe tinnitus. 

]]> Wed, 06 Dec 2023 08:00:00 -0800 Moira Gunn Moira Gunn 944 This week we visit the brain, and look at what a flexible brain implant might do – from sensing how your brain is working to actual treatment. Nicolas Vachicouras from Neurosoft Bioelectronics in Geneva, Switzerland talks about the target for their first treatment: severe tinnitus. 

]]> Neurosoft Bioelectronics, Biotech, Tech, Brain Implants, tinnitus No The Next Ozempic or Wegovy... But Without the Injection??? Dr. Steffen-Sebastian Bolz, CSO, Aphaia (ah-phi-ah) Pharma 23048 23048 The Next Ozempic or Wegovy... But Without the Injection??? Dr. Steffen-Sebastian Bolz, CSO, Aphaia (ah-phi-ah) Pharma full f3dd8727-2dd0-4658-845c-b9b527909d7a https://share.transistor.fm/s/c85912e8 What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2. 

]]> What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2. 

]]> Wed, 29 Nov 2023 08:00:00 -0800 Moira Gunn Moira Gunn 1476 What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2. 

]]> biotech, biotech nation, moira gunn, Aphaia Pharma, Ozempic, Wegovy, Weight loss No Who Could Forget About Dolly The Sheep??? Sir Ian Wilmut, Director, Scottish Centre for Regenerative Medicine 23047 23047 Who Could Forget About Dolly The Sheep??? Sir Ian Wilmut, Director, Scottish Centre for Regenerative Medicine full 9f7970f5-1620-47b1-b3a9-761918ebee6d https://share.transistor.fm/s/d3b90933 We honor Sir Ian Wilmut, the Scottish embryologist who gained worldwide renown as the leader of the scientific research group that cloned the equally famous Dolly. With his recent passing, we air our 2007 BioTech Nation interview, when David Ewing Duncan and I spoke with Dr. Wilmut on the 10th anniversary of Dolly’s birth. 

]]> We honor Sir Ian Wilmut, the Scottish embryologist who gained worldwide renown as the leader of the scientific research group that cloned the equally famous Dolly. With his recent passing, we air our 2007 BioTech Nation interview, when David Ewing Duncan and I spoke with Dr. Wilmut on the 10th anniversary of Dolly’s birth. 

]]> Wed, 22 Nov 2023 08:00:00 -0800 Moira Gunn Moira Gunn 1791 We honor Sir Ian Wilmut, the Scottish embryologist who gained worldwide renown as the leader of the scientific research group that cloned the equally famous Dolly. With his recent passing, we air our 2007 BioTech Nation interview, when David Ewing Duncan and I spoke with Dr. Wilmut on the 10th anniversary of Dolly’s birth. 

]]> Dolly, clone, moira gunn, ian wilmut, biotech, biotech nation, tech nation No Everybody Has a Thyroid... What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma 23046 23046 Everybody Has a Thyroid... What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma full f7a93e47-24db-47bc-90f0-217d2400f8ec https://share.transistor.fm/s/67f4c50d Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your
parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

]]> Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your
parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

]]> Wed, 15 Nov 2023 10:19:02 -0800 Moira Gunn Moira Gunn 1699 Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your
parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

]]> moira gunn, amolyt pharma, mark sumeray, tech nation, biotech nation, thyroid No It’s All About Cancer, and Covid??? Dr. Andrew Allen, President, CEO, & Co-Founder Gritstone Bio 23045 23045 It’s All About Cancer, and Covid??? Dr. Andrew Allen, President, CEO, & Co-Founder Gritstone Bio full cd12f0dd-9dd2-497f-8cb0-99147c9d132c https://share.transistor.fm/s/262d1a7e This week on BioTech Nation, Andrew Allen, President, CEO and Co-Founder of Gritstone Bio – a full spectrum look at how cancer starts and cancer treatments have developed … and what next-generation treatment means today with Gritstone’s work in colorectal cancer.  And wait for it … the next generation of Covid vaccines. 

]]> This week on BioTech Nation, Andrew Allen, President, CEO and Co-Founder of Gritstone Bio – a full spectrum look at how cancer starts and cancer treatments have developed … and what next-generation treatment means today with Gritstone’s work in colorectal cancer.  And wait for it … the next generation of Covid vaccines. 

]]> Wed, 08 Nov 2023 08:00:00 -0800 Moira Gunn Moira Gunn 2608 This week on BioTech Nation, Andrew Allen, President, CEO and Co-Founder of Gritstone Bio – a full spectrum look at how cancer starts and cancer treatments have developed … and what next-generation treatment means today with Gritstone’s work in colorectal cancer.  And wait for it … the next generation of Covid vaccines. 

]]> biotech, biotech nation, cancer, moira gunn, tech nation, gritstone bio, covid, andrew allen No Is Medical School Curriculum Outdated??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 23044 23044 Is Medical School Curriculum Outdated??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full 1a56be85-7bc7-4163-ba03-88556c344c47 https://share.transistor.fm/s/e206de22 Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about how Medical Schools decide what to teach. You might be surprised that it’s based on the Flexner Report … written in … 1910. Is it time for a do-over? And what might that be?

]]> Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about how Medical Schools decide what to teach. You might be surprised that it’s based on the Flexner Report … written in … 1910. Is it time for a do-over? And what might that be?

]]> Wed, 01 Nov 2023 08:00:00 -0700 Moira Gunn Moira Gunn 703 Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about how Medical Schools decide what to teach. You might be surprised that it’s based on the Flexner Report … written in … 1910. Is it time for a do-over? And what might that be?

]]> biotech, medical school, daniel kraft, moira gunn, tech nation, biotech nation, flexnor report No Your Digital Twin May Already Exist!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 23043 23043 Your Digital Twin May Already Exist!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full fdcdcc4d-6615-42e2-808b-9e391a06a1ce https://share.transistor.fm/s/2672f542 Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about your Digital Twin … your Digital Twin … yes, you have one.

]]> Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about your Digital Twin … your Digital Twin … yes, you have one.

]]> Wed, 25 Oct 2023 08:00:00 -0700 Moira Gunn Moira Gunn 410 Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about your Digital Twin … your Digital Twin … yes, you have one.

]]> biotech, moira gunn, daniel kraft, digital health, digital twin, healthcare, tech nation, biotech nation No A New Approach To Treating Diabetes... Dr. Anthony Japour, President & CEO, iTolerance 23042 23042 A New Approach To Treating Diabetes... Dr. Anthony Japour, President & CEO, iTolerance full 1f195290-45ba-4c71-82da-6ad5cf5178c7 https://share.transistor.fm/s/77b93b27 Dr. Anthony Japour, President and CEO from iTolerance in Miami, Florida tells us about implanting insulin-producing cells in your pancreas – it’s been tried before, but they have a new approach which just might work.

]]> Dr. Anthony Japour, President and CEO from iTolerance in Miami, Florida tells us about implanting insulin-producing cells in your pancreas – it’s been tried before, but they have a new approach which just might work.

]]> Wed, 18 Oct 2023 08:00:00 -0700 Moira Gunn Moira Gunn 760 Dr. Anthony Japour, President and CEO from iTolerance in Miami, Florida tells us about implanting insulin-producing cells in your pancreas – it’s been tried before, but they have a new approach which just might work.

]]> moira gunn, biotech, biotechnation, tech, technation, itolerance, diabetes, type1, insulin, pancreas, anthony japour No What's New in Digital Health!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent 23041 23041 What's New in Digital Health!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent full d0e078e3-0ecc-487a-8032-3717fc22c476 https://share.transistor.fm/s/07e89cbc Tech Nation Health Chief Correspondent Dr. Daniel Kraft tells us about the explosion of digital health.

]]> Tech Nation Health Chief Correspondent Dr. Daniel Kraft tells us about the explosion of digital health.

]]> Wed, 11 Oct 2023 08:00:00 -0700 Moira Gunn Moira Gunn 677 Tech Nation Health Chief Correspondent Dr. Daniel Kraft tells us about the explosion of digital health.

]]> moira gunn, tech nation, biotech nation, daniel kraft, digital health No Google's First Radio Interview Ever!!! Larry Page & Sergey Brin, Co-Founders, Google 23040 23040 Google's First Radio Interview Ever!!! Larry Page & Sergey Brin, Co-Founders, Google full c485981d-c876-4d93-9691-5866e76d112f https://share.transistor.fm/s/be140018 It’s the 25th anniversary of the founding of Google … and 23 years ago, Google founders - Larry Page and Sergey Brin – came to the Tech Nation studios to do their very first radio interview. There’s lots to learn there, including they believed what humans demanded of search, and why they did what they did. 

]]> It’s the 25th anniversary of the founding of Google … and 23 years ago, Google founders - Larry Page and Sergey Brin – came to the Tech Nation studios to do their very first radio interview. There’s lots to learn there, including they believed what humans demanded of search, and why they did what they did. 

]]> Wed, 04 Oct 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1695 It’s the 25th anniversary of the founding of Google … and 23 years ago, Google founders - Larry Page and Sergey Brin – came to the Tech Nation studios to do their very first radio interview. There’s lots to learn there, including they believed what humans demanded of search, and why they did what they did. 

]]> biotech, tech, google, larry page, sergey brin, moira gunn, tech nation, biotech nation No Old Dog, New Tricks ??? ... Dr. Robert Ladner, CEO & Founder, CV6 Therapeutics 23039 23039 Old Dog, New Tricks ??? ... Dr. Robert Ladner, CEO & Founder, CV6 Therapeutics full 7fcc445a-115a-4ad4-b27e-577ecc2880ca https://share.transistor.fm/s/3cdafc60 Dr. Robert Ladner, the Founder of CV6 Therapeutics in Belfast, Northern Ireland, tells us about their work to make a cornerstone cancer chemotherapy, even more effective. First trials are in colorectal and gastrointestinal cancers...  

]]> Dr. Robert Ladner, the Founder of CV6 Therapeutics in Belfast, Northern Ireland, tells us about their work to make a cornerstone cancer chemotherapy, even more effective. First trials are in colorectal and gastrointestinal cancers...  

]]> Wed, 27 Sep 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1271 Dr. Robert Ladner, the Founder of CV6 Therapeutics in Belfast, Northern Ireland, tells us about their work to make a cornerstone cancer chemotherapy, even more effective. First trials are in colorectal and gastrointestinal cancers...  

]]> Biotech, Biotech nation, moira gunn, cancer, robert ladner, CV6, therapeutics No Can Good Viruses Kill Deadly Infections??? Tom Ireland, Science Journalist & Author 23038 23038 Can Good Viruses Kill Deadly Infections??? Tom Ireland, Science Journalist & Author full 50492a78-fc3a-406d-a970-171f19f1759f https://share.transistor.fm/s/42920853 Science journalist Tom Ireland tells us about a burgeoning field of science, which is changing the fight to successfully treat antibiotic infections. His book is “The Good Virus: The Amazing Story and Forgotten Promise of the Phage”. 

]]> Science journalist Tom Ireland tells us about a burgeoning field of science, which is changing the fight to successfully treat antibiotic infections. His book is “The Good Virus: The Amazing Story and Forgotten Promise of the Phage”. 

]]> Wed, 20 Sep 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1737 Science journalist Tom Ireland tells us about a burgeoning field of science, which is changing the fight to successfully treat antibiotic infections. His book is “The Good Virus: The Amazing Story and Forgotten Promise of the Phage”. 

]]> biotech, biotech nation, moira gunn, viruses, phages, tom ireland No Osteoarthritis... Mostly in the Knee, But Pick a Joint!!! Dr. Diem Nguyen, CEO of Xalud Therapeutics 23037 23037 Osteoarthritis... Mostly in the Knee, But Pick a Joint!!! Dr. Diem Nguyen, CEO of Xalud Therapeutics full e258d416-3821-476f-8000-78c9c8ba5ae1 https://share.transistor.fm/s/ae3045d6 Osteoarthritis – mostly in the knee, but pick a joint. Dr. Diem (Zem) Nguyen (N’Win) is the CEO of Xalud (Za-lood) Therapeutics. We’ll talk about their work to reduce the inflammation that drives pain. It’s now in human clinical trials.

]]> Osteoarthritis – mostly in the knee, but pick a joint. Dr. Diem (Zem) Nguyen (N’Win) is the CEO of Xalud (Za-lood) Therapeutics. We’ll talk about their work to reduce the inflammation that drives pain. It’s now in human clinical trials.

]]> Wed, 13 Sep 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1119 Osteoarthritis – mostly in the knee, but pick a joint. Dr. Diem (Zem) Nguyen (N’Win) is the CEO of Xalud (Za-lood) Therapeutics. We’ll talk about their work to reduce the inflammation that drives pain. It’s now in human clinical trials.

]]> moira gunn, tech nation, biotech nation, osteoarthritis, xalud, joint, inflammation, diem nguyen No Why Do AI One Way, When You Can Do it 25??? Dr. Ben Thomas and Dermot Tierney, CEO & CCO, Amply Discovery 23036 23036 Why Do AI One Way, When You Can Do it 25??? Dr. Ben Thomas and Dermot Tierney, CEO & CCO, Amply Discovery full 5107749e-ebce-4113-b96d-8927cc7cb0fa https://share.transistor.fm/s/59255bd8 Why use one AI approach when you can use 25? CEO Dr. Ben Thomas and Chief Commercial Officer Dermot Tierney from Amply Discovery talks about how their novel approach to AI in drug discovery.

]]> Why use one AI approach when you can use 25? CEO Dr. Ben Thomas and Chief Commercial Officer Dermot Tierney from Amply Discovery talks about how their novel approach to AI in drug discovery.

]]> Wed, 06 Sep 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1309 Why use one AI approach when you can use 25? CEO Dr. Ben Thomas and Chief Commercial Officer Dermot Tierney from Amply Discovery talks about how their novel approach to AI in drug discovery.

]]> Moira Gunn, Tech Nation, Biotech Nation, Drug Discovery, AI, Artificial Intelligence, Ben Thomas, Dermot Tierny, Amply Discovery No Acute Cannabis Intoxication... Is There An Antidote??? Dr. Ken Cundy, CSO at Anebulo Pharmaceuticals 23035 23035 Acute Cannabis Intoxication... Is There An Antidote??? Dr. Ken Cundy, CSO at Anebulo Pharmaceuticals full 6901c280-3a30-4d78-b740-b17b429eda6f https://share.transistor.fm/s/b1155861 Modern cannabis products, with higher potency than those from the past, can lead to acute cannabis intoxication. Anebulo Pharmaceuticals, led by Chief Scientific Officer Dr. Ken Cundy, is working on an antidote that counteracts the negative effects of THC overdose, potentially benefiting both adults and children.

]]> Modern cannabis products, with higher potency than those from the past, can lead to acute cannabis intoxication. Anebulo Pharmaceuticals, led by Chief Scientific Officer Dr. Ken Cundy, is working on an antidote that counteracts the negative effects of THC overdose, potentially benefiting both adults and children.

]]> Wed, 30 Aug 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1133 Modern cannabis products, with higher potency than those from the past, can lead to acute cannabis intoxication. Anebulo Pharmaceuticals, led by Chief Scientific Officer Dr. Ken Cundy, is working on an antidote that counteracts the negative effects of THC overdose, potentially benefiting both adults and children.

]]> biotech, biotech nation, moira gunn, ken cundy, cannabis, cannabis intoxication, antidote, anebulo, pharmaceuticals No Gliobastoma + New View on Clinical Trials... Dr. Fahar Merchant, President & CEO Medicenna Therapeutics 23033 23033 Gliobastoma + New View on Clinical Trials... Dr. Fahar Merchant, President & CEO Medicenna Therapeutics full 74fca797-9282-4f8e-9288-32dd795b1656 https://share.transistor.fm/s/5e6ba2fc Glioblastoma is the most aggressive form of brain cancer, and progress in treating Glioblastoma has been elusive. Now, Toronto-based Medicenna has completed a successful Phase 2 with its innovative drug, and is now deep into planning the Phase 3 Trial. Also of interest, the FDA agreed to an unprecedented approach in Phase 2, which not only yields better science, but reduces the cost of the clinical trials themselves. To be sure, this approach will be carried forward into Phase 3. Dr. Fahar Merchant is the President & CEO of Medicenna Therapeutics. 

]]> Glioblastoma is the most aggressive form of brain cancer, and progress in treating Glioblastoma has been elusive. Now, Toronto-based Medicenna has completed a successful Phase 2 with its innovative drug, and is now deep into planning the Phase 3 Trial. Also of interest, the FDA agreed to an unprecedented approach in Phase 2, which not only yields better science, but reduces the cost of the clinical trials themselves. To be sure, this approach will be carried forward into Phase 3. Dr. Fahar Merchant is the President & CEO of Medicenna Therapeutics. 

]]> Wed, 16 Aug 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1358 Glioblastoma is the most aggressive form of brain cancer, and progress in treating Glioblastoma has been elusive. Now, Toronto-based Medicenna has completed a successful Phase 2 with its innovative drug, and is now deep into planning the Phase 3 Trial. Also of interest, the FDA agreed to an unprecedented approach in Phase 2, which not only yields better science, but reduces the cost of the clinical trials themselves. To be sure, this approach will be carried forward into Phase 3. Dr. Fahar Merchant is the President & CEO of Medicenna Therapeutics. 

]]> Moira Gunn, Biotech, Biotech Nation, Gliobastoma, Clinical Trials, Fahar Merchant, Medicenna Therapeutics No Innovation in Head & Neck Cancers!!! Dr. Mark Newman, CSO, GeoVax 23032 23032 Innovation in Head & Neck Cancers!!! Dr. Mark Newman, CSO, GeoVax full f1f938ee-26cd-4321-9437-2707c31643d8 https://share.transistor.fm/s/67b144e3 In this week's BioTech Nation, we discuss Geovax, a company working on a novel approach to treat head and neck cancers, which are often difficult to treat after standard options have been exhausted. Geovax is developing A2 component therapy, using an enzyme delivered directly to the tumor by a needle injection, followed by an infusion of an inactive form of a chemotherapeutic drug, which becomes toxic to the tumors when processed by the enzyme. The treatment aims to localize the effects, reduce side effects, and potentially activate the immune system to target other tumor cells in the body. Phase two trials are underway, with promising results so far.

]]> In this week's BioTech Nation, we discuss Geovax, a company working on a novel approach to treat head and neck cancers, which are often difficult to treat after standard options have been exhausted. Geovax is developing A2 component therapy, using an enzyme delivered directly to the tumor by a needle injection, followed by an infusion of an inactive form of a chemotherapeutic drug, which becomes toxic to the tumors when processed by the enzyme. The treatment aims to localize the effects, reduce side effects, and potentially activate the immune system to target other tumor cells in the body. Phase two trials are underway, with promising results so far.

]]> Wed, 09 Aug 2023 08:00:00 -0700 Moira Gunn Moira Gunn 880 In this week's BioTech Nation, we discuss Geovax, a company working on a novel approach to treat head and neck cancers, which are often difficult to treat after standard options have been exhausted. Geovax is developing A2 component therapy, using an enzyme delivered directly to the tumor by a needle injection, followed by an infusion of an inactive form of a chemotherapeutic drug, which becomes toxic to the tumors when processed by the enzyme. The treatment aims to localize the effects, reduce side effects, and potentially activate the immune system to target other tumor cells in the body. Phase two trials are underway, with promising results so far.

]]> Moira Gunn, Biotech, Biotech Nation, Head, Neck, Cancer, Mark Newman, GeoVax No We Still Can't Ignore Long Covid... Dr. Jeffrey Cleland, CEO Ashvattha Therapeutics 23031 23031 We Still Can't Ignore Long Covid... Dr. Jeffrey Cleland, CEO Ashvattha Therapeutics full c35ff2f0-e818-4e87-b643-70086f7a573c https://share.transistor.fm/s/03b42b9e In this week's episode of Biotech Nation, Dr. Jeffrey Cleland, the President and CEO of Ashvattha Therapeutics, discusses their drug development efforts to address long COVID. They discuss the definition of long COVID by the World Health Organization, the prevalence of the condition, and the chronic inflammation that occurs in the body, including the brain. Dr. Cleland explains how their nanomedicine approach aims to selectively target and turn off reactive inflammatory cells, potentially offering a treatment for long haul COVID and other diseases.

]]> In this week's episode of Biotech Nation, Dr. Jeffrey Cleland, the President and CEO of Ashvattha Therapeutics, discusses their drug development efforts to address long COVID. They discuss the definition of long COVID by the World Health Organization, the prevalence of the condition, and the chronic inflammation that occurs in the body, including the brain. Dr. Cleland explains how their nanomedicine approach aims to selectively target and turn off reactive inflammatory cells, potentially offering a treatment for long haul COVID and other diseases.

]]> Wed, 02 Aug 2023 08:00:00 -0700 Moira Gunn Moira Gunn 594 In this week's episode of Biotech Nation, Dr. Jeffrey Cleland, the President and CEO of Ashvattha Therapeutics, discusses their drug development efforts to address long COVID. They discuss the definition of long COVID by the World Health Organization, the prevalence of the condition, and the chronic inflammation that occurs in the body, including the brain. Dr. Cleland explains how their nanomedicine approach aims to selectively target and turn off reactive inflammatory cells, potentially offering a treatment for long haul COVID and other diseases.

]]> Long Covid, Covid, Jeffrey Cleland, Ashvattha Therapeutics, moira gunn, biotech, biotech nation No Can The Time Needed for CAR-T be shortened? EXUMA Says Yes!!! Dr. Gregory Frost, CEO, EXUMA Biotech 23030 23030 Can The Time Needed for CAR-T be shortened? EXUMA Says Yes!!! Dr. Gregory Frost, CEO, EXUMA Biotech full 36f45031-5043-4605-aaad-d49a47acd231 https://share.transistor.fm/s/e006f818 In this week's episode of Biotech Nation, Dr. Greg Frost, CEO of Exuma Biotech, discusses their innovative approaches to cancer treatment. They are working on a method to shorten the time and eliminate hospital stays for CAR-T therapy, while also developing a new technology called G-car that combines T cells and NK cells to create a more gentle and effective cancer therapy.

]]> In this week's episode of Biotech Nation, Dr. Greg Frost, CEO of Exuma Biotech, discusses their innovative approaches to cancer treatment. They are working on a method to shorten the time and eliminate hospital stays for CAR-T therapy, while also developing a new technology called G-car that combines T cells and NK cells to create a more gentle and effective cancer therapy.

]]> Wed, 26 Jul 2023 08:00:00 -0700 Moira Gunn Moira Gunn 621 In this week's episode of Biotech Nation, Dr. Greg Frost, CEO of Exuma Biotech, discusses their innovative approaches to cancer treatment. They are working on a method to shorten the time and eliminate hospital stays for CAR-T therapy, while also developing a new technology called G-car that combines T cells and NK cells to create a more gentle and effective cancer therapy.

]]> moira gunn, biotech, biotech nation, CAR-T, Gregory Frost, EXUMA Biotech No Temporal Lobe Epilepsy - TLE - Will Cell Therapy Work??? Dr. Cory Nicholas, CEO, Neurona Therapeutics 23029 23029 Temporal Lobe Epilepsy - TLE - Will Cell Therapy Work??? Dr. Cory Nicholas, CEO, Neurona Therapeutics full d0cf8c55-e9cf-44b6-9dc7-b2da5fce9993 https://share.transistor.fm/s/2d2b177e A new cell therapy, just entering human clinical trials. It focuses on a particular type of Epilepsy - Temporal Lobe Epilepsy. I speak with Dr. Cory Nicholas, the Co-Founder and CEO of Neurona Therapeutics, about their idea, what they’ve done, and how they plan to approach testing this unprecedented treatment. 

]]> A new cell therapy, just entering human clinical trials. It focuses on a particular type of Epilepsy - Temporal Lobe Epilepsy. I speak with Dr. Cory Nicholas, the Co-Founder and CEO of Neurona Therapeutics, about their idea, what they’ve done, and how they plan to approach testing this unprecedented treatment. 

]]> Wed, 19 Jul 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1461 A new cell therapy, just entering human clinical trials. It focuses on a particular type of Epilepsy - Temporal Lobe Epilepsy. I speak with Dr. Cory Nicholas, the Co-Founder and CEO of Neurona Therapeutics, about their idea, what they’ve done, and how they plan to approach testing this unprecedented treatment. 

]]> Temporal Lobe Epilepsy, TLE, Cell Therapy, Cory Nicholas, Neurona Therapeutics, Moira Gunn, Biotech, Biotech Nation No New Hope For Glaucoma... Dr. Chris Nave, Managing Director of Brandon Capital and Chair of PolyActiva 23028 23028 New Hope For Glaucoma... Dr. Chris Nave, Managing Director of Brandon Capital and Chair of PolyActiva full 2059c205-add7-4290-8fcd-a73c07061ab0 https://share.transistor.fm/s/00c879e8 Join us as Dr. Chris Nave, the managing director of Brandon Capital and Chair of PolyActiva, reveals groundbreaking advancements in eye treatments on this week's episode of Biotech Nation! Discover how their innovative technology is revolutionizing the way we deliver drugs to the eye, offering extended therapy periods and eliminating the need for frequent injections or daily drops. Don't miss out on this eye-opening discussion about the future of ophthalmology and the potential to transform the lives of millions affected by glaucoma and other eye diseases. 

]]> Join us as Dr. Chris Nave, the managing director of Brandon Capital and Chair of PolyActiva, reveals groundbreaking advancements in eye treatments on this week's episode of Biotech Nation! Discover how their innovative technology is revolutionizing the way we deliver drugs to the eye, offering extended therapy periods and eliminating the need for frequent injections or daily drops. Don't miss out on this eye-opening discussion about the future of ophthalmology and the potential to transform the lives of millions affected by glaucoma and other eye diseases. 

]]> Wed, 12 Jul 2023 08:00:00 -0700 Moira Gunn Moira Gunn 552 Join us as Dr. Chris Nave, the managing director of Brandon Capital and Chair of PolyActiva, reveals groundbreaking advancements in eye treatments on this week's episode of Biotech Nation! Discover how their innovative technology is revolutionizing the way we deliver drugs to the eye, offering extended therapy periods and eliminating the need for frequent injections or daily drops. Don't miss out on this eye-opening discussion about the future of ophthalmology and the potential to transform the lives of millions affected by glaucoma and other eye diseases. 

]]> biotech nation, biotech, tech nation, moira gunn, glaucoma, polyactiva, brandon capital, chris nave No The Beauty Contest... Winner Goes to Phase I - Dr. Richard Austin, Founder & CEO Reglagene 23027 23027 The Beauty Contest... Winner Goes to Phase I - Dr. Richard Austin, Founder & CEO Reglagene full 74b8c407-9432-43f8-b119-39232ba52289 https://share.transistor.fm/s/82ef1b54 Join Dr. Richard Austin, Founder and CEO of Reglagene, as he reveals the intense process of selecting the most promising drug candidate for treating brain cancer. Delve into the intriguing world of the "Bake Off" or "beauty contest" where molecules compete to be the breakthrough therapy in human clinical trials. Discover the challenges of penetrating the blood-brain barrier and the quest to revolutionize brain cancer treatment. 

]]> Join Dr. Richard Austin, Founder and CEO of Reglagene, as he reveals the intense process of selecting the most promising drug candidate for treating brain cancer. Delve into the intriguing world of the "Bake Off" or "beauty contest" where molecules compete to be the breakthrough therapy in human clinical trials. Discover the challenges of penetrating the blood-brain barrier and the quest to revolutionize brain cancer treatment. 

]]> Wed, 05 Jul 2023 08:00:00 -0700 Moira Gunn Moira Gunn 996 Join Dr. Richard Austin, Founder and CEO of Reglagene, as he reveals the intense process of selecting the most promising drug candidate for treating brain cancer. Delve into the intriguing world of the "Bake Off" or "beauty contest" where molecules compete to be the breakthrough therapy in human clinical trials. Discover the challenges of penetrating the blood-brain barrier and the quest to revolutionize brain cancer treatment. 

]]> biotech, biotechnation, moira gunn, reglagene, richard austin, brain cancer, treatments No Sticky Proteins??? Alzheimer's, Parkinson's, and ALS...Dr. Maria Maccecchini, President & CEO, Annovis Bio 23026 23026 Sticky Proteins??? Alzheimer's, Parkinson's, and ALS...Dr. Maria Maccecchini, President & CEO, Annovis Bio full 2d916386-b014-4264-9419-2b684bfc3ba6 https://share.transistor.fm/s/a6e1c2ef This week we explore the commonalities among neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS. Dr. Maria Macccecchini, Founder and CEO of Annovis Bio, discusses the role of sticky proteins in these diseases and how her company is developing a drug to prevent the aggregation of these proteins. The episode also touches on their ongoing clinical trials for Alzheimer's and Parkinson's and their potential application in treating traumatic brain injuries.

]]> This week we explore the commonalities among neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS. Dr. Maria Macccecchini, Founder and CEO of Annovis Bio, discusses the role of sticky proteins in these diseases and how her company is developing a drug to prevent the aggregation of these proteins. The episode also touches on their ongoing clinical trials for Alzheimer's and Parkinson's and their potential application in treating traumatic brain injuries.

]]> Wed, 28 Jun 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1160 This week we explore the commonalities among neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS. Dr. Maria Macccecchini, Founder and CEO of Annovis Bio, discusses the role of sticky proteins in these diseases and how her company is developing a drug to prevent the aggregation of these proteins. The episode also touches on their ongoing clinical trials for Alzheimer's and Parkinson's and their potential application in treating traumatic brain injuries.

]]> biotech, biotech nation, Sticky Proteins, Alzheimer's, Parkinson's, ALS, Maria Maccecchini, Annovis Bio, Moira Gunn No When Your Distant Cousins ID You For Murder… Ed Humes, Author of "The Forever Witness" 23025 23025 When Your Distant Cousins ID You For Murder… Ed Humes, Author of "The Forever Witness" full d1840254-5286-4229-bebf-029560ec4b12 https://share.transistor.fm/s/e9a30d03 Moira speaks with Pulitzer Prize-winning author, Ed Humes. His latest is “The Forever Witness … How DNA and Genealogy Solved a Cold Case Double Murder.” We get an object lesson in the Three Ages of DNA, and while it reads like a fast-paced Cold Case on steroids – it provides details no fiction writer would dare to make up, like the unexpected involvement of the famous true crimes writer, Ann Rule, and a person whose DNA skills are familiar to fans of the PBS documentary series, “Finding your roots with Henry Louis Gates, Jr.”

]]> Moira speaks with Pulitzer Prize-winning author, Ed Humes. His latest is “The Forever Witness … How DNA and Genealogy Solved a Cold Case Double Murder.” We get an object lesson in the Three Ages of DNA, and while it reads like a fast-paced Cold Case on steroids – it provides details no fiction writer would dare to make up, like the unexpected involvement of the famous true crimes writer, Ann Rule, and a person whose DNA skills are familiar to fans of the PBS documentary series, “Finding your roots with Henry Louis Gates, Jr.”

]]> Wed, 21 Jun 2023 08:00:00 -0700 Moira Gunn Moira Gunn 2973 Moira speaks with Pulitzer Prize-winning author, Ed Humes. His latest is “The Forever Witness … How DNA and Genealogy Solved a Cold Case Double Murder.” We get an object lesson in the Three Ages of DNA, and while it reads like a fast-paced Cold Case on steroids – it provides details no fiction writer would dare to make up, like the unexpected involvement of the famous true crimes writer, Ann Rule, and a person whose DNA skills are familiar to fans of the PBS documentary series, “Finding your roots with Henry Louis Gates, Jr.”

]]> biotech, moira gunn, DNA, Genealogy, Murder Ed Humes No Are Fibroblasts All Over My Body??? Dr. Hamid Khoja, CSO at FibroBiologics 23024 23024 Are Fibroblasts All Over My Body??? Dr. Hamid Khoja, CSO at FibroBiologics full 49d3b465-6165-488e-8f7a-d2153d327839 https://share.transistor.fm/s/82efea47 Dr. Hamid Khoja, Chief Scientific Officer of Fibro Biologics, discusses the potential of fibroblasts in regenerative medicine, highlighting their abundance and diverse functions in the body. He shares insights from their ongoing human clinical trials, including the use of fibroblasts for treating degenerative disc disease and multiple sclerosis. Dr. Khoja also mentions their promising findings in animal studies related to diabetic foot ulcers.

]]> Dr. Hamid Khoja, Chief Scientific Officer of Fibro Biologics, discusses the potential of fibroblasts in regenerative medicine, highlighting their abundance and diverse functions in the body. He shares insights from their ongoing human clinical trials, including the use of fibroblasts for treating degenerative disc disease and multiple sclerosis. Dr. Khoja also mentions their promising findings in animal studies related to diabetic foot ulcers.

]]> Wed, 14 Jun 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1513 Dr. Hamid Khoja, Chief Scientific Officer of Fibro Biologics, discusses the potential of fibroblasts in regenerative medicine, highlighting their abundance and diverse functions in the body. He shares insights from their ongoing human clinical trials, including the use of fibroblasts for treating degenerative disc disease and multiple sclerosis. Dr. Khoja also mentions their promising findings in animal studies related to diabetic foot ulcers.

]]> biotech, biotech nation, moira gunn, hamid khoja, fibroblasts, fibrobiologics No Engineering Viruses to Treat Solid Tumors... Dr. Paul Peter Tak, CEO of Candel Therapeutics 23023 23023 Engineering Viruses to Treat Solid Tumors... Dr. Paul Peter Tak, CEO of Candel Therapeutics full b9213727-5f4a-4b91-a63d-1a305486f804 https://share.transistor.fm/s/46f791fb Dr. Paul Peter Tack, CEO of Candel Therapeutics, unveils their groundbreaking approach to cancer treatments using engineered viruses. Discover how these viruses are harnessed to target solid tumors, deliver therapeutic genes, and activate the patient's immune system for a powerful anti-cancer response.

]]> Dr. Paul Peter Tack, CEO of Candel Therapeutics, unveils their groundbreaking approach to cancer treatments using engineered viruses. Discover how these viruses are harnessed to target solid tumors, deliver therapeutic genes, and activate the patient's immune system for a powerful anti-cancer response.

]]> Tue, 06 Jun 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1344 Dr. Paul Peter Tack, CEO of Candel Therapeutics, unveils their groundbreaking approach to cancer treatments using engineered viruses. Discover how these viruses are harnessed to target solid tumors, deliver therapeutic genes, and activate the patient's immune system for a powerful anti-cancer response.

]]> biotech nation, moira gunn, paul peter tak, candel therapeutics, tumors, solid tumors No AI Three Different Ways to a New Drug??? Dr. Francois Vigneault, Co-Founder & CEO Shape Therapeutics 23022 23022 AI Three Different Ways to a New Drug??? Dr. Francois Vigneault, Co-Founder & CEO Shape Therapeutics full c53c33ac-9379-4071-8751-665575893962 https://share.transistor.fm/s/932464d0 Discover the limitless potential of mRNA engineering as Dr. Francois Vigneault, Co-Founder and CEO of Shape Therapeutics, discusses their groundbreaking work in using mRNA to address genetic mutations in diseases like Parkinson's and Alzheimer's, offering hope for effective treatments and prevention strategies. Join us as we delve into the world of mRNA technology and its transformative impact on healthcare.

]]> Discover the limitless potential of mRNA engineering as Dr. Francois Vigneault, Co-Founder and CEO of Shape Therapeutics, discusses their groundbreaking work in using mRNA to address genetic mutations in diseases like Parkinson's and Alzheimer's, offering hope for effective treatments and prevention strategies. Join us as we delve into the world of mRNA technology and its transformative impact on healthcare.

]]> Wed, 31 May 2023 08:00:00 -0700 Moira Gunn Moira Gunn 1655 Discover the limitless potential of mRNA engineering as Dr. Francois Vigneault, Co-Founder and CEO of Shape Therapeutics, discusses their groundbreaking work in using mRNA to address genetic mutations in diseases like Parkinson's and Alzheimer's, offering hope for effective treatments and prevention strategies. Join us as we delve into the world of mRNA technology and its transformative impact on healthcare.

]]> biotech, biotech nation, moira gunn, francois vigneault, shape therapeutics, mRNA, Parkinsons, alzheimers, covid, vaccine No Fighting the Most Advanced Prostate Cancer... Dr. Philip Kantoff, CEO Convergent Therapeutics 23021 23021 Fighting the Most Advanced Prostate Cancer... Dr. Philip Kantoff, CEO Convergent Therapeutics full 428cd1af-9a1f-43e3-98e7-9d57ed7d9eec https://share.transistor.fm/s/f4e173e0 200,000 men at diagnosed each year with Prostate cancer … beginning a journey of many successive treatments. Still, 35,000 men die as a result of prostate cancer. Convergent Therapeutics is focusing on the most advanced, intractable cases of prostate cancer. We speak with, Dr. Philip Kantoff is its Co-Founder, Chief Medical Officer and CEO.

]]> 200,000 men at diagnosed each year with Prostate cancer … beginning a journey of many successive treatments. Still, 35,000 men die as a result of prostate cancer. Convergent Therapeutics is focusing on the most advanced, intractable cases of prostate cancer. We speak with, Dr. Philip Kantoff is its Co-Founder, Chief Medical Officer and CEO.

]]> Wed, 24 May 2023 08:00:00 -0700 Moira Gunn Moira Gunn 629 200,000 men at diagnosed each year with Prostate cancer … beginning a journey of many successive treatments. Still, 35,000 men die as a result of prostate cancer. Convergent Therapeutics is focusing on the most advanced, intractable cases of prostate cancer. We speak with, Dr. Philip Kantoff is its Co-Founder, Chief Medical Officer and CEO.

]]> biotech, moira gunn, Philip Kantoff, Convergent Therapeutics, prostate cancer, therapeutics No A Different Approach, A New Cancer Drug... Dr. Paul Lammers, CEO Triumvira Immunologics 23020 23020 A Different Approach, A New Cancer Drug... Dr. Paul Lammers, CEO Triumvira Immunologics full 0907a02a-87af-444b-9cee-95516ababc9c https://share.transistor.fm/s/6f4720a6 Cancer treatments which work with the immune system are making great strides, with Keytruda from Merck being perhaps the best known. Still there is much work to be done – both in developing unprecedented new treatments, as well as treatments which might combine with our existing treatments to make them even more effective. Triumvera (try-um-VEERA) Immunologics is working on both. Dr. Paul Lammers is its CEO. 

]]> Cancer treatments which work with the immune system are making great strides, with Keytruda from Merck being perhaps the best known. Still there is much work to be done – both in developing unprecedented new treatments, as well as treatments which might combine with our existing treatments to make them even more effective. Triumvera (try-um-VEERA) Immunologics is working on both. Dr. Paul Lammers is its CEO. 

]]> Wed, 17 May 2023 08:00:00 -0700 Moira Gunn Moira Gunn 811 Cancer treatments which work with the immune system are making great strides, with Keytruda from Merck being perhaps the best known. Still there is much work to be done – both in developing unprecedented new treatments, as well as treatments which might combine with our existing treatments to make them even more effective. Triumvera (try-um-VEERA) Immunologics is working on both. Dr. Paul Lammers is its CEO. 

]]> Cancer, Therapeutics, Triumvera Immunologics, Paul Lammers, Moira Gunn, BioTech Nation, Biotech No Are Your Genes Failing You??? Dr. Noah Davidsohn, Co-Founder & CSO Rejuvenate Bio 23019 23019 Are Your Genes Failing You??? Dr. Noah Davidsohn, Co-Founder & CSO Rejuvenate Bio full 485990dc-5839-4ec2-9e8c-2fc10774fc30 https://share.transistor.fm/s/eadd6ba0 Dr. Nolan Davidson, the Co-Founder and Chief Scientific Officer of Rejuvenate Bio, discusses the importance of regulating protein expression and the role it plays in aging. He talks about the three primary genes that drive health and the need to maintain their ideal levels to avoid diseases such as heart disease, liver disease, or kidney disease. 

]]> Dr. Nolan Davidson, the Co-Founder and Chief Scientific Officer of Rejuvenate Bio, discusses the importance of regulating protein expression and the role it plays in aging. He talks about the three primary genes that drive health and the need to maintain their ideal levels to avoid diseases such as heart disease, liver disease, or kidney disease. 

]]> Wed, 10 May 2023 08:00:00 -0700 Moira Gunn Moira Gunn 970 Dr. Nolan Davidson, the Co-Founder and Chief Scientific Officer of Rejuvenate Bio, discusses the importance of regulating protein expression and the role it plays in aging. He talks about the three primary genes that drive health and the need to maintain their ideal levels to avoid diseases such as heart disease, liver disease, or kidney disease. 

]]> biotech, gene therapy, proteins, therapeutics, biotech nation, tech nation, moira gunn, noah davidsohn, rejuvenate bio No 25 Years in the Making - Treatment in Schleroderma? Dr. Darren Kelly, CEO, Certa Therapeutics 23016 23016 25 Years in the Making - Treatment in Schleroderma? Dr. Darren Kelly, CEO, Certa Therapeutics full 161e47c6-1357-44b9-8528-c7544bf94b69 https://share.transistor.fm/s/291c6df2 Dr. Darren Kelly, a professor and researcher at the University of Melbourne and the Founder and CEO of Certa Therapeutics, tells us about their clinical trials addressing the skin condition: schleroderma. Their unprecedented approach and the results of their latest trial are worth noting. 

]]> Dr. Darren Kelly, a professor and researcher at the University of Melbourne and the Founder and CEO of Certa Therapeutics, tells us about their clinical trials addressing the skin condition: schleroderma. Their unprecedented approach and the results of their latest trial are worth noting. 

]]> Wed, 19 Apr 2023 07:00:00 -0700 Moira Gunn Moira Gunn 972 Dr. Darren Kelly, a professor and researcher at the University of Melbourne and the Founder and CEO of Certa Therapeutics, tells us about their clinical trials addressing the skin condition: schleroderma. Their unprecedented approach and the results of their latest trial are worth noting. 

]]> biotech, entrepreneurship, bioentrepreneurship No Fatty Liver, NASH, Cirrhosis - Can They Be Stopped??? Dr. Robert Foster, CEO Hepion Pharmaceuticals 23015 23015 Fatty Liver, NASH, Cirrhosis - Can They Be Stopped??? Dr. Robert Foster, CEO Hepion Pharmaceuticals full b748e339-9fef-4f3d-9eae-38ba905f0156 https://share.transistor.fm/s/8cdab64a Did you know that 1 in 4 Americans suffer from fatty liver disease? And that can lead to a more serious condition called Nash, which can ultimately cause cirrhosis of the liver. Hepion Pharmaceuticals is currently in clinical trials to successfully treat Nash. Learn more about how to take care of your liver on today's episode of BioTech Nation with Dr. Robert Foster, CEO of Hepion Pharmaceuticals. 

]]> Did you know that 1 in 4 Americans suffer from fatty liver disease? And that can lead to a more serious condition called Nash, which can ultimately cause cirrhosis of the liver. Hepion Pharmaceuticals is currently in clinical trials to successfully treat Nash. Learn more about how to take care of your liver on today's episode of BioTech Nation with Dr. Robert Foster, CEO of Hepion Pharmaceuticals. 

]]> Wed, 12 Apr 2023 07:00:00 -0700 Moira Gunn Moira Gunn 1658 Did you know that 1 in 4 Americans suffer from fatty liver disease? And that can lead to a more serious condition called Nash, which can ultimately cause cirrhosis of the liver. Hepion Pharmaceuticals is currently in clinical trials to successfully treat Nash. Learn more about how to take care of your liver on today's episode of BioTech Nation with Dr. Robert Foster, CEO of Hepion Pharmaceuticals. 

]]> #liverhealth #fattyliverdisease #Nash #clinicaltrials #biotech #HepionPharmaceuticals #biotechnation #moiragunn No Hand Foot Skin Reaction - A Painful Chemotherapy Side Effect - Could There Be a Treatment?? Dr. Mike McCullar, CEO of OnQuality Pharmaceuticals 23012 23012 Hand Foot Skin Reaction - A Painful Chemotherapy Side Effect - Could There Be a Treatment?? Dr. Mike McCullar, CEO of OnQuality Pharmaceuticals full badc0657-364e-4585-bf4c-daf1284c5a2d https://share.transistor.fm/s/74c43140 A side effect of chemotherapy, where hands and feet may be raw, painful, and immobilized. With no current treatment, a new candidate has just finished Phase II clinical trials. We’ll hear from Dr. Michael McCullar, the CEO of OnQuality Pharmaceuticals.

]]> A side effect of chemotherapy, where hands and feet may be raw, painful, and immobilized. With no current treatment, a new candidate has just finished Phase II clinical trials. We’ll hear from Dr. Michael McCullar, the CEO of OnQuality Pharmaceuticals.

]]> Wed, 22 Mar 2023 08:00:00 -0700 Moira Gunn Moira Gunn 807 A side effect of chemotherapy, where hands and feet may be raw, painful, and immobilized. With no current treatment, a new candidate has just finished Phase II clinical trials. We’ll hear from Dr. Michael McCullar, the CEO of OnQuality Pharmaceuticals.

]]> biotechnation, biotech, biotech nation, chemotherapy, onquality, pharamceuticals, moira gunn, tech nation, hand foot reaction No Has Medtech Excluded Persons of Color & Women?? Dr. Patrice Matchaba President, Novartis US Foundation 23010 23010 Has Medtech Excluded Persons of Color & Women?? Dr. Patrice Matchaba President, Novartis US Foundation full 586512a0-1d39-4aae-b240-9dbf0926fdc4 https://share.transistor.fm/s/583c95cb Dr. Patrice Matchaba, the President of the Novartis US Foundation, shows us how medical technology can create systemic racism, both in the medical field and in human clinical trials.

]]> Dr. Patrice Matchaba, the President of the Novartis US Foundation, shows us how medical technology can create systemic racism, both in the medical field and in human clinical trials.

]]> Wed, 08 Mar 2023 16:55:49 -0800 Moira Gunn Moira Gunn 1820 Dr. Patrice Matchaba, the President of the Novartis US Foundation, shows us how medical technology can create systemic racism, both in the medical field and in human clinical trials.

]]> biotech, biotech nation, moira gunn, medtech, systemic racism, novartis, patrice matchaba No Safe NON-OPIOID Pain Relief - Is It Possible? Dr. Hernan Bazan, Co-Fdr & CEO, South Rampart Pharma 23009 23009 Safe NON-OPIOID Pain Relief - Is It Possible? Dr. Hernan Bazan, Co-Fdr & CEO, South Rampart Pharma full 20cdfdaa-9f26-4787-a6f1-c4d0a1d23d68 https://share.transistor.fm/s/20cdfa8e The next generation of pain relief – non-opioid pain relief - with the goal of being equally powerful pain relief without addiction. Dr Hernan Bazan is the Co-Founder & CEO of South Rampart Pharma in New Orleans.

]]> The next generation of pain relief – non-opioid pain relief - with the goal of being equally powerful pain relief without addiction. Dr Hernan Bazan is the Co-Founder & CEO of South Rampart Pharma in New Orleans.

]]> Wed, 01 Mar 2023 16:25:30 -0800 Moira Gunn Moira Gunn 1021 The next generation of pain relief – non-opioid pain relief - with the goal of being equally powerful pain relief without addiction. Dr Hernan Bazan is the Co-Founder & CEO of South Rampart Pharma in New Orleans.

]]> biotech, biotechnation, technation, pain relief, opioid addiction, addiction, non-opioids, opioids, south rampart pharma, Hernan Bazan, moira gunn, tylenol No Long Covid related to Fibromyalgia? Dr. Seth Lederman, Tonix Pharmaceuticals 23008 23008 Long Covid related to Fibromyalgia? Dr. Seth Lederman, Tonix Pharmaceuticals full 58b5239b-2fac-4408-9a7c-ea63d464326f https://share.transistor.fm/s/026ecafe Dr. Seth Lederman, Co-Founder and CEO of Tonix Pharmaceuticals, tells us that Long Covid may be related to Fibromyalgia. Now recruiting in advanced Human Clinical Trials ... www.tonixpharma.com

]]> Dr. Seth Lederman, Co-Founder and CEO of Tonix Pharmaceuticals, tells us that Long Covid may be related to Fibromyalgia. Now recruiting in advanced Human Clinical Trials ... www.tonixpharma.com

]]> Wed, 22 Feb 2023 16:47:39 -0800 Moira Gunn Moira Gunn 2021 Dr. Seth Lederman, Co-Founder and CEO of Tonix Pharmaceuticals, tells us that Long Covid may be related to Fibromyalgia. Now recruiting in advanced Human Clinical Trials ... www.tonixpharma.com

]]> biotech, biotechnation, technation, long covid, fibromyalgia, tonix pharmaceuticals, tonix, seth lederman, moira gunn No The Oxford Dodo? ... Joe Hernandez, Blue Water Vaccines 23007 23007 The Oxford Dodo? ... Joe Hernandez, Blue Water Vaccines full abd0edde-4247-4cbc-acf6-7bf751c2a97a https://share.transistor.fm/s/96a5d541 Even Saturday Night Live couldn’t resist the story of a “genetics engineering company” trying to de-extinct the dodo bird. Blue Water Vaccines, founder and CEO Joe Hernandez tells us about his early quest to develop a universal flu vaccine, bringing him face-to-face – so to speak – with the Oxford Dodo. And of course, he funds decoding its DNA.

]]> Even Saturday Night Live couldn’t resist the story of a “genetics engineering company” trying to de-extinct the dodo bird. Blue Water Vaccines, founder and CEO Joe Hernandez tells us about his early quest to develop a universal flu vaccine, bringing him face-to-face – so to speak – with the Oxford Dodo. And of course, he funds decoding its DNA.

]]> Wed, 15 Feb 2023 09:24:14 -0800 Moira Gunn Moira Gunn 715 Even Saturday Night Live couldn’t resist the story of a “genetics engineering company” trying to de-extinct the dodo bird. Blue Water Vaccines, founder and CEO Joe Hernandez tells us about his early quest to develop a universal flu vaccine, bringing him face-to-face – so to speak – with the Oxford Dodo. And of course, he funds decoding its DNA.

]]> biotech, dodo bird, dodo, Joe Hernandez, Blue Water Vaccines, Tech Nation, BioTechNation, Moira Gunn No Getting Immune Systems to Recognize HER2+ tumors - Dr. Randy Schatzman, President & CEO, Bolt Biotherapeutics 23006 23006 Getting Immune Systems to Recognize HER2+ tumors - Dr. Randy Schatzman, President & CEO, Bolt Biotherapeutics full 9e61d591-97ae-49ef-8998-7c8f0328f65d https://share.transistor.fm/s/73ac4267 Bolt Biotherapeutics’ Dr. Randy Schatzman talks about the role of myeloid cells in teaching our immune systems to recognize tumors in our own bodies and then eliminate them. Nearly two dozen forms of HER2-related cancers are being studied. (16 mins)

]]> Bolt Biotherapeutics’ Dr. Randy Schatzman talks about the role of myeloid cells in teaching our immune systems to recognize tumors in our own bodies and then eliminate them. Nearly two dozen forms of HER2-related cancers are being studied. (16 mins)

]]> Thu, 09 Feb 2023 11:27:45 -0800 Moira Gunn Moira Gunn 981 Bolt Biotherapeutics’ Dr. Randy Schatzman talks about the role of myeloid cells in teaching our immune systems to recognize tumors in our own bodies and then eliminate them. Nearly two dozen forms of HER2-related cancers are being studied. (16 mins)

]]> biotech, entrepreneurship, bioentrepreneurship No 22-45 Getting a Vaccination? What about a nasal spray? 23005 23005 22-45 Getting a Vaccination? What about a nasal spray? full 76cde57b-1f9a-4457-977e-34b683cd975f https://share.transistor.fm/s/5b7ca99f Dr. Robert Coleman, the Co-Founder and CEO of Codagenix, shows us how to precisely engineer viruses to be effective vaccines, which can be delivered nasally – you heard that right – no needle. 

]]> Dr. Robert Coleman, the Co-Founder and CEO of Codagenix, shows us how to precisely engineer viruses to be effective vaccines, which can be delivered nasally – you heard that right – no needle. 

]]> Wed, 01 Feb 2023 17:05:27 -0800 Moira Gunn Moira Gunn 1568 Dr. Robert Coleman, the Co-Founder and CEO of Codagenix, shows us how to precisely engineer viruses to be effective vaccines, which can be delivered nasally – you heard that right – no needle. 

]]> biotech, entrepreneurship, bioentrepreneurship No 23-03 Dr. Rob Ross, CEO, Surface Oncology 23003 23003 23-03 Dr. Rob Ross, CEO, Surface Oncology full 697a3b78-f3d9-4304-be3d-3b39c242f4a3 https://share.transistor.fm/s/d49b7b7d Sun, 15 Jan 2023 07:12:42 -0800 Moira Gunn Moira Gunn 974 Surface Oncology's strategy to improve on the first generation of immuno-oncology drugs. Their Phase 2 trials in lung cancer and liver cancer are underway and recruiting. Surface Oncology's strategy to improve on the first generation of immuno-oncology drugs. Their Phase 2 trials in lung cancer and liver cancer are underway and recruiting. biotech, entrepreneurship, bioentrepreneurship No 23-01 Gene Kinney, President & CEO, Prothena Biosciences 23001 23001 23-01 Gene Kinney, President & CEO, Prothena Biosciences full 6e7f4fe8-235b-4b03-b485-78af4a9cf343 https://share.transistor.fm/s/c7edac95 Sat, 07 Jan 2023 09:51:01 -0800 Moira Gunn Moira Gunn 1824 Prothena's 1-2-3 punch for Alzheimer’s + their work in Parkinson’s, ALS, and the role of Amyloids in Down Syndrome Prothena's 1-2-3 punch for Alzheimer’s + their work in Parkinson’s, ALS, and the role of Amyloids in Down Syndrome biotech, entrepreneurship, bioentrepreneurship No 22-52 Edward Humes, Pulitzer Prize Winner, "The Forever Witness" 22052 22052 22-52 Edward Humes, Pulitzer Prize Winner, "The Forever Witness" full 6eb13cfc-cfd0-4434-b5e1-4a26352c9338 https://share.transistor.fm/s/87d665c7 Tue, 27 Dec 2022 18:51:59 -0800 Moira Gunn Moira Gunn 2973 In a long-form feature from Tech Nation, it’s Pulitzer Prize-winning author, Edward Humes, with “The Forever Witness … How DNA and Genealogy Solved a Cold Case Double Murder.” We get an object lesson in the Three Ages of DNA from a forensic investigation standpoint, and while it reads like a fast-paced Cold Case on steroids – it provides details no fiction writer would dare to make up, including the unexpected involvement of the famous true crimes writer, Ann Rule, and a person whose DNA skills are familiar to fans of the PBS documentary series, “Finding Your Roots with Henry Louis Gates, Jr.” In a long-form feature from Tech Nation, it’s Pulitzer Prize-winning author, Edward Humes, with “The Forever Witness … How DNA and Genealogy Solved a Cold Case Double Murder.” We get an object lesson in the Three Ages of DNA from a forensic investigation biotech, pulitzer prize, Edward Humes No 22-51 Keven Ali, CEO, Organon 22051 22051 22-51 Keven Ali, CEO, Organon full 7f119985-5ead-4ede-a7e2-4024ee6adadc https://share.transistor.fm/s/da4886af Sat, 17 Dec 2022 01:00:00 -0800 Moira Gunn Moira Gunn 759 A new global company with 64 products, many of which are for women? Kevin Ali is the CEO of Organon. A new global company with 64 products, many of which are for women? Kevin Ali is the CEO of Organon. biotech, entrepreneurship, bioentrepreneurship No 22-50 Dr. Steve Worland, Co-Founder & CEO, eFFECTOR Therapeutics 22050 22050 22-50 Dr. Steve Worland, Co-Founder & CEO, eFFECTOR Therapeutics full 0fd066bd-0829-4116-8787-17e5ec6bca88 https://share.transistor.fm/s/f505e2cb Wed, 14 Dec 2022 01:00:00 -0800 Moira Gunn Moira Gunn 827 Cancer is a hijacker, hijacking cells for its own purposes. And that’s where eFFECTOR Therapeutics is determined to intervene. Dr. Steve Worland, the Co-Founder & CEO, talks about just two of the candidates in its pipeline: One is for Non-small cell lung cancer and another for ER+ breast cancer, with these and other clinical trials enrolling now. Cancer is a hijacker, hijacking cells for its own purposes. And that’s where eFFECTOR Therapeutics is determined to intervene. Dr. Steve Worland, the Co-Founder & CEO, talks about just two of the candidates in its pipeline: One is for Non-small cell l Non-small cell lung cancer, ER+ breast cancer No 22-49 Dr. Zandy Forbes, Pres & CEO, MeiraGTx 22049 22049 22-49 Dr. Zandy Forbes, Pres & CEO, MeiraGTx full b5c76a2e-d49f-4a85-a3d2-ec827f079771 https://share.transistor.fm/s/81171b3a Sat, 10 Dec 2022 01:00:00 -0800 Moira Gunn Moira Gunn 1311 Like the idea of replacing some of your DNA with DNA that works better? And what if you want that new DNA to stop? Dr. Alexandria Forbes, the President & CEO of MeiraGTx, tells us about their work in retinitis pigmentosa and Parkinson’s – two of many clinical trials enrolling right now. Like the idea of replacing some of your DNA with DNA that works better? And what if you want that new DNA to stop? Dr. Alexandria Forbes, the President & CEO of MeiraGTx, tells us about their work in retinitis pigmentosa and Parkinson’s – two of many retinitis pigmentosa, Parkinson's, biotech No 22-48 Dr. Robert Ang, President & CEO, Vor Biopharma 22023 22023 22-48 Dr. Robert Ang, President & CEO, Vor Biopharma full 873d20ea-7e9b-404d-bcf1-8a6cb0fdd5f8 https://share.transistor.fm/s/02618df1 Wed, 07 Dec 2022 01:00:00 -0800 Moira Gunn Moira Gunn 881 Vor Biopharma has a unique approach to a particular kind of cancer – Acute Myeloid Leukemia – perhaps better known to you, as AML. Dr. Robert Ang is Vor's President & CEO. Vor Biopharma has a unique approach to a particular kind of cancer – Acute Myeloid Leukemia – perhaps better known to you, as AML. Dr. Robert Ang is Vor's President & CEO. biotech, entrepreneurship, bioentrepreneurship No 22-47 Dr. James Mackay, President & CEO, Aristea Therapeutics 22047 22047 22-47 Dr. James Mackay, President & CEO, Aristea Therapeutics full 468badb6-0298-46ea-90d0-830f252c34d2 https://share.transistor.fm/s/cff1fd66 Sun, 04 Dec 2022 01:00:00 -0800 Moira Gunn Moira Gunn 1000 Too much of a good thing spells trouble - in this case, that would be neutrophils – the white blood cells that act as our immune system’s first line of defense. It's called PPP, or Palmoplantar Pustulosis. Dr. James Mackay is the President & CEO of Aristea Therapeutics. Too much of a good thing spells trouble - in this case, that would be neutrophils – the white blood cells that act as our immune system’s first line of defense. It's called PPP, or Palmoplantar Pustulosis. Dr. James Mackay is the President & CEO of Ar biotech, bioentrepreneurship, entrepreneurship, Palmoplantar pustulosis, PPP, post-menopausal women No 22-46 Dr. Maria Maccecchini, Founder, President & CEO, Annovis Bio 22046 22046 22-46 Dr. Maria Maccecchini, Founder, President & CEO, Annovis Bio full 721230c4-0937-419a-9622-1f6faeb2ef20 https://share.transistor.fm/s/919bebc2 Wed, 30 Nov 2022 01:00:00 -0800 Moira Gunn Moira Gunn 1157 Alzheimer’s, Parkinson’s and ALS, among others, are often grouped as Neurodegenerative Disorders. While they each present a different profile of symptoms, what do they have in common? Dr. Maria Maccecchini, the Founder, President & CEO of Annovis Bio, says, "Sticky proteins". Alzheimer’s, Parkinson’s and ALS, among others, are often grouped as Neurodegenerative Disorders. While they each present a different profile of symptoms, what do they have in common? Dr. Maria Maccecchini, the Founder, President & CEO of Annovis Bio, biotech, bioentrepreneurship, entrepreneurship, Alzheimer’s, Parkinson’s, ALS, neurodegenerative disorders No 22-16 Triple-Negative Breast Cancer is the most aggressive of all 22045 22045 22-16 Triple-Negative Breast Cancer is the most aggressive of all full 04183d90-e66e-4308-b917-a2f056351b67 https://share.transistor.fm/s/6dbec987 Sun, 27 Nov 2022 10:44:14 -0800 Moira Gunn Moira Gunn 1504 Anixa is pioneering a new approach to preventing the truly aggressive triple-negative form of breast cancer. Based on research from Cleveland Clinic, this approach has the potential to treat other breast cancers as well as ovarian cancer. Dr. Amit Kumar is the President & CEO. More information is available at anixa.com. Anixa is pioneering a new approach to preventing the truly aggressive triple-negative form of breast cancer. Based on research from Cleveland Clinic, this approach has the potential to treat other breast cancers as well as ovarian cancer. Dr. Amit Kumar i biotech, bioentrepreneurship, entrepreneurship, triple negative breast cancer, breast cancer, ovarian cancer No Dr. George Yancopoulos, CEO, Regeneron 22022 22022 Dr. George Yancopoulos, CEO, Regeneron full e2e3d535-de38-44c3-aecb-12f38883f32e https://share.transistor.fm/s/20f05d21 Tue, 14 Jun 2022 08:01:34 -0700 Moira Gunn Moira Gunn 2159 Dr. George Yancopoulosis is the President and Chief Scientific Officer of Regeneron. Regeneron is successful on many levels but is perhaps best known for its Covid treatment, directly infusing antibodies. This, of course, requires innovative science … but how do get students to become scientists? Dr. Yancopoulos has an answer. Dr. George Yancopoulosis is the President and Chief Scientific Officer of Regeneron. Regeneron is successful on many levels but is perhaps best known for its Covid treatment, directly infusing antibodies. This, of course, requires innovative science … but George Yancopolous, Regeneron, Covid anitbody treatments, bioentrepreneurship No Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics 22021 22021 Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics full b5c26619-c350-4fa6-ad60-93fa6eb74c14 https://share.transistor.fm/s/f11d9bb8 Blood clots of any sort are dangerous. So dangerous in fact, that 1 in 4 people die from blood clots - independent of medical condition, medicines they take, or medical procedures they undergo. Dr. Daniel Bloomfield, the Chief Medical Officer of Anthos Therapeutics, describes their approach to preventing bleeding while avoiding blood clotting. 

]]> Blood clots of any sort are dangerous. So dangerous in fact, that 1 in 4 people die from blood clots - independent of medical condition, medicines they take, or medical procedures they undergo. Dr. Daniel Bloomfield, the Chief Medical Officer of Anthos Therapeutics, describes their approach to preventing bleeding while avoiding blood clotting. 

]]> Mon, 13 Jun 2022 11:50:48 -0700 Moira Gunn Moira Gunn 832 Blood clots of any sort are dangerous. So dangerous in fact, that 1 in 4 people die from blood clots - independent of medical condition, medicines they take, or medical procedures they undergo. Dr. Daniel Bloomfield, the Chief Medical Officer of Anthos Therapeutics, describes their approach to preventing bleeding while avoiding blood clotting. 

]]> bleeding, clotting, biotech, bioentrepreneurship, entrepreneurship No Mark Litton, President & CEO, Athira Pharma 22020 22020 Mark Litton, President & CEO, Athira Pharma full 7667cf33-f0ea-49a1-a7bf-83597781d3fb https://share.transistor.fm/s/7b9f87ce Thu, 09 Jun 2022 15:01:54 -0700 Moira Gunn Moira Gunn 1319 Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovative treatments, and one such approach has entered late-stage human clinical trials. Dr. Mark Litton is the President and CEO of Athira Pharma. Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovativ biotech, entrepreneurship, bioentrepreneurship, alzheimer's, parkinson's, neurodegenertive diseasesons No